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Rheumatoid Arthritis poses a major health concern with an ever rising global 
burden. Owing to the chronic nature of the disease and limitations and risks of 
conventional therapy, the past decade has witnessed use of herbal medicines as potent 
therapeutic agents. Atropa acuminata and Ajuga bracteosa have been widely used in 
folk medicine for rheumatism and other related inflammatory disorders. Our aim was 
to study immunomodulation of autoimmune arthritis by these two herbs and to 
delineate their possible mode of action using several animal models. 
Since Rheumatoid arthritis has a strong T-cell based immune mediated 
pathogenesis, our first aim was to investigate the possible immunoregulatory effects 
of the herbs if any on systemic T helper immunity in SRBC immunized Balb/C mice. 
Circulating antibody titers, DTH responses and spleenocyte proliferation were 
monitored as markers of Th1 and Th2 immune responses. Lymphocyte 
immunophenotying (CD4/CD8 cell counts) and intracellular Th1/Th2 cytokine 
concentrations were determined using flow cytometry. Our results indicated a unique 
immunomodulatory profile for each herbal extract. A.accuminata demonstrated mixed 
biphasic modulation of effector T-helper immunity. At lower doses, significant up 
regulation of Th1 immunity was observed. However, contrastingly at higher doses 
significant Th2 upregulation was observed. It was therefore considered that 
A.accuminata at higher doses induces and stimulates Th2 immune response and 
concomitantly inhibits the Th1 pathway at the same dose via inhibition of Th1 
cytokines and the T-cell proliferation. Contrastingly, A.bracteosa exhibited dual 
Th1/Th2 immunopotentiating effects at lower doses with significant down regulation 
at higher doses. 
Also, since both the test extracts were found to downregulate T- cell immune 
responses in the higher dose range,  this premised evaluation of  extracts for  anti-
inflammatory properties on in vitro and in vivo acute inflammatory models. Our 
findings summarized novel anti-inflammatory mechanisms  for both A.accuminata  
and A.bracteosa based on dual in vitro Cycloxygenase 1&2/5-Lipoxygenase 
inhibitory activities and also significant downregulation of nitric oxide (NO)  and pro-
inflammatory cytokine (TNF-α and Il-1 β) release in LPS-stimulated RAW 246.7 
macrophage cell line . In acute inflammatory models in vivo (carrageenan induced 
 Abstract 
-ix- 
 
edema, carrageenan induced pleurisy in rats and vascular permeability in mice), the 
test extracts exhibited an extensive diverse mechanism for anti-inflammatory 
properties. This was indicated on the basis of dose dependent suppression of multi 
targeted inflammatory mediators., NO,TNF-α and IL-1β, eicosanoids (PGE2) and 
leukotrienes (LTB4) along with significantly decreased  leucocyte migration , 
exudation and decreased vascular permeability .These effects were more potent and 
prolonged than traditional NSAIDS, thereby indicating fewer side effects .Both test 
extracts were found to be safe for long term administration, as confirmed by the 
results of acute toxicity studies and MTT assay. The complex mode of action of the 
herbs was attributed possibly due to the high polyphenolic, flavanol and  flavonoid 
content present in the extracts as observed by means of qualitative and quantitative 
screening for phytochemicals. 
To study further the effects of the test extracts on the progression of  the 
disease and to explore the underlying mechanisms of action in view of immunological 
responses, we evaluated the extracts for their effectiveness against the Mycobacterium 
tuberculli - induced model of arthritis in male Wistar rats. The polyarthiritis test 
revealed a significant anti-arthritic activity both in the developing and developed 
phase of the disease. This was associated with significant suppression of the array of 
pro-inflammatory mediators  (PGE2 , NO and LTB4 ) and Th1 cytokines  (IL-2, TNF-
α, IFN-γ, IL-6)  as measured in arthritic paw tissue homogenate, slpeenocytes and  
serum of  AA & AB treated animals . Significant upregulation of Th2 cytokines (IL-4 
and IL-10) was observed only for A.accuminata. This finding strongly indicated that 
the test extract  not only inhibited the T cells and Th1 cytokines but also elevated the 
natural capacity of the immune system to keep the Th1 cytokines under control by 
increasing IL-4 and IL-10. Both the test extracts were also observed to protect rats 
against the primary and secondary arthritic lesions, body weight changes and 
haematological perturbations (Hb, ESR, WBC and RBC) induced by CFA. The serum 
markers of inflammation and arthritis, such as C-reactive protein and rheumatoid 
factor, were also reduced in the AA & AB treated arthritic rats. The overall severity of 
arthritis as determined by radiological analysis and pain scores indicated that the 
extracts quite potently decelerated the progression of arthritis in rats. 
Histopathological assessment and biochemical parameters (SOD, GSH , GRX) further 
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confirmed  the reduced signs of  chronic inflammatory response  and cartilage 
damage. 
The study indicates a possiblility of using Atropa accuminata and Ajuga 
bracteosa as promising therapeutic agents in the treatment of Rheumatoid 
arthritis.The diverse set of properties might be due to the additive / antagonistic 
effects of bioactive constituents present in the extracts. The multipronged attack on 
the inflammatory mediators and Th1 /Th2 cytokines and strong potency of these 
extracts may have relevance for inhibition of the acute and chronic inflammatory 
responses in arthritis and other related diseases. It is further suggested that for an 
insight into the molecular mechanism of such effects, bioassay guided fractionation 
and isolation of active constituents and in depth studies on transcripiton factors for 
cytokines, iNOS, COX 1/2, 5-LOX and others is required. This could provide us with 
novel immunostimulatory /anti-arthritic leads for newer and safer therapeutic options 
in the management of arthritis and related disorders. 
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rthritis is one of the most common debilitating diseases affecting millions 
across the world. In the Western world and USA, arthritis and related 
conditions have been identified as the third largest contributor to health 
expenditure after cardiovascular disease and neurological disorders. It affects 
approximately 46 million people in the USA and by 2030 the number is expected to 
rise to 67 million (Helmick et al., 2008). Though arthritic disorders comprise a group 
of more than hundred rheumatic diseases., osteoarthritis and rheumatoid arthritis are 
the most prevalent forms.The two diseases differ in their etiology and profiles but 
both share a similar outcome - joint destruction (Kraan & Berg, 2000). 
 
Our present study is mainly focussed towards Rheumatoid arthritis (RA). RA 
is a systemic inflammatory autoimmune disorder that mainly targets the joints. It is a 
chronic crippling disease which can lead to long term joint damage, loss of function 
and disability. The annual incidence of RA is estimated to be about 30 per 100,000 
and it affects approximately 0.5%–1.0% of the world population (Alamanos et al., 
2006).  
A 
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Clinically, RA manifests as symmetric polyarthritis associated with swelling 
and pain in multiple joints, often initially occurring in joints of the hands, wrists and 
feet. The most striking characteristic of RA is the inflammation of the synovial 
membrane in the joints which leads to cartilage degradation and erosion of the 
underlying bone. In addition to joint damage, RA is often accompanied with extra-
articular manifestations mainly lung and cardiovascular diseases (Firestein et al., 
2003). 
The etiology of this disease is multifactorial. Genetic predisposition, 
environmental and  hormonal effect has been reported to contribute in the initiation 
and progression of the disease (Kupier et al., 2001, Symmons et al., 2002). It is 
proposed that the disease is triggered by unknown antigens of infectious origins which 
when presented to immune cells in the joint tissue initiate an event that is followed by 
the induction of an immune response, resulting in inflammation in the lining of the 
joints. RA mainly represents a typical T-cell mediated disease (Cope, 2008). The most 
convenient evidence concerning the involvement of T cells in RA comes from 
immunogenetics of RA (MacGregor et al., 2000) and the fact that in experimental 
animal models such as adjuvant arthritis, the disease can be transferred by isolated T 
cell lines. Once T cells are activated in RA, it consequently leads to multiple effects, 
including activation and  proliferation of synovial lining and recruitment of additional 
pro-inflammatory cells like mononuclear phagocytes, lymphocytes, and plasma cells 
from the bone marrow and circulation into the synovium sublining layer. These cells 
in the synovium next induce a hyperplastic reaction of the resident fibroblasts which 
eventually cause tissue destruction and cartilage and bone erosion as mediated by 
secretion of inflammatory mediators and pro-inflammatory cytokines (McInnes et al., 
2001).  
Inflammation is the main exacerbation of the arthritic problems. Although, 
inflammation  itself  is a beneficial host response, yet any breakdown in the regulation 
of the inflammatory process results in excessive tissue damage (Klegeris et al., 2005). 
Inflammation can  be acute in nature or can have more chronic form  such as that seen 
in arthritis. Acute inflammatory response has been demonstrated to be a multi-step 
process characterized by increased sequestration of leukocytes to target sites and over 
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production of an array of complex inflammatory mediators by immune cells including 
macrophages and monocytes (Zedler et al.,2006). Among the key mediators of 
inflammation are the arachidonic acid derived eicosanoids (prostaglandins, 
leukotrienes), nitric oxide (NO) and inflammatory cytokines., TNF-α and IL-1β 
recruited by the activated monocytes and macrophages. 
 Prostaglandins (PGE2), the lipid mediators derived from cycloxygenase 
pathway of arachidonic acid (AA) metabolism produce the classical signs of 
inflammation in the joints: redness, swelling, and pain. These also mediate the 
augmentation of arterial dilatation and increased microvascular permeability (Funk   
et al., 2001). Leukotriene (LTB4) is another lipid mediator derived from AA via the 
lipoxygenase (LOX) pathway. It induces vasoconstriction of arteries, release of 
lysosomal enzymes and reactive oxygen species (ROS) by the granulocytes. In 
addition, it promotes production of TNF-α and IL-1β and also acts as a chemo 
attractant for leukocytes (Kanoaka et al., 2004). Of late dual inhibition of biosynthesis 
of prostaglandins and leukotrienes has evolved as a promising anti-inflammatory 
therapeutic target (Martel-Petllier et al., 2003). Such agents have been found to be 
effective for reducing the deleterious side effects by balancing the arachidonic acid 
metabolism. Nitric oxide (NO) is another ubiquitous mediator of inflammation which 
reacts with the super oxide radical to form peroxynitrate anion and stimulates the 
COX enzymes. It also enhances the production of a variety of other mediators such 
TNF-α and IL-1β (Marcinkiewicz et al., 1995).  
Cytokines (IL-1β,TNF-α,IL-6,IFN-γ,IL-8,etc.) are  considered to play a 
pivotal role in the pathogenesis of arthritis and exhibit pleiotropic effects that 
contribute to the inflammatory process. TNF-α in particular has an early and crucial 
role in the cascade of pro-inflammatory cytokine production and subsequent 
inflammatory processes. It also enhances the release of IL-1β from  macrophages and 
that of superoxide from neutrophils. In addition, it enhances chemotaxis of 
macrophages and neutrophils and increases their phagocytotic activity (McInnes & 
Schett, 2007, Raza et al., 2005).  
Further, TNF-α and IL-1β both further escalate the pro-inflammatory cellular 
actions like stimulating production of collagenases, hyperexpression of leukocyte 
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adhesion molecules and  increased leukocyte extravasation (Moser et al., 1989).  Both 
stimulate the proliferation of fibroblasts and increase the production of IL-6, IL-8, 
granulocyte–macrophage colony stimulating factor (GM-CSF) and other chemokines 
which perpetuate the inflammatory cascade. IL-8 once released from the activated 
endothelial cells activates neutrophils. Other cytokines like IL-1β,TNF-α and IL-17 
induce the release of  metalloproteinases and aggrecans  by synoviocytes and these 
proteases  then largely mediate  cartilage destruction. Whereas eicosanoids mediate 
much of the early phase in inflammatory diseases, cytokines are involved in the later 
destructive phase in rheumatoid arthritis (Brenan & McInnes, 2008).  
Contrary to the action of pro-inflammatory cytokines some cytokines (IL-4, 
IL-10, etc.) act antagonistically to decelerate the inflammatory response in RA. IL-4 
inhibits the synthesis of pro-inflammatory cytokines such as IL-1, TNF-α and IL-12 
by macrophages and monocytes.  Moreover, IL-4 also stimulates the synthesis of 
several cytokine inhibitors such as interleukin-1 receptor antagonist (IL-1Ra) 
(Vannier et al.,1992) and suppresses the metalloproteinase production in human 
mononuclear phagocytes (Lacraz et al.,1992). IL-10 is another powerful anti-
inflammatory cytokine produced by leukocytes which inhibits the synthesis of IL-1β 
and TNF-α in macrophages. Any imbalance between pro and anti-inflammatory 
cytokine activities favours the induction of autoimmunity, chronic inflammation and 
thereby joint damage as is the case in RA (McInnes & Schett, 2007). Therefore, 
modulation of Th1/Th2 cytokine balance has become a new paradigm for employing 
immune modulatory therapy in rheumatoid arthritis. 
Reactive oxygen species (ROS) such as super oxide radical, hydroxyl radical 
and hypochlorous acid have also significantly contributed to tissue injury facet in RA. 
Several mechanisms are involved in the generation and action of ROS in the joints of 
RA patient, including increased pressure in synovium cavity, reduced capillary 
density, vascular changes and increased metabolic rate of synovial tissue (Fairburn     
et al.,1993).  
The past decade has been an era of revolution in the field of anti-rheumatic 
drugs. Most of the conventional therapies employed for rheumatoid arthritis are 
directed against non specific suppression of the inflammatory and immunologic 
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processes and have shown only limited success against all forms of arthritis. The most 
widely used anti–arthritic drugs have been the symptom-modifying anti-rheumatic 
drugs (SMARDs) and these include the analgesics, traditional non steroidal anti-
inflammatory drugs (NSAIDs) and cyclooxygenase-2 (COX- 2) inhibitors, all of 
which control the symptoms of pain and stiffness associated with RA. NSAIDs have 
lost their historical role as a first-line treatment for RA because of their limited 
effectiveness, inability to modify the long-term course of the disease, and the 
associated toxic gastrointestinal and cardiac effects (Schaffer et al.,2006). COX 2 
inhibitors although boasted with minimized risks of gastrointestinal side effects, 
however, have been reported to cause kidney and cardiovascular dysfunction 
(Feldmann et al.,2000). 
Glucocorticoids (GCs) have also been used extensively in patients with RA 
and have been reported to reduce synovitis on short term usage and decrease joint 
damage on long term usage (Townsend & Saag, 2004). GCs are therefore reported as 
very potent anti-inflammatory and immunomodulatory drugs but again they pose very 
adverse effects such as osteoporosis, hypertension, hyperglycemia etc. and hence their 
overall risk/benefit ratio is quite unfavorable (Steinbuch et al., 2004). The use of GCs 
has been replaced with the use of disease modifying anti-rheumatic drugs 
(DMARDs). For long these drugs have been the mainstay of treatment for rheumatoid 
arthritis (Kremer et al., 2001). The use of many DMARDs such as 
hydroxychloroquine, cyclosporine, azathioprine, D-penicillamine, auranofin and 
intramuscular gold has been found to decelerate the progression of diseases and also 
improve function. However, again these are often associated with considerable 
toxicity (Feist & Burmester, 2009). The most frequently used DMARD, methotrexate 
(follic acid antaganoist ) has been used in intermittent low doses (7.5-30 mg once 
weekly). 
Currently various biological anti-rheumatic agents such as TNF-α blocking 
agents, IL-1 receptor antaganoist, monoclonal antibodies against B-cells, IL-6 
blockers, etc. are being used either as monotherapy or in combination with DMARDs 
against RA. Although they are much more effective than the older DMARDs in 
reducing symptoms, inhibiting joint damage and preventing functional disability in 
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arthritic patients but none of these newer agents could achieve a permanent drug-free 
remission (Salliot et al.,2011). TNF-blockers for example have been reported to 
induce antibodies and  lupus like syndromes. Additionally, higher costs and increased 
risk of malignancies again limit the use of such agents in many populations (Valesini 
et al., 2007).  
On account of such limitations and risks of conventional therapy, the arthritic 
patients tend to search for alternative treatments that are effective, less toxic and 
reduce the pill burden. Herbal therapies based on traditional medicine have emerged 
to occupy significance in alternative therapy. In the recent past there has been a 
growing interest to use herbal medicines as an adjunct therapy to prevent the 
development of arthritis and other related diseases (Ahmed et al. 2005).  
Since ages natural products and herbal remedies used in folk medicine have 
been as the source of many medically beneficial drugs. Looking back upon the last 
2000 years of medicine, mankind has mainly used plants as the best source of 
medicine. Over 248,000 species of higher plants have been  identified and from these 
12,000 are known to have medicinal properties. More than 2000 plants of medicinal 
value are mentioned in Indian ancient Ayurvedic, Unani and Tibbi systems of 
medicine (Ernst et al.,2000). The demand for medicinal plants based drugs is growing 
at the rate 15% to 25% annually and according to an estimate of WHO, the demand 
for medicinal plants is likely to increase to more than 5 trillion US Dollar in 2050 
(Kala et al.,2004). However, despite the increasing usage and popularity of herbal 
products, one of the main limitations of their use is the meagre information about their 
mechanisms of action and the objectivity in evaluating their efficacy/side effects. This 
impends the need for continued studies on the mechanistic aspects of action of such 
traditionally used medicinal herbs. 
Of late many such plants with traditional knowledge of anti-arthritic efficacy 
have been studied world over and their mechanism of action has been elucidated. 
Many such herbal extracts have been an important source of new bioactive substances 
with potential therapeutic effects and innumerable therapeutically indispensable 
compounds have been  isolated from such plants. For example, Uncaria tomentosa, a 
traditional medicinal plant from Peruvian Amazaon used since centuries against 
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immunologic disorders, reported an extract having potent anti-inflammatory activity 
which was explored to be mediated through suppression of TNF-α synthesis. Clinical 
studies, on a purified extract from this plant demonstrated it to be safer and 
moderately effective in patients with active rheumatoid arthritis as compared with 
sulfasalazine or hydroxychloroquinine (Allen-Hall et al., 2010). Similarly Bergin, a 
glycoside isolated from rhizomes of Bergenia straheye (Sabafrgaceae) was reported to 
show anti-arthritic activity through possible modulation of Th1/Th2 cytokine 
balance., it was observed to inhibit the production of proinflammatory cytokines and 
potentiate the anti-inflammatory cytokines (IL-4, IL-5) in adjuvant induced arthritic 
models (Nazir et al.,2007). Another plant, Cetrria islandica called island moss has 
demonstrated  inhibition of antigen induced arthritis in Wistar rats via up- regulation 
of IL-10 cytokine (Freysdottir et al.,2008). In addition, Madimadi, a Korean folk 
medicine has been observed to down regulate the TNF-α, IL-1β and IL-8 production 
in RA patients (Kim et al., 2004). Tripterygium wilfordii Hook F. also called 
‘Thunder God Vine’, (TwHF) occupies the foremost place in the Chinese traditional 
medicine system for the treatment of autoimmune and inflammatory diseases such as 
RA. Tripterygium was reported to cause symptomatic improvement in 50% of RA 
cases during the first 4 weeks of treatment.  This anti-inflammatory action was found 
to be based on suppression of adhesion molecules like E selectin, intracellular 
adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) 
and down regulates nuclear factor-kappa B (NF-κB) DNA binding activity via  
inhibition of iNOS expression (Lu et al.,2006, Goldbach-Mansky et al., 2009). Many 
Chinese herbal formulations have also been used since centuries against arthritis for 
example Huo Luo Xio Ling Dan (HXHL) comprising of several medicinal herbs has 
been reported to mediate suppressive effects on pro-inflammatory cytokines (Zhang et 
al., 2009).  
Herbal extracts produce a diverse range of natural products including 
isoflavonoids, indoles, phytosterols, polysaccharides, sesquiterpenes, alkaloids, 
glucans and tannins which exhibit complex pharmacological properties. Unlike most 
synthetic drugs that have pure ingredients, medicinal herbs represent a complex 
mixture of ingredients. Such different ingredients may balance, buffer each other, or 
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act synergistically to make the systemic effect more powerful. Therefore, contrary to 
the allopathic medicines, herbal therapy has emerged as a promising alternative with 
least toxicities and fewer complications. There is an over growing interest in 
investigating different medicinal plants in order to identify their potential therapeutic 
applications. 
OBJECTIVES OF THE STUDY: 
Kashmir valley has an extensive area of forest enriched with plant diversity 
and is considered as a storehouse of medicinal and aromatic plants. There is a big 
potential for the evaluation and in depth assessment of the mechanistic action of such 
medicinal plants. The present study is a step in this direction. The present work was 
designed to investigate the immune modulating effects of Atropa acuminata and 
Ajuga bracteosa based on their reported traditional knowledge against inflammation/ 
arthritis (Kaul, 1997, Wealth of India,1985).The aim is to understand their anti 
arthritic potential  and also to elucidate a probable mechanism  of action for such 
effects. In the present study only alcoholic extracts of both the plants have been used 
based upon the data generated in our earlier unpublished studies. 
 
The broad objectives of the study were: 
 To bridge the gap between the folklore claims and experimental evidences of 
the potential arthritic activities of the plants.  
 To assess the immune modulatory potential of the two testing plants in an 
animal model and give a possible mechanism for immune related anti-
arthritic effects of the extracts, if any. 
 To determine suitable markers for humoral and cell mediated immunity in 
order to elucidate the mechanism for immune modulatory effects. 
 To develop an experimental model of acute inflammation for mechanistic 
understanding of the anti-inflammatory effects of the plants under study. 
 To evaluate various parameters of the inflammatory process using in-vivo 
experimentation in order to elucidate on the pathway for the anti-
inflammatory effects of the testing plants. 
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 To develop an animal model of arthritis for evaluation of inhibitory effects 
on pathogenesis of arthritis. 
 To elucidate on the mechanism of anti-arthritic effects based on evaluation 
of several markers of inflammatory responses and immune regulation using 
in vivo experimentation  
 To consolidate all the data and suggest a plausible mechanism for the anti-
arthritic effects/potential of the plants in order to pave the way for 
identification of lead molecules in future. 
  
 
 
 
 
 
Chapter - 2 
Review of Literature 
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rthritis literally meaning ―joint inflammation‖ refers to a group of more 
than hundred rheumatic diseases and other conditions that cause pain, 
stiffness and swelling particularly in the joints. Many rheumatic conditions 
are accompanied with systemic complications resulting in debilitating, life threatening 
conditions. The two most common and basic forms of arthritis are rheumatoid arthritis 
and osteoarthritis. These two forms have very different aetiologies, risk factors and 
effects on the human body, yet they share a common symptom–persistent joint pain. 
Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease 
predominantly characterized by joint inflammation and progressive destruction of the 
joints, leading to decreased functional capacity, work disability and reduced quality of 
life (Blumenauer et al.,2003). Its prevalence is estimated at 2.5-3% in the adults 
above 50 years of age. The aetiology of RA has not been completely clarified so far. 
Many environmental and genetic factors are found to contribute to the development of 
the disease. The genetic basis for RA is complex. It has been reported that RA does 
not aggregate in families with very high frequency. In addition, the concordance rates 
in identical (monozygotic) twins are relatively low (12-15%) (Barton et al.,2009). 
A 
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However RA has been found to be closely associated with human leukocyte antigen 
(HLA) and this therefore supports the hypothesis that genetic factors are important for 
susceptibility to RA. Based on this it has been suggested that genetic susceptibility 
explains 40% of the risk of developing RA (Dieude et al., 2005). Several 
environmental/lifestyle factors have been identified as important risk factors and 
causative agents for RA which also include smoking. A number of infectious diseases 
such as those caused by Epstein-Barr virus (EBV), Mycobacterium tuberculosis, 
Escherichia coli and Proteus mirabilis have also been associated with this debilitating 
disease (Ebringer et al.,2007, Tousirat et al.,2007).  
RA is an autoimmune disease which affects mainly diarthrodial joints and 
periarticular structures. In RA joints are affected in a symmetrical fashion i-e both 
hands, both wrists and both hips causing inflammation, stiffness and immobility. 
Small joints are involved earlier than large joints (axial joints). The condition is often 
associated with systemic disturbances most commonly fatigue, stiffness, weight loss 
and extra articular features such as rheumatoid nodules (Majithia et al., 2007). 
2.1 Pathophysiology  
 Rheumatoid arthritis has a complex and multi factorial pathogenesis Synovial 
hyperplasia and joint deformation is a striking characteristic of RA patients. The 
synovium thickens, and the joint becomes swollen and painful. The normally 
hypocellular synovium becomes infiltrated with immune cells (T cells, B cells, 
macrophages, and neutrophils). Mononuclear cells infiltrating the joint produce large 
quantities of pro-inflammatory cytokines that induce further synoviocyte activation 
and proliferation leading to ―pannus‖ formation. Pannus is a hyperplastic membrane 
of synoviocytes that invades the tissues and targets the underlying bone and cartilage. 
Further production of matrix-degrading enzymes results in the loss of cartilage and 
the formation of osteoclasts. In RA joint destruction is irreversible. Osteoclasts 
reabsorb bone, and cause release of proteolytic enzymes, such as metalloproteinases, 
aggrecanases, and cathepsins. These in turn are responsible for further destruction of 
extracellular matrix constituents, including bone and cartilage proteoglycans. As a 
result of this, cartilage and bone lose their normal architecture and function which 
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leads to joint deformation, instability, pain, and severe inflammation. Also the 
synovial fluid, which is normally acellular, becomes highly infiltrated with cells 
predominantly with neutrophils. All these changes result in reduced functioning of the 
joint accompanied by pain and stiffness (Goronzy & Weyand, 2009).   
 Autoimmune nature of RA 
 Approximately 70% of patients with RA have rheumatoid factor (RF) in their 
serum that is, antibodies directed against the Fc portion of immunoglobulins of the 
IgG class. RF can form immune complexes that are deposited in arthritic synovium 
and activate the complement system there by reinforcing B cell activation (Edwards & 
Cambridge, 2006). A positive RF reaction is considered a characteristic hallmark of 
the disease. Recently, another kind of autoantibody namely, ACPA (anti-citullinated 
peptide antibody), has been identified as more specific serologic marker of RA 
(Szodorav et al., 2010). In addition to these diagnostic antibodies, autoantibodies 
directed to cartilage components, such as collagen type II (CII), have been described 
in RA patients. The presence of the auto-antibodies in the serum provides an 
autoimmune character to the disease. These auto antibodies have been observed to 
form immune complexes which trigger inflammation and also cause release of 
cytokines such as IL-1β and TNF-α by the macrophages. The potential impairment of 
multiple organs in RA has been associated with the presence of these auto antibodies 
(Nandakumar et al., 2010). 
 Serum CRP as a biomarker of RA severity 
 C-reactive protein, an acute-phase protein produced in the liver is considered 
as a very useful marker of inflammation that reflects the inflammatory load of the 
body. It is also a potential biomarker for the anti-inflammatory effect of a new therapy 
because the half-life remains unchanged under conditions of health and disease. In 
patients with clinically active RA, the serum level of CRP is increased 100 to 200 
fold. In addition, low but significant increase of serum CRP concentration is 
observed, years before the onset of RA symptoms. CRP is shown to induce the 
expression of cell adhesion molecules; ICAM-1 and E-selectin in endothelial cells 
which activates the entire recruitment cascade of cells (Pasceri et al., 2000). 
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Fig. 2.1 A. *Adapted from Feldman M. et al. 1996. 
 
 
 
 
 
 
Fig. 2.1B. *Adapted from Choy EH, et al., 2001; Silverman GJ, et al., 2003; Smolen JS ,2003. 
 
Figure 2.1(A) & (B): Pathogenesis of Rheumatoid Arthritis. 
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2.2 Role of immune cells in RA pathogenesis: 
a) Role of Macrophages and osteoclasts 
 Macrophages are the primary source of the pro-inflammatory cytokines and 
express HLA class II molecules. In RA, macrophages due to their proximity to T cells 
function as antigen-presenting cells and perpetuate the immunological responses 
within the joint. Synovial macrophages are involved in cytokine and chemokine 
production, matrix degradation, and angiogenesis. In joints affected by RA, the 
number of synovial macrophages correlates with articular destruction (Ma et al., 
2005) {See Figure 2.2}. 
b) Role of Neutrophils 
 Neutrophils normally function as a first line of defense against invading 
pathogens. In a joint affected by RA, neutrophils are the most abundant cellular 
infiltrators constituting about 90% of the cells found in synovial fluid (SF). These 
neutrophils expressing class II MHC molecules, have recently been found to stimulate 
T-cell proliferation. Such an interaction between neutrophils and T cells could 
eventually prove important in the pathogenesis of RA. Besides, neutrophils produce 
high levels of ROS and enzymes such as matrix metalloproteinase (MMP or 
gelatinase B), LTB4 and a wide variety of cytokines, including IL-1β, IL-6 and TNF-α 
(Cascao et al., 2010). 
c) Role of Endothelial cells 
 Endothelial cells and synoviocytes in the rheumatoid synovium exhibit 
distinctive features. Endothelial cells have the appearance of high endothelial venules, 
which are characteristic of lymphoid organs. They express specific cell adhesion 
molecules (CAMs) on their surface, including intercellular adhesion molecule-1 
(ICAM-1), vascular cell adhesion molecule-1 (VCAM-1) and E-selectin, which 
control the infiltration of inflammatory cells into the joint (Lipsky et al.,2001). 
d) Role of B cells 
 In the pathogenesis of RA, B cells have been found to be involved in the 
production of autoantibodies such as RF, ACPA and anti-collagen II antibodies and  
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*Adapted from Arend and Dyer., 1990 
Figure 2.2: Cellular interactions in the pathophysiology of joint 
destruction in Rheumatoid Arthritis. 
also contribute to the inflammatory response by producing cytokines, such as IL-6 
and by serving as antigen-presenting cells (APCs) to activate T cells (Takemora et al., 
2001). Recently it has been demonstrated that collagen induced arthritis (CIA) could 
not be induced in mice deficient for B cells (Svensson et al.,1998) which affirms the 
role of B-cells in the pathogenesis of RA. In this context, targeting B cells has proven 
to be a very successful therapeutic option in the treatment of RA. Rituximab, a CD 20 
specific monoclonal antibody which depletes all B cell subsets (except plasma cells), 
                                                                                                                                                                                                                                                                                                                                                                                                 
Review of literature 
 
- 16 - 
 
has been reported to result in significant clinical benefit in patients with RA (Shaw et 
al., 2003). 
e) Role of T cells 
 It has been postulated that T and B cells play important roles in autoimmune-
mediated processes for perpetuating inflammation. T cells in the rheumatoid joint are 
found in close proximity to antigen-presenting cells and express various activation 
markers. The general association of disease severity and progression with HLA-DR4 
and DR1 alleles suggests that T cells are important in RA pathogenesis (Cope et al., 
2008). T cells constitute 75%–90% of the lymphocytic infiltrate in the inflamed 
synovial membrane of RA patients (Bankhurst et al.,1976).Also based on the 
association of RA with class II MHC genes it is speculated that T cells are implicated 
in the pathogenesis of RA (Weyand et al.,2000).This provides convincing evidence 
for involvement of T cells in pathogenesis of RA. The cellular infiltrate in the 
inflamed synovium is similar to that seen in delayed-type hypersensitivity (DTH) 
mediated inflammation, therefore RA is considered to be Th1-driven diseases 
(Firestein et al., 2002). 
2.3 Modulation of Th1/Th2 balance-a new paradigm for 
          immunomodulatory therapy. 
Immunomodulation denotes any change in the immune response and may 
involve induction, expression, amplification or inhibition of any part or phase of 
immune response. Stimulation of immune response is required in certain patients 
whereas suppression of immune response is mediated in other conditions. Novel 
immunomodulatory agents are used for the treatment of various conditions such as 
cancer, rheumatoid arthritis, organ transplantation, infections etc.  
 Immune response requires timely interaction of multiple cell types and its 
modulation aims to restore immune homeostasis and one of the proposed targets for 
immune homeostasis is the balance between Th1 and Th2 activity and many T-cell 
directed therapies have provided modest clinical benefits. Modulation of Th1/Th2 
immunity is emerging as one of biological targets for such immunostimulants 
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(Patwardhan et al., 2005).  
It is suggested that Th1 and Th2 cells are important regulators of immune 
response and immune regulation involves homeostasis between Th1 and Th2 activity. 
This hypothesis of Th1 / Th2 balance which arose in 1986 has been considered to 
regulate the humoral and cell mediated immune responses and hence coordinates the 
entire immune system (Kidd, 2003). 
Th1cells have been found to lead the attack on intercellular pathogen, raise classic 
delayed type hypersensitivity skin response to bacterial and viral infections. Th2 cells 
have been considered to provide protection against extracellular pathogens such as 
multicellular parasites. These cells secrete a wide range of interleukins, which 
stimulate proliferation of B cells, and stimulate antibody production. Th1 cells secrete 
cytokines, for example IFN-γ, which improves the killing efficiency of macrophages, 
and also improves the proliferation efficiency of cytotoxic T-cells (McGuirk et 
al.,2002). It has been reviewed that the Th1 pathway is often portrayed as being the 
more aggressive of the two, and apparently, whenever it is over reactive, it can lead to 
organ-specific autoimmune diseases such as arthritis, multiple sclerosis, Type-1 
diabetes. (Abbas et al.,1996). The Th2 pathway is seen to accompany allergy and 
related IgE based diseases and involves predisposition to autoimmune disease (Dent 
et al., 2002). 
 Reciprocal inhibition of Th1 and Th2 cells 
A Th1 response inhibits the Th2 path by secretion of cytokines., IFN-γ and IL-
12 which inhibit the formation of Th2 cells. IFN-γ also inhibits class-switching in B 
cells. On the other hand, a Th2 response inhibits the Th1 path by production of IL-4 
cytokine which suppresses Th1 cell activation and proliferation (Romangani et 
al.,2000). 
 Arthritis –Th1 driven disease 
RA has been considered to involve mainly the Th1 cells which are reactive 
against self antigens. There is evidence, that all individuals carry such auto reactive 
Th1 cells but in healthy people they are kept silent by natural regulatory mechanisms. 
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Th1 cells have a penchant for displaying auto antigenic fragments of the normal T-
cell receptor (TCR) on their surface. According to the Th1/Th2 hypothesis this can be 
sensed by Th2 cells, as signals and they release Th2 cytokines mainly IL-10 which in 
turn down-regulates auto reactive Th1 cell activity. Also a decreased prevalence of 
allergic diseases, which is a Th2-dominant condition, has been reported in RA 
patients (Schulze-Koops et al., 2001). In addition, it has been demonstrated that in 
75% of RA patients, pregnancy was found to ameliorate the progression of RA and 
also improves the symptoms of RA (DaSilva et al.,1992). This has been attributed to 
diminished Th1 activity during pregnancy.  
2.4 Biochemical mediators of inflammation and arthritis 
 Inflammation is physiological response of the organism to different stimuli 
such as trauma, infection or immune reactions. A variety of biochemical mediators act 
in concert to initiate and perpetuate the inflammatory reaction in arthritis. The major 
biochemical mediators include cyclooxygenase (COX), lipoxgenase (LOX), matrix 
metalloproteases (MMPs), nitric oxide synthases (NOS), tissue inhibitors of 
metalloproteases (TIMPs), prostaglandins (PG), leukotrienes (LT) and nitric oxide 
(NO). These mediators act via different interconnected pathways resulting in arthritic 
inflammation. 
2.4.1 Cyclooxygenase (COX) and prostaglandins (PG) 
 Cycloxygenase (COX) is known to be a biosynthetic enzyme responsible for 
conversion of arachidonic acid (AA) to prostaglandins. COX converts AA into 
prostaglandin H2 (PGH2), which is further catalyzed by distinct synthases into 5 major 
bioactive prostaglandins {PGE2, PGI2, PGF2 and PGD2} and thromboxane A2 
(TXA2).Cycloxygaense basically has two isoforms; COX 1 and   COX 2. It is well 
known that COX 1 is a housekeeping enzyme present in most cells and its expression 
is generally constitutive. In contrast, COX 2 is an inducible enzyme of cancer, 
inflammation. Its expression is low and undetectable in most cells but upon 
stimulation by cytokines, endotoxin, tumor promoters, growth factors etc. the 
expression of COX 2 expression is dramatically up regulated at sites of inflammation 
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(Vane et al., 1998).  In case of osteoarthritis, COX-2 expression is induced in the 
cartilage and in rheumatoid arthritis it is induced in the synovial tissue (Amin et 
al.,1997).  In many animal models of RA, increased prostaglandin production in 
inflamed joint tissues has been associated with increased expression of COX-2 
(Anderson et al., 1996). The earliest prostanoid production is dependent on COX-1 
isoform but as the inflammatory process progresses, COX-2 becomes a major source 
of prostanoids. 
 PGE2, a potent contributor to the pathogenesis of RA causes vasodilatation 
and recruits neutrophils to the affected joints in RA  through the production of  IL-23-
induced IL-17 and the impaired production of IL-12 and IFN-γ production (Chizzolini 
et al., 2008). Moreover, PGE2 mediates matrix degradation and cartilage destruction 
(Miwa et al.,2000). It also stimulates the production of vascular endothelial growth 
factor (VEGF) and mediates angiogenesis leading to edema (Akaogi et al., 2006). In 
addition, the effects of IL-1, IL-6 and TNF-α on bone resorption have been shown to 
be dependent on PGE2 (Yano et al., 2001). 
2.4.2 Lipoxygenases (LOX) and leukotrienes (LTs) 
 Lipoxygenase (LOX), another important mediator of inflammation constitutes 
a group of non-heme iron-containing dioxygenases ., 5-LOX, 12- LOX, and 15-LOX. 
In mammals, LOX enzymes convert arachidonic acid to leukotriene A4 (LTA4) which 
is then converted enzymatically to bioactive leukotrienes (LTs)., LTB4, or LTC4, 
LTD4 and LTE4. 5-LOX is especially known to play a vital role in the pathogenesis of 
RA (Mathis et al., 2007) whereas 12-LOX and 15-LOX represent major anti-
inflammatory enzymes which regulate the course of inflammatory joint disease 
(Kronke et al.,2009). LTB4 is considered as the most potent chemotactic agent and 
mediates the infiltration of leukocytes into the RA joint. It stimulates several 
leukocyte functions related to inflammation for example, aggregation, release of 
lysosomal enzymes and production of superoxide anion. In addition, it induces the 
formation of suppressive and cytotoxic T-lymphocytes (Peter-Golden et al.,2008). 
LTB4 is also reported to induce the production and release of cytokines for example 
TNF-α and IL- 1β and also activates neutrophils to release superoxides and 
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proteolytic enzymes, which in turn cause matrix destruction (Marcoullier et al.,2005). 
In view of these properties, inhibitors of leukotriene synthesis are thought to possess 
therapuetic potential for treatment of arthritic and inflammatory diseases (Ammon et 
al.,1992).  
 
 
Figure 2.3 Biosynthesis of inflammatory mediators., eicosanoids (PGE2 and LTB4) 
from Arachidonic acid. 
 
2.4.3 Nitric oxide (NO) 
 Nitric oxide (NO) is a highly reactive free radical that has been implicated in 
tissue injury in rheumatoid arthritis and osteoarthritis. NO is a small molecule that is 
synthesized by a family of enzymes in mammalian cells during the conversion of     
L-arginine to L-citrulline. This reaction is catalyzed by one of three isoforms of nitric 
oxide synthase (NOS). Two of the NOS enzymes, namely endothelial NOS and 
neuronal NOS, constitutively produce relatively low levels of NO. The inducible 
isoform, inducible NOS (iNOS) when activated is expressed for a longer period of 
time (Grabowski et al., 1996). It is activated by a variety of factors such as the 
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cytokines, microbial products (e.g., endotoxin), immune complexes, and others. NO is 
reported to induce the production of cytokines such as TNF-α, IL-1β and IFN-γ, as 
well as collagenase  in arthritis patients (Wienberg et al.,2007). In addition, NO also 
stimulates the synthesis of matrix metalloproteinases (MMPs) and reduce the 
anabolism of cartilage by inhibiting the synthesis of the major matrix components, 
collagen and proteoglycans. In RA, several cell types in the synovium produce NO for 
example osteoblasts, osteoclasts, macrophages, fibroblasts, neutrophils and 
endothelial cells.However, macrophages and chondrocytes are found the most potent 
contributors (Stadler et al., 1991). 
 It has been observed that in arthritis patients levels of NO are elevated in 
serum and synovial fluid and the serum nitrite concentration is found to be correlated 
with disease activity or radiological progression in RA. Moreover, decreased 
production of NO via suppression of iNOS has been reported to reduce the arthritic 
symptoms and also afford protection against the loss of body weight. This suggests 
that overproduction of NO is critical in the pathogenesis of RA (Nagy  et al., 2007). 
Recently it was also shown that T cells from RA patients produce more than 2.5 times 
more NO than healthy donor T cells (Nagy et al., 2010) . 
2.5 Association of Free Radicals with RA 
 Reactive oxygen species (ROS) and reactive nitrogen species (RNS) are 
produced endogenously during aerobic metabolism and at the site of chronic 
inflammation. In the pathogenesis of RA, ROS such as super oxide radical, hydroxyl 
radical and hypochlorous acid have been reported to contribute significantly to tissue 
injury (Mirshafeiy et al.,2008). Several mechanisms are involved in the generation 
and action of ROS in the joint of RA patient which include increased pressure in 
synovium cavity, reduced capillary density, vascular changes and increased metabolic 
rate of synovial tissue. In addition activated leukocytes also produce ROS (Fay et 
al.,2006). Super oxide radical and hydrogen peroxide do not directly damage the 
majority of biomolecules in the joint but they are converted into the highly reactive 
hydroxyl radicals (OH), which react with almost all molecules in living cells. Patients 
with RA have been reported with significant decrease in vitamins E and A levels that 
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in turn increases oxidative stress. Oxidative stress further exacerbates inflammation 
and worsens joint tissue damage (Tak et al.,2004). Similarly, activities of enzymes 
like glutathione reductase also get disturbed in the synovial fluid. Thioredoxine, 
which is a marker of oxidative stress is also significantly elevated in the synovial fluid 
(Alorainy et al.,2008). 
2.6 Cytokines in Rhuematoid Arthritis 
 Cytokines produced by inflammatory cells play a pivotal role in synovial 
inflammation and joint destruction in rheumatoid arthritis. The progression and 
chronicity of arthritis is associated with sustained production of inflammatory 
cytokines and dysregulation of anti-inflammatory cytokines (Kokkonen et al., 2010). 
            The most abundant cytokines promoting inflammatory responses are TNF-α, 
IL-1β and IL-6. TNF-α is considered to be a hallmark cytokine in the pathogenesis of 
RA. The importance of TNF-α was reflected by the spontaneous development of 
arthritis in TNF-α transgenic mice that over expresses a modified human TNF-α 
transgene (Keffer et al.,1991). TNF-α induces the production of other pro 
inflammatory cytokines, activates polymorphnuclear cells and enhances cartilage 
breakdown (Zwerina et al.,2005) and also regulates the expression of IL-1β (Petrovic-
Rackov et al.,2006). Together IL-1β and TNF-α play an important role in the 
communication among the many cells in the rheumatoid joint.These cytokines up-
regulate the expression of CAMs on endothelial cells, thereby direct the emigration of 
blood cells from the circulation into the synovium (Proudman et al.,1999). They also 
stimulate the production of chemokines, which provide important signals for the 
process of cell infiltration.IL-1β is  considered to be the key mediator with regard to 
cartilage and bone destruction (Joosten et al.,1999).IL-1β along with TNF-α 
stimulates synoviocytes and chondrocytes to release MMPs and other proteinases and 
also up-regulates the expression of pro-inflammatory genes, including 
cyclooxygenase-2 and nitric oxide synthase (Dayer et al., 1986). IL-1β has been 
readily detected in serum of RA patients and its levels are found to correlate with 
disease severity (Eklund et al., 2007). It has been observed that mice that are deficient 
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for the IL-1β receptor antagonist, a naturally occurring counter regulatory cytokine, 
develops a spontaneous inflammatory arthritis (Horai et al., 2008). 
 Interleukin (IL)-6 is a pleiotropic pro-inflammatory cytokine that induces 
osteoclast differentiation and contributes for joint destruction in RA.IL-6 is found to 
act as a growth factor for T cells and also enhances B cell proliferation and 
subsequent antibody production (Gabay et al., 2006).  
 Cytokines, such as IL-4, IL-10 and IL-13, function mainly as anti-
inflammatory molecules. Although anti-inflammatory cytokines are present in 
rheumatoid joints however in progressive RA their levels are too low to neutralize the 
deleterious effects of pro-inflammatory cytokines (Isomaki et al.,1997). 
 Interleukin (IL)-4 is T-cell-derived cytokine that can exert either suppressive 
or stimulatory effects on different cell types. IL-4 is produced by activated CD4
+
 T 
cells and it promotes the maturation of Th2 cells and inhibits the differentiation of 
naïve T cells to Th1 cells (Fiorentino et al.,1989). IL-4 stimulates proliferation, 
differentiation or activation of several cell types, including fibroblasts, endothelium 
cells and epithelium cells (Chomarat et al.,1997). It is known to be a potent anti-
inflammatory cytokine that acts by inhibiting the synthesis of pro-inflammatory 
cytokines such as IL-1β, TNF-α, IL-6, IL-8 and IL-12 by macrophages and  
monocytes (El-Kady et al.,2008). Moreover, IL-4 stimulates the synthesis of several 
cytokine inhibitors such as interleukin-1 receptor antagonist (IL-1Ra). In addition it 
exerts protective effect towards extracellular matrix degradation by suppressing 
metalloproteinase production and stimulating the production of tissue inhibitor of 
metalloproteinase-1 in human mononuclear phagocytes (Cawston et al.,1996).In 
addition, IL-10 and IL-13 inhibit the production of a wide range of pro-inflammatory 
cytokines in monocytes/macrophages, B cells, natural killer cells and endothelial cells 
(Isomaki et al.,1997). 
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2.7 Treatment  
 The treatment of rheumatoid arthritis (RA) has gone through many major 
changes in the past 100 years. Historically, it was essentially untreatable and many 
patients like the French impressionist painter, Renoir had to live with the ravages of 
the disease through sheer courage and determination. A number of modern therapies 
and drugs are now employed for the treatment of arthritis.  
 Symptom-modifying anti-rheumatic drugs (SMARDs) are widely used to 
control symptoms of rheumatoid arthritis. Analgesics are used to reduce pain, and 
non-steroidal anti-inflammatory drugs (NSAIDs) including traditional or non-
selective NSAIDs as well as selective cyclooxygenase-2 (COX-2) inhibitors are used  
to lessen pain and stiffness  in arthritic patients (Schaffer et al., 2006) . 
 NSAIDs are placed into three categories with respect to inhibition of COX-1 
and COX-2 enzymes: conventional, non-selective NSAIDs which either preferentially 
inhibit COX-1 or inhibit COX-1 and COX-2, both at about the same plasma 
concentration; COX-2-selective NSAIDs, which preferentially inhibit COX-2, but at 
higher therapeutic concentrations can also inhibit COX-1 and COX-2-specific 
NSAIDs, which even at higher therapeutic concentrations inhibit only COX-2 and 
spare COX-1 (Gierse et al.,1995).Traditional NSAIDs have been reported to cause 
several adverse effects, the most important being gastrointestinal toxicity and renal 
damage. Such undesirable side-effects of NSAIDs have been attributed to the 
inhibition of constitutive isoform of cycloxygenase enzyme, COX-1. Treatment with 
traditional NSAIDs is often prescribed with gastro protective agents or a combination 
therapy is accompanied. At the turn of this century two new highly selective COX-2 
inhibitors, known as Coxibs (celecoxib and rofecoxib) were introduced both of which 
were claimed to have low gastrointestinal (GI) side effects. Coxibs were found to 
spare COX1 and so enhanced the safety profile in the gastrointestinal tract, but on the 
other side increased the risk of heart attack and stroke. In 2004, rofecoxib was 
withdrawn worldwide because of serious cardiovascular events (Rainsford et 
al.,2007) . 
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 Dual inhibitors of cyclooxygenase and 5-lipoxygenase - A new avenue in anti-
inflammatory therapy 
 Dual inhibition of cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX) 
emerged as a new strategy to provide safer non-steroidal anti-inflammatory drugs. 
Such drugs inhibit 5-LOX, COX-1 and COX-2 simultaneously leading to decreased 
production of LTs and PGs. 
  
 
Figure 2.4 Biological effects and side effects of COX1/2 and 5-LOX 
inhibitors used to treat Rheumatoid Arthritis. 
 
 Such drugs have the potential to provide anti-inflammatory and analgesic 
effects with a reduction in the GI side-effects associated with the use of COX enzyme 
inhibitors. These dual acting anti-inflammatory drugs therefore, though retain the 
activity of classical NSAIDs but alleviate symptoms of rheumatic diseases without 
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any deleterious effects (Aracio et al., 2007). Some dual inhibitors have also been 
reported to show specific protective activity in neuro degeneration. Limbrel and 
licofelone are some of the examples of such drugs presently in market. 
 The fundamental goal of RA treatment is to eliminate synovitis and disease 
activity (Kremer et al.,2001). Although low dose glucocorticoids has been widely 
used to suppress signs and symptoms of inflammation for more than 60 years but the 
use has been associated with uncertainty  due to severe side effects of its long-term 
therapy limiting their usage . 
 Disease-modifying antirheumatic drugs such as hydroxychloroquine, 
cyclosporine, azathioprine, D-penicillamine, auranofin, and intra muscular gold have 
been the only choices for RA treatment for many years with the abilities to reduce 
joint swelling, pain, decrease acute-phase markers, limit progressive joint damage, 
and improve function. However, there is no evidence that such treatments alter the 
course of RA (Fries et al.,1986). Moreover these drugs are associated with 
considerable toxicity which makes careful patient monitoring necessary. Major 
toxicity includes gastrointestinal upset, oral ulceration and liver function abnormalities 
that appear to be dose related and reversible and hepatic fibrosis that can be quite 
insipidous (Park et al., 2010). 
 
 
 Targeted Therapy – Chance of a Cure? 
 The advances made in the understanding of autoimmunity led to identify new 
targets for therapy including biological anti-rheumatic agents  which specifically 
target cytokines and their receptors, B cells, T-cells and have  become one of the 
major advances in the treatment of inflammatory arthritis. TNF-α blocking agents 
(etanercept, infliximab) are found to be remarkably effective at controlling signs and 
symptoms of RA in patients where DMARD therapy has failed (Beavers et al., 2010). 
Inhibiting TNF-α may produce very effective control of the disease but it does not 
constitute a cure, since the disease returns after a variable interval when treatment is 
stopped (Bongartz et al., 2006). In a substantial proportion of patients, the disease 
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progresses even if treatment is sustained. Other approaches including following 
biological agents have been shown to be effective: 
 interleukin 1 (IL-1) blockers — anakinra (ANA)  
 monoclonal antibodies against B cells — rituximab (RTX)  
 T cell costimulation blocker — abatacept (ABT)  
  interleukin 6 (IL-6) blockers — tocilizumab (TCZ)  
 
 Although these agents are much more effective than the older DMARDs in 
reducing symptoms, none of these newer agents achieve a permanent drug-free 
remission and reducing joint damage and preventing functional disability. They have 
been shown to be maximally effective in patients who are refractory to conventional 
DMARDs. Many are associated with side effects which include potential for 
increased risk of infections and development of anti–DNA antibodies (Botsios et al., 
2005). 
2.8 Herbal Medicines: Potent Therapeutic Agents for Rheumatoid 
Arthritis.  
 Conventional (allopathic) anti-inflammatory drugs are the mainstay of 
treatment for rheumatic diseases. However in wake of the side effects and the high 
cost of conventional therapy; people of late have increasingly started exploring 
alternative measures to treat the disease. Commonly used alternative approaches 
include dietary modifications, nutritional supplements and botanicals. These 
alternative treatments have been used both, as adjunct and an alternative to 
conventional therapy.  
 Herbal medicine provides a strong foundation for such alternative modalities 
of treatment (Soeken et al.,2003). Traditional Chinese medicine, Ayurvedic medicine, 
Kampo, and Homeopathy are among the major contributors to the herbal products 
consumed by arthritic patient populations. India, along with its wealth, is rich in wide 
variety of medicinal plants with a large number of popular remedies many of which 
are in common use even today. More than 2000 plants of medicinal value are 
mentioned in Indian ancient Ayurvedic, Unani and Tibbi systems of medicine (Ernst 
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et al., 2000). In Ayurveda alone which is the oldest medical system in the Indian sub-
continent, approximately 2000 medicinal plant species have been reported. Some 
corroborative plants generally known as Raysana Drugs in Ayurveda are known to 
prevent ageing, increase longevity and offer resistance to disease by augmenting 
immune system. Some other plants like Ashwagandha are widely used as a remedy 
for several ailments and used as ingredients in many formulations précised for a 
variety of musculoskeletal conditions, improving health and longevity, prevention of 
disease in athletes, pregnant women and elderly (Ayurvedic herbal pharmacopeia, 
1987, Patwardhan,2005). Similarly several Indian plants are also being used in Siddha 
and Unani systems of medicine. These traditional knowledge systems have started to 
disappear with the passage of time due to scarcity of written documents and relatively 
low income in these traditions. Over the past few years, however the medicinal plants 
have regained a wide recognition due to an escalating faith in herbal medicine in view 
of its lesser side effects compared to allopathic medicine (Patwardhan and Gautum, 
2005).  
 The demand for medicinal plants based drugs is growing at the rate 15% to 
25% annually and according to an estimate of WHO, the demand for medicinal plants 
is likely to increase more than 5 trillion US Dollar in 2050. In India, medicinal plants 
related trade is estimated to be a approximately 1 billion US Dollars per year (Kala et 
al., 2004). 
 A number of plants with traditional knowledge of immunomodulatory and 
anti-arthritic efficacy have been studied world over and their usages have been 
validated. Newer activities have been assigned to them and many have been 
transferred to other regions where their potential is being explored, tested and utilized. 
Some of the examples are: 
The roots of Aralia continentalis (Araliaceae) have been used in Chinese 
medicine to treat inflammatory disorders including rheumatism, lumbago and 
lameness (Perry, 1980). Several constituents of roots of Aralia continentalis also 
possess anti-inflammatory activity in vitro and in vivo. The methanol extracts and 
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dichloromethane fractions of the plant are also reported to inhibit IL-8 production by 
LPS treated peritoneal macrophages (Lim et al., 2009).  
Another Chinese herbal medicine Gentiana macrophylla, family Gentianaceae 
(also called as Qin Jiao) has been used for ages in the treatment of diabetes, paralysis 
and rheumatism. It has been reported that roots of Gentiana exhibit anti-inflammatory 
effect in RA patients, which is quite comparable to Prednislone, the conventional drug 
used to treat RA (Yu et al., 2004). 
 Another plant Shiraia bambusicola has long been utilized in the treatment of 
RA in Chinese folk medicine The active component of this plant, Shiraiachrome A, 
has been found to significantly inhibit  the  proliferation, migration  and angiogenesis 
in diseased synovium in arthritis (Tong et al.,2004) 
The chloroform extract of Byonia lacemonia has been reported to exhibit 
significant anti- inflammatory activity in acute and chronic models in rats. It belongs 
to the family of Cucurbitacea readily distributed in India, Philippines and some parts 
of Africa (Gupta et al., 2003). 
Turbinaria ornata, a kind of brown algae widely distributed in South-east 
coast of India is reported to have potent in vivo anti-inflammatory activity. It showed 
inhibition of NO and carrageen induced paw oedema (Ananthi et al., 2009).Similarly 
the extracts of aerial parts of Zataria mulleflora have shown anti-inflammatory effects 
against acute and chronic inflammation in mice and rats (Hosseinzadeh et al., 2000). 
Semecarpus anacardium is a deciduous tree distributed in Sub-Himalayan 
tract and in tropical parts in India. The nut milk extract of this plant  is reported to 
have a potential protective immunomodulatory effect on  humoral and cell mediated 
immune responses, it was found to  significantly reduce TNF-α and NO levels  and 
has exhibited  potential  anti-inflammatory effects in xylene induced ear oedema  
(Ramprasanth et al., 2006). 
Swertia chirayita, a herb found abundantly in the temperate regions of 
Himalaya, is commonly used for chronic fever, anemia and asthma. Chirayita is 
reported to reduce the elevated levels of IL-1β, TNF-α and IL-6 (pro-inflammatory 
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cytokines) in experimental arthritis as well as in asthmatic conditions (Kumar et al., 
2003). 
Nyctanthes arbortristis Linn. also called Harshingar has been used widely as a 
decoction for the treatment of arthritis and sciatica in Indian ayurvedic system of 
medicine since centuries. Water soluble ethanolic extract of its leaves has been 
reported to reduce significantly the levels of inflammatory cytokines (IL-1β, TNF-α) 
in experimental arthritis (Paul et al., 1997). 
Crocus sativus commonly called Saffron (Iridaceae) is commonly used as folk 
medicine for various purposes. Commonly cultivated in the Kashmir  and ranges to 
Northern America, Greece and Spain. Saffron stigma has been reported to possess 
anti-inflammatory action due to presence of its components, crocetin and carotenoids. 
Aqueous and ethanolic extracts of saffron petals have been shown to exhibit anti-
inflammatory effects in xylene and formalin induced inflammation and selective Th1 
up regulating activity in Balb/c mice (Hosseinzadeh et al., 2002). 
Withania somnifera plant has been reported to be immunoprotective and 
immune adjuvant. Treatment with root aqueous extract of this plant is reported to 
have significantly increased the CD4
+
 and CD8
+
 T-cells and has exhibited significant 
Th-1 up regulating activity (Bani et al., 2006). 
Glossgyne tenufolia which is native to Taiwan has been reported to inhibit 
production of pro-inflammatory mediators, TNF-α and NO in LPS activated 
macrophages; olenic acid and luteolin-7-glycoside are its major constituents (Ha et 
al., 2006). 
 In the valley of Kashmir, a number of medicinal plants have been traditionally 
used in managing arthritic disorders but their efficacy claims and mechanistic actions 
have not been tested specifically. This evaluation forms the basis of the present study. 
The traditional medicinal plants used in our present study are as follows: 
 Atropa accuminata 
 Ajuga bracteosa 
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(I)Atropa accuminata. Royle ex.Lindl 
         Botanical description 
 (a) Taxanomic classification  
Kingdom : Plantae 
Phylum :Tracheophyta 
Class :Magnoliopsida 
Subclass :Asteridae 
Superorder :Solananae 
Order :Solanales 
Family: Solanaceae 
Genus: Atropa 
Species: accuminata-Royle* 
 
 (b) Vernacular names: 
 English : Indian Belladona  
 Kashmiri: Mait Brand 
 Hindi : Jharka, Shafoo 
  Urdu :Rubluffah 
  Dogri :Angurshafa 
 
*As published in Royle ex Lindl. Publication: in Journal of  
Horticultural Society of London., 306 (1846) 
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(I)  Ajuga bracteosa. Wall ex.Benth  
         Botanical description 
 (a) Taxanomic Profile  
Kingdom : Plantae 
Phylum :Tracheophyta 
Class :Magnoliopsida 
Subclass :Lamiidae 
Superorder :Lamianae 
Order :Lamianae 
Family: Lamiidae 
Genus: Ajuga 
Species :bracteosa-Benth# 
 
 (b) Vernacular names: 
English : Bungle 
Kashmiri :Jan-i-adam 
Hindi :Koribooti 
Sanskrit :Neelkanthi 
Punjabi :Khurbanti 
 
# As published in Benth. Publication: Pl. Asiat. Rar.(Wallich). i. 59. 
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2.6.1 Atropa accuminata  
 The genus Atropa consists of four species distributed in the Mediterranean 
region, South Europe and Asia (Wealth of India, 1952) of these Atropa belladonna 
has long been used as a reputed drug in Europe but its properties do not seem to have 
attracted the attention of Indian systems of Medicine. The species of this genus found 
in Indian sub- continent is Atropa accuminata Royle ex Lindl. 
Atropa accuminata Royle  ex Lindl. belongs to the family Solonaceae and is a 
tall perennial sub-alpine plant. In the Indian sub-continent, it is widely distributed 
across North-western Himalayas, Muzazafarabad and Chakrata (Dhar and 
Kachroo,1983). It is commonly known as Indian belladonna. In Kashmir, the plant 
grows wild in Apharwat area of Gulmarg, Freozpur and Thajwass glaciers of 
Sonamarg in the valley of Kashmir. It is a straight plant about 3-5 inches high with 
yellow bell shaped flowers. The fruit is a purple black berry of the size of a cherry 
(Wealth of India, 1952). 
It has been abundantly been used as a folklore medicine and has an immense 
medicinal value. In Kashmir, the rhizome of A.accuminata has been used since ages 
in traditional system of medicine for the treatment of arthritis related inflammatory 
disorders, muscle and joint pain, muscle spasms (Kaul, 1997, Wealth of India, 1952). 
In addition, the aerial parts of this plant have been used  to treat innumerable ailments 
such as muscle and joint pain, inflammation, arthritis, pancreatitis,  peritonitis, scarlet 
fever, parkinsons disease and neuorodisorders (Kahn et al.,1991; King et al.,1966) 
acute infections, anxiety, asthma, chicken pox (Bergmans et al.,1987; Kumar et 
al.,1997), conjunctivitis, fever ,encephalitis, fever (Ceha et al.,1997; Duncan  et 
al.,2003). The roots of the plant has been used as sedative (Rhodes et al., 1978) and 
also against sore throat, ulcerative colitis (Shanafelt et al.,2002), whooping cough 
(Walach et al.,2001).It has also been used externally as leminent to relieve 
neurological pain (Kaul,1997). 
Chemically A.accuminata has been found to contain tropane alkaloids and 
highly ogygenated triterpenes (Mehmood et al.,2002). Previously these alkaloids have 
                                                                                                                                                                                                                                                                                                                                                                                                 
Review of literature 
 
- 34 - 
 
been    found   to have anti-cholinergic and anti-spasmodic activity and have been 
used as an antidote for poisoning (Tyler et al., 1988).  
2.6.2 Ajuga bracteosa 
 Ajuga bracteosa Wall ex Benth. is a perennial herb, belonging to the family of 
Labitacea of the genus Ajuga. It comprises of about 50 species distributed in Pakistan, 
Arabia, East Africa and North America. It is distributed in subtropical and temperate 
regions from Kashmir to Nepal in Western Himalaya and also in Pakistan, 
Afghanistan, China and Malaysia (Ali and Nasir, 1990, Kirtikar and Basu, 1918). In 
Pakistan, it is found in northern hilly areas, where in local Punjabi language it is 
called koribooti owing to its bitter taste. A.bracteosa is found on rock crevices as an 
erect or ascending hairy herb. The flowers are white or purplish-violet tinged from 
lower surface in distant, axillary whorls in spikes. 
 Ayurveda describes Ajuga bracteosa as ―Neelkanthi‖ and is a rich medicinal 
herb used since ages in traditional medicine for the treatment of gout, rheumatism and 
various neuro inflammatory disorders (Wealth of India, 1985). It also has been used 
traditionally in a variety of inflammatory disorders (Indian herbal pharmacopeia, 
1998). Also the leaves of A.bracteosa have been used as stimulant, diuretic, astringent 
and febrifuge (Ali and Nasir,1990).The juice of the plant is applied as hot 
fermentations against carcinomas and also plastered on burns and insect bites. Even 
the seeds of the plant are used to relieve stomach ache and diarrhoea (Perry and 
Metzger, 1980).In India it has also been used for long as a traditional remedy for 
malaria (Chandel & Bagai, 2010). In Taiwan also A.bracteosa has been used 
traditionally for treatment of various inflammatory disorders such as hepatitis, 
pneumonia and bone diseases (Chiu & Chang, 1992).
  
Various other species of this 
genus have also been used as analgesics to dissolve blood clots and to relieve fever, 
diarrhoea, eye problems and diseases of the bladder. Another member of this genus 
Ajuga ducumbens has been used in China for relief of joint pain and has been reported 
to upregulate synthesis of collagen in aged model rats (Ono et al.,2008). 
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 Chemically Ajuga bracteosa contains sphingolides, bractic acid, diterpenoids 
and withanoloides which have been found to have various enzyme inhibiting activities 
such as that of Lipoxygenase and cholinesterase (Riaz et al.,2007). Many higher 
plants of Ajuga species are also known to produce considerable amounts of 
ecdysteroids, neoclerodane, diterpenes and other secondary plant metabolites (Lafont 
et al.,1998).Whole plant ethanolic extract of Ajuga bracteosa using phytochemical 
studies has been reported to exhibit three withanolides namely Bracteosin A, B, C; 
these have been isolated and their structure elucidated (Naheed et al.,2007,Narendra 
et al.,2006).  
 Previously A.bracteosa has been credited with cancer chemopreventive 
(Ghufran et al., 2009), anti-plasmodial (Chandel & Bagai, 2010), cardiostimulant 
(Patel   et al., 1962) and hepatoprotective (Hsieh et al.,2011) properties. 
 Plants contain a variety of organic compounds including fatty acids, sterols, 
alkaloids, flavanoids, glycosides, saponins, tannins, terpenes etc. Medicinal plants 
therefore present a large source of structural novel compounds that might serve leads 
for the development of novel drugs. These drugs provide substantial potential for 
treatment of human ailments.  
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3.1.1 Chemicals: 
 Fluorescein isothiocyanate (FITC)-labeled anti-CD4 mouse monoclonal 
antibody; Phycoerytherin (PE)-labeled anti-CD8, IL-2, IFN-γ and IL-4 mouse 
monoclonal antibodies; FACS lysing solution (BD Biosciences, USA); 
Cyclophosphamide, levamisole, E.coli polysaccharide (LPS), Concanavalin A (Con A) 
(Sigma–Aldrich, India); Gum acacia (Hi Media, India). Unless otherwise specified, all 
other chemicals were purchased from Hi Media  and Merck and all solvents used were 
of HPLC grade (Ranbaxy Chemicals Ltd., Mohali , Punjab, India). 
3.1.2 Test material: 
 Atropa accuminata (whole plant) was collected from the higher reaches of 
Kangdoori, Khilanmarg, Afarwarth areas of Gulmarg and Thajwas glaciers of 
Sonamarg. Ajuga bracteosa (whole plant) was collected from Ferozpur and Drang areas 
in Kashmir. The site and location of plant collection is given in Table 3.1. The plants 
were correctly identified by Centre of Biodiversity and Toxonomy, University of 
Kashmir, Srinagar, India and authenticated by a botanist, Dr. Irshad Wanchoo. A 
voucher sample is retained and deposited at Central Herbarium, Department of Botany, 
University of Kashmir, India as 1758 KASH (16/05/2009) [Atropa acumminata] and 
1760 KASH (26/06/2010) [Ajuga bracteosa]. The material was ensued to be free from 
pathogens, aflatoxins, pesticidal residues and heavy metals according to guidelines of 
WHO, 1998. 
3.3 Preparation of extracts:  
 The authentically identified whole parts of plant material were shade dried and 
then powdered. About 1.6 kg of Atropa accuminata and 1.2 kg of Ajuga bracteosa 
were each subjected to Soxhlet extraction separately with absolute ethanol (EtOH). The 
solvent was removed under reduced pressure on a vacuum rotary evaporator to get a 
darkish green extract for A.accuminata referred from here as AAEE (yield: 32.2 %). 
and dark brownish A.bracteosa referred as ABEE extract (yield: 39.2 %). The crude 
extract was stored at 4°C for experimental use. Both the extracts were studied at  doses 
ranging from 6.25 to 100 mg/kg/b.w. and the test materials for experimentation were 
prepared as fresh suspensions each time using 1%  sterile gum acacia.  
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Table 3.1.1: Site and location of plant collection 
S.No 
Collection 
site 
Altitude 
(m) 
Latitude 
longitude 
Distance 
from 
Srinagar
(km) 
Direction 
with 
respect to 
Srinagar 
1 Ferozpur 2125-2150 
34° 04  N 
74° 20  E 
50 North West 
2 Gulmarg 2310-2650 
34° 04  N 
74° 20  E 
63 North West 
3 Khilanmarg 2900-3100 
34° 04  N 
74° 20  E 
65 North West 
4 Sonamarg 2750-3100 
34° 04  N 
75° 30  E 
91 North East 
5 Apharwat 3100-3300 
34° 04  N 
74° 20  E 
75 North West 
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3.1.4 Animals: 
 All experimental procedures used in the present study were in accordance with 
institutional guidelines for animal research (CPCSEA, 2003). The study was conducted 
on male Balb/c mice obtained from healthy animal colony at the Department of 
pharmacology, Indian Institute of Integrated Medicine (IIIM), Jammu. Balb/c mice 
(male, 3-4 weeks old, weighing 18-22gms) were randomly distributed in groups as per 
experimental protocols (n=6). The animals were bred and maintained under standard 
laboratory conditions; temperature (25°C), humidity (55.6±10%) and regulated 
photoperiod of 12h hours. Standard laboratory chow (Amrut Mills, Nashik, India) and 
water were given ad libitum. Institutional Animal Use and Care Committee of IIIM, 
Jammu approved all the study protocols. Blood samples were collected through   retro-
orbital bleeding at specified time points, under ether anesthesia and subsequently 
assayed for antibody titers, cell counts and cytokines. 
3.1.5 Effect on general behavior and acute safety:  
 The effect of test extracts on general behavior and safety was evaluated in mice 
using the up and down procedure (Organization of Economic Co-operation and 
Development (OECD), Guideline No. 423, 1996). Mice of either sex (three females and 
three males; weight: 20–25 grams; age: 4–6 weeks) were administered graded doses of 
AAEE/ABEE (single dose) upto 2500 mg/kg orally by gavage. The animals were 
observed for toxic symptoms continuously for the first 4 hours after dosing. Finally, the 
number of survivors was noted after 24 hours and these animals were then maintained 
for a further 13 days with observations made daily. The animals were observed for any 
changes in general behavior, weight, mortality or other physiological activities. 
3.1.6 Drugs: 
 Levamisole (2.5mg/kg b.w) was used as a positive control and 
cyclophosphamide (100mg/kg b.w) as an immunosuppressive agent. They were 
administered orally during the study and prepared fresh in 1% gum acacaia. 
3.1.7 Antigenic stimulus: 
 Fresh sheep red blood cells (SRBC) were collected aseptically in cold Alsevers 
solution from the jugular vein of animals housed at IIIM, Jammu. The cells were 
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washed thrice with sterile pyrogen free normal saline (0.9% NaCl,w/v). For 
immunization and challenge each mouse received 5×10
9
 cells / ml i.p. at required time 
schedule, Day 1 and Day 7. Under our assay conditions, this cell count has been 
reported to induce optimum immune response. 
3.1.8 Treatment: 
 The animals were divided into groups of 6 animals each. Group I, received 1% 
gum acacia (Sensitized control); Group II received Levamisole (2.5 mg/kg b.w) 
(Positive control); Group III; Cyclophosphomide (50 mg/kg b.w) (Negative control); 
Group IV: AAEE/ABEE (6.25 mg/kg b.w.); Group V: AAEE/ABEE (12.5 mg/kg b.w); 
Group VI: AAEE/ABEE (25mg/kg b.w); Group VII: AAEE/ABEE  (50mg/kg b.w); 
Group VIII: AAEE/ABEE (100mg/kg b.w). All the test extracts and standard drugs 
dissolved in 1% guma acacia were administered orally for 14 days in a dose volume of 
0.2 ml. All the groups were given antigenic treatment using SRBC on Day 1 and Day 7. 
3.1.9 Effect of AAEE/ABEE on in vivo SRBC specific humoral immune responses: 
 The estimation of circulating antibody titres was done using standard 
haemaglutination test (Nelson & Mildenhall, 1967). Blood samples were collected in 
micro centrifuge tubes from individual animals by retro-orbital plexus on DAY 7 for 
primary antibody titer and for secondary antibody titer on DAY 15. Serum was 
separated and briefly equal volumes of individual serum samples of each group were 
pooled. Two fold dilutions of pooled serum samples were made in 25µl volumes of 
normal saline in a micro titration plate to which were added 25µl of 1% suspension of 
SRBC in saline. After mixing, the plates were incubated at room temperature for 1 hour 
and examined for haemaggltination titer under the microscope. The reciprocal of the 
highest dilution of the test serum giving agglutination was taken as the antibody titer. 
The mean titer values of the drug and test extracts treated groups were compared of the 
control (Sensitized). 
3.1.10 Effect of AAEE/ABEE on in vivo SRBC specific cellular immune responses: 
 To assess SRBC induced delayed type hypersensitivity (DTH) responses in 
mice, the test extracts AAEE/ABEE and other agents as per the protocol were 
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administered 2 hours after SRBC injection and once daily on consecutive days. On 
DAY 7
th
 SRBC primed mice were challenged and immunized with 20µl of SRBC 
antigen (5×10
9 
cells) in right hind footpad and 50µl of normal saline was given in left 
hind footpad. The difference between left and right paw thickness/swelling of foot was 
measured using speromicrometer (0.01mm pitch) after 24 hours and 48 hours (Bafna & 
Mishra, 2009). 
3.1.11. Splenocyte proliferation assay 
 At 14
th
 day, spleens were removed from mice of the control and the experimental 
groups, under aseptic conditions and then homogenized in complete medium, RPMI 
1640 medium supplemented with 12mM HEPES-buffered. Splenocytes were 
sedimented by centrifugation at 300×3g for 7 min at 4°C; washed and re-suspended in 
RPMI 1640 medium containing 10% heat inactivated FCS, penicillin G (100 U/ml), 
streptomycin (100 µg/ml), amphotericin B (0.25 µg/ml), 2-mercaptoethanol (50 µM), 
2mM L-glutamine (Sigma) and 1mM sodium pyurvate. The cell count was determined 
with a haemocytometer by the Trypan blue dye exclusion technique. Cell suspensions 
(1×10
7
 viable cells/ml/well) were pipetted into 96 well flat bottom plates (Costar, 
Cambridge, MA) and cultured in presence of  Con A and LPS both used at 10 µg /ml as 
B and T cell mitogens, respectively. The plates were incubated for 72 hours at 37°C in 
saturated atmosphere containing   humid 5% CO2 followed by addition of 20µl MTT 
solution (5mg/ml) to each well and incubated for 4 hours. The plates were then 
centrifuged (1400 × g) (5 min). Untransformed MTT was removed carefully and to each 
well 100 µl working DMSO solution (192 µl DMSO / 8 µl 1M HCL ) was added .The 
plates were then read at OD 570 nm after 15 mins to assay the proliferation responses. 
3.1.12 Lymphocyte immunophenotyping: Estimation of lymphocyte percentages   
          (CD4
+
, and CD8 
+
 subsets): 
 The analysis of T-helper subsets namely CD4
+
 (T-helper cells) and CD8
+
 
(cytotoxic cells) was performed using multiparametric flow cytometric analysis on 
peripheral blood. Mouse monoclonal antibodies conjugated to a fluorochrome and 
directed against receptors CD4 and CD8 were used for the study. Briefly, mice from 
different experimental groups were bled at required time schedules and 100 µl of   
whole blood was added to each tube. FITC-Anti CD4 /PE- Anti CD8 monoclonal abs 
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were added directly to the tubes. After mixing and incubating at room temperature for 
30 min in the dark, FACS lysing solution was added. The samples were then incubated 
for 10 min at 37°C and spinned at 300-400g. Supernatant was aspirated and washed 
thrice with phosphate buffer saline (7.4). After washing enumeration of lymphocytes 
subsets was done using flow cytometer (BD, Biosciences) using Cell Quest Pro 
Software (BD, Biosciences). 10,000 events were collected to analyze CD4
+
, CD8
+
 T 
cells. 
3.1.13 Intracellular cytokine estimation: 
 The detection of cytokines was performed in peripheral blood based on BD 
Biosciences protocol end reported method. Briefly, to 100µl of peripheral blood 
collected from the animals CD4
+
 and CD8
+
 monoclonal antibody (mabs) was added. 
The tubes were mixed and incubated at 37 °C in dark followed by addition of FACS 
lysing solution. Subsequently the samples were incubated and centrifuged for 10 min at 
10,000 rpm. Cells were washed, permeabilized and stained with phycoerythrin (PE) 
coupled IL-2, IL-4, IFN-γ mabs. The cells stained were then acquired using flow 
cytometer (BD, Biosciences). Cell quest software (BD, Biosciences) was used for 
gating and calculation. 10, 000 cells were determined with at least 100 cells in every 
gate of lymphocyte subpopulations. The resulting numbers are percentages of cytokine 
expression of those subpopulations.  
3.1.14 Data analysis and statistical considerations: 
 Data is expressed as mean ±S.E.M. Statistical significance of differences was 
assessed by One way ANOVA followed by Bonferroni test for multiple comparisons. 
The level of significance was set at P < 0.05. Percent immunomodulatory activity in 
different experimental groups was derived using following method:  
 
  x 100 
 
 
 
  
 
 
 
 
 
Chapter – 3.2 
Results 
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3.2.1 Effect on normal behaviour and acute safety:  
Groups of animals treated with AAEE and ABEE at all graded doses upto 2500 
mg/kg b.w showed no signs of any abnormal behaviour and no mortality was observed, 
which indicates that the test extracts were well tolerated upto 2500 mg/kg b.w. and 
hence are safe to use. A broad range of oral dosage of  the test extracts (6.25-100 mg/kg 
b.w.) was taken up to get dose response and to determine the dose with most significant 
effect. 
3.2.2. Effect of AAEE / ABEE on antigen specific responses: 
As a first step to study the effect on T-helper (Th) immunity, effect of 
senstization protocol on Humoral and Cell mediated response was established. 
    (A) Humoral responses: 
i) Effect of A.accuminata: 
AAEE when administered orally at 6.25-100 mg/kg b.w. doses produced 
a dose dependent increase in the circulating antibody titers with maximum 
stimulation at higher doses. Under similar conditions, levamisole (positive 
control) resulted in significant increase (41.9%) indicating immunostimulation 
and cyclophophomide (negative control) resulted in significant 
immunosupression with decrease in secondary antibody titers, (−32.25%) as 
compared to sensitized control (Group 1). Our test extract, AAEE also showed 
maximum immunostimulatory action which was observed at 100 mg/kg b.w. 
dose. About 65.5% (P < 0.001) increase in primary and 74.19% (P < 0.001) in 
secondary antibody synthesis was observed at 7
th
 and 14
th
 day of the treatment 
respectively [Table 3.2.1(A)]. 
ii) Effect of A.bracteosa: 
ABEE, on the other hand when administered orally at 6.25–100mg/kg 
b.w. doses also resulted in a dose dependent increase in antibody titers. 
Maximal immunnomodulatory action was observed at 50 mg/kg b.w. dose with 
56.7% increase in primary and 64.2 % in secondary antibody synthesis. 
However when the dose was raised to 100 mg/kg b.w, primary and secondary 
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antibody titers decreased to 26.6 % and 25 % respectively indicating biphasic 
modulatory activity for ABEE [Table 3.2.1(B)]. 
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TREATMENT Doses 
(mg/kg) 
Antibody Response 
Log 2 Titre (Mean ± SEM ) 
( %Change 
DAY 7 Day 15 
Control (sensitized) - 5.8 ±0.26 6 .2 ±0.26 
Levamisole 2.5 7.8 ± 0.20*** 
(34.44 ) 
8.8 ± 0.14*** 
(41.9 ↑) 
Cyclophosphomide 100 4.8 ± 0.18*** 
(17.24↓) 
4.2 ± 0.16 *** 
(32.25↓) 
AAEE 6.25 6.4 ± 0.20 
(10.3↑) 
7.0 ± 0.20
 
(12.9↑)
 
AAEE 12.5 7.0 ± 0.25 * 
(20.6↑) 
7.6 ± 0.30 **
 
(22.6↑) 
AAEE 25 7.6 ± 0.24 *** 
(31.03↑) 
8.6 ± 0.21 *** 
(38.7↑) 
AAEE 50 8.6 ± 0.26 *** 
(48.2↑) 
9.4 ± 0.26 *** 
(51.6↑) 
AAEE 100 9.6 ± 0.14 *** 
(65.5↑) 
10.8 ± 0.14 *** 
(74.19 ↑)a 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TABLE 3.2.1: Immunomodulatory effect of AAEE (A) and ABEE (B) on SRBC induced humoral 
immune response in vivo.  
aHATitres were determined on day 7  for primary antibody synthesis and day 15 for secondary antibody synthesis,                                         
( ↑) stimulaton , ( ↓ ) suppression . 
b Number of mice are 6 for each group . 
cData is expressed as mean ± S.E.M. N= 6; Percent modulatory activity was calculated using formulae given section 3.1. 
 *Denotes comparison between Control (Sensitized) group I and other experimental groups. The P values were calculated by One 
Way ANNOVA. *P < 0.05, ** P < 0.01, *** P < 0.001, followed by Bonferroni correction multiple comparison test. 
 
TREATMENT 
 
 
Doses 
(mg/kg) 
Antibody Response 
Log 2 Titre (Mean ± SEM ) 
( %Change ) 
DAY 7 Day 15 
Control (sensitized) SRBC  
6 .0±0.18 
 
5.6 ±0.22 
Levamisole 2.5 8.2 ± 0.16 *** 
(36.7↑) 
8.0 ± 0.24*** 
( 42.8 ↑) 
Cyclophosphomide 100 4.8 ± 0.20*** 
(20.0↓) 
3.8 ± 0.14 *** 
(32.1↓) 
ABEE 6.25 6.4 ± 0.18 
(6.7↑) 
6.2 ± 0.18 
(10.71↑) 
ABEE 12.5 6.8 ± 0.12 * 
(13.4↑) 
6.8 ± 0.16 ** 
(21.4↑) 
ABEE 25 8.0 ± 0.14 *** 
(33.4↑) 
8.2 ± 0.26 *** 
(46.4↑) 
ABEE 50 9.4 ± 0.10 ***
 
(56.7↑) 
9.2 ± 0.18 *** 
(64.2↑) 
ABEE 100 7.6 ± 0.14 ** 
(26.6 ↑) 
7.0 ± 0.28 ***
 
( 25↑) 
(B) 
(A) 
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      (B) Cellular responses (SRBC specific DTH responses):  
ii) Effect of A.accuminata: 
As depicted in Figure 3.2.1 (A), AAEE exhibited dose dependent 
increase in the DTH response upto 25 mg/kg b.w dose. At this dose 68.18% and 
48.57% modulatory activity as compared to control (Sensitized) was observed 
respectively, at 24 hours and 48 hours time interval after SRBC injection in the 
footpad. At higher doses of 50 and 100 mg/kg b.w, AAEE caused only 38.63% 
and 25% increase in food pad thickness after 24 hours. Levamisole resulted in 
56.8% upregulation and cyclophosphomide in similar conditions caused 52.27% 
down regulation of DTH compared to control (sensitized) after 24 hours. 
Similar response was seen at 48 hour time slot. 
b) Effect of A.bracteosa on cellular response: 
Maximal increase in food pad thickness was observed on treatment with 
ABEE at 50 mg/ kg b.w. dose with 67.85% and 59.18% stimulation after 24 
hours and 48 hours, respectively. However, when the dose was raised to 100 
mg/kg b.w. the DTH responses after 24 hours comparatively got reduced as 
seen in Figure 3.2.1(B). 
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FIGURE 3.2.1 Immunomodulatory effect of AAEE (A) and ABEE (B) on SRBC induced cellular 
immune response (DTH) in vivo.  
Data is expressed as mean ± S.E.M. N= 6; *Denotes comparison between Control (Sensitized) group I and other experimental 
groups. The P values were calculated by One Way ANNOVA. *P < 0.05, ** P < 0.01, *** P < 0.001, followed by Bonferroni 
correction multiple comparison test. 
(A) 
(B) 
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3.2.3 Effect of AAEE/ABEE on lymphocyte proliferation: 
a) Effect of A.accuminata: 
We investigated the effects of AAEE on the proliferation of spleen cells 
in presence of CON A (T-cell mitogen) and LPS (B-cell mitogen) [Figure 
3.2.2(A)]. In case of Group II, the levamisole group, proliferative responses to 
CON A and LPS increased by 56.7% and 61.9% respectively. In Group III 
receiving cyclophosphomide 46.67% and 36.4% immunosuppression was 
respectively, observed for CON A and LPS induced proliferation studies. All 
the groups treated with AAEE (6.25-100 mg /kg b.w) resulted in significant 
increase in proliferation index but different patterns were observed with respect 
to CON A and LPS induced proliferation. In case of CON A treated cells, 
maximal proliferation was observed in spleen cells obtained from Group VI 
treated with 25 mg/kg b.w. AAEE dose. Lymphocyte proliferative responses to 
CON A were relatively suppressed in groups receiving higher doses of AAEE. 
Interestingly in presence of LPS, lymphocyte proliferation was stimulated in all 
the groups treated with AAEE and in a dose dependent manner. 
b) Effect of A.bracteosa: 
ABEE (6.25-100 mg/kg b.w) also resulted in significant increase in the 
proliferation index. In case of CON A treated cells, maximal increment of 
68.05%  proliferation as compared to control (sensitized) was seen in cells 
obtained from group treated with ABEE 50 mg/kg b.w. The percentage increase 
however decreased in cells from group VIII treated with 100 mg/kg b.w. ABEE 
(38.86 %). In presence of LPS, ABEE enhanced the cellular proliferation to 
18.25%, 36.86%, 48.8%, 61.09% and 36.17% at 6.25, 12.5, 25, 50 and 100 
mg/kg b.w. respectively [Figure 3.2.2(B)].  
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Figure 3.2.2 Effect of AAEE (A) and ABEE (B) on lymphocyte proliferation. 
Splenocytes (5×106 viable cells/(mLwell)) from the different experimental groups were cultured in  presence of mitogens (LPS or 
Con A) stimulus. Histograms represent mean ± SEM. absorbance units. Statistical significance was evaluated using One Way 
ANNOVA followed by  Bonferroni test for multiple comparisons was used to compute P-values. *P < 0.05,  **P < 0.01, ***P < 
0.001 vs. control. 
 
Figure 2 (A) 
(A) 
(B) 
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      3.2.4. Effect of AAEE/ABEE on CD4+ and CD8+ T cell percentages: 
i) Effect of A.accuminata: 
Flow cytomertic analysis was used to monitor the effect of test material 
on T-cell response. In unsensitized conditions, no significant results were 
observed on CD4
+
 and CD8
+  
T-cell percentages as compared to the control. In 
contrast in sensitized conditions, AAEE at all doses resulted in significant does 
dependant increase in CD4
+
 and CD8
+  
T-cell subsets. Maximal effect of AAEE 
was observed at a dose of 25 mg/kg b.w with 59.85% and 18.84%. upregulation 
of CD4
+
 and CD8
+  
cell counts, respectively as compared to control (sensitized)  
(Figure 3.2.3 & Table 3.2.2). Cyclophosphomide as expected resulted in 
significant reduction of CD4
+
 and CD8
+
 percentages as compared to control.  
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Figure 3.2.3 Flow cytometry scatter plots for T-cell populations (CD4+ T-helper cells subset and CD8+ cytolytic/cytotoxic T-cells).The plots represent 
events for one representative mouse from each group of control(sensitized), levamisole  and AAEE(6.25-100 mg/kg b.w.).The gating and the quadrants are set 
according to the standard procedures of the BD-LSR flow cytometer.  
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Table 3.2.2 The table represents the comparative analysis of the T cell 
subsets (CD4
+
, CD8
+
) on treatment with AAEE. 
 
Each column is the mean±S.E. of 6 mice per group. Data is expressed as mean 
± S.E.M. N= 6; *Denotes comparison between Control (Sensitized) group I and other 
experimental groups. The P values were calculated by One Way ANNOVA. *P < 
0.05, ** P < 0.01, *** P < 0.001, followed by Bonferroni correction multiple 
comparison test. Percent modulatory activity was calculated using formulae given in 
section 3.1. 
 
 
 
 
TREATMENT 
 
Doses 
(mg/kg) 
 
T HELPER 
CELLS 
 
T CYTOTOXC 
CELLS 
 
% MODULATORY  
ACTIVITY 
CD 4
+
 CD 8
¯
 (%) CD 8
+ 
CD 4
¯
 (%) CD 4 CD 8 
Control (sensitized) SRBC 24.96  ± 0.98 13.80  ± 0.29 NA NA 
Levamisole 2.5 36.80 ± 0.75*** 19.06  ± 0.25*** 47.4 38.11 
AAEE 6.25 28.3 ± 0.86 15.16 ± 0.28* 27.3 7.96 
AAEE 12.5 32.9 ± 0.94*** 15.6 ± 0.21*** 54.9 13.04 
AAEE 25 39.9 ± 1.24*** 16.4 ±0.26*** 42.27 18.84 
AAEE 50 34.6 ± 0.73*** 15.8 ±0.22*** 30.08 14.49 
AAEE 100 30.2 ± 1.33* 15.27 ±0.3** 20.99 10.65 
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ii) Effect of A.bracteosa: 
Maximal immunostimulatory effects for ABEE were observed at a dose 
of 50 mg/kg b.w with 57.6% up regulation of CD4
+
 and 18.4% of CD8
+
 cell 
counts (See Figure 3.2.4 & Table 3.2.3). The effects were observed to decrease 
to 33.3 % (CD4
+
) and 9.8% (CD8
+
) at the higher dose of 100 mg/kg b.w.  
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Figure 3.2.4 Flow cytometry scatter plots for T-cell populations (CD4+ T-helper cells subset and CD8+ cytolytic/cytotoxic T-cells). The plots represent 
events for one representative mouse from each group of control (sensitized), levamisole  and ABEE (6.25-100 mg/kg b.w). The gating and the quadrants are 
set according to the standard procedures of the BD-LSR flow cytometer. 
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Figure 3.2.3. The table represents the comparative analysis of the T cell 
subsets (CD4
+
, CD8
+
) on treatment with ABEE. 
 [ 
 
Each column is the mean±S.E. of 6 mice per group. Data is expressed as mean ± 
S.E.M. N= 6; *Denotes comparison between Control (Sensitized) group I and other 
experimental groups. The P values were calculated by One Way ANNOVA. *P < 0.05, 
** P < 0.01, *** P < 0.001, followed by Bonferroni correction multiple comparison 
test. Percent modulatory activity was calculated using formulae given in section 3.1. 
 
 
TREATMENT 
 
Doses 
(mg/kg) 
 
T HELPER 
CELLS 
 
T CYTOTOXC 
CELLS 
 
% MODULATORY  
ACTIVITY 
CD 4
+
 CD 8
¯
 (%) CD 8
+
 CD 4
¯
(%) CD 4 CD 8 
Control (sensitized) SRBC 24.80  ± 0.25 14.02  ± 0.26 NA NA 
Levamisole 2.5 36.8 ±1.12*** 19.56  ± 0.20*** 46.7 39.5 
ABEE 6.25 28.04  ± 1.24 15.25  ± 0.28 13.06 8.77 
ABEE 12.5 30.26  ± 1.18 * 16.14  ± 0.32*** 22.01 15.12 
ABEE 25 34.9 ± 0.97*** 16.35  ± 0.22*** 40.7 16.6 
ABEE 50 39.1 ±1.76*** 16.6 ±0.30 *** 57.6 `18.4 
ABEE 100 33.08 ± 1.22*** 
15.4 ± 0.28*
 
 
33.3 9.87 
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3.2.5. Effect on Th1 and Th2 cytokines: 
To determine the effect of ABEE on Th1/Th2 immunity selected cytokine levels 
were measured in vivo using flow cytometry. 
    (A) Effect on Th1 cytokines: 
i) Effect of A.accuminata: 
Oral dministration of AAEE caused a significant dose dependent up 
regulation of IL-2 and IFN-γ cytokines as compared to control in sensitized 
conditions. Under unsensitized conditions, no significant increase in cytokine 
levels was observed. Levamisole resulted in 59.23% and 64.9% increase in IL-2 
and IFN-γ levels whereas cyclophosphomide caused a noted suppression for 
both cytokines [Figure 3.2.6 & 3.2.7].  At a dose of 25 mg/kg of AAEE, 
maximal stimulation was observed in IL-2 (62.36%) and IFN-γ (70.3 %) in 
comparison to control.  
ii) Effect of A.bracteosa: 
Treatment with extract of A.bracteosa also resulted in dose dependent 
increase of IL-2 and IFN-γ cytokines [Figures 3.2.8 & 3.2.9]. IL-2 and IFN-γ 
levels are stimulated maximally at 50 mg /kg b.w but with increase in dosage 
their levels are reduced. ABEE shows a biphasic activity of ABEE where up 
regulation and down regulation of these cytokine levels was observed at lower 
and higher doses, respectively. 
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Figure 3.2.6 The histograms represent the intracellular concentration of the two Th1 cytokines —   
IL-2(A) and IFN-γ (B) after treatment with AAEE in different groups.  
Data is expressed as mean ± S.E.M. N= 6; *Denotes comparison between Control (Sensitized) group I and other experimental 
groups. The P values were calculated by One Way ANNOVA. *P < 0.05, ** P < 0.01, *** P < 0.001, followed by Bonferroni 
correction multiple comparison test. 
(A) 
(B) 
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Figure 3.2.7 Flow cytometry histogram representation for signature  Th-1 cytokine, IL-2 and IFN-γ. Each histogram represents the counts for one 
representative mouse from each group of control (sensitized), levamisole and AAEE-25 mg/kg b.w. The histograms area is acquired according to the standard 
procedures of the BD-LSR flow cytometer. 
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Figure 3.2.8 The histograms represent the intracellular   concentration of the two Th1 cytokines — 
IL-2(A) and IFN-γ (B) after treatment with ABEE in different groups.  
Data is expressed as mean ± S.E.M. N= 6; *Denotes comparison between Control (Sensitized) group I and other experimental 
groups. The P values were calculated by One Way ANNOVA. *P < 0.05, ** P < 0.01, *** P < 0.001, followed by Bonferroni 
correction multiple comparison test. 
(A) 
(B) 
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Figure 3.2.9 (A) Flow cytometry histogram representation for signature  Th-1 cytokine, IL-2 and IFN-γ. Each histogram represents the counts for one 
representative mouse from each group of control (sensitized), levamisole and ABEE-50 mg/kg b.w. The histograms area is acquired according to the standard 
procedures of the BD-LSR flow cytometer.  
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      (B) Effect on Th2 cytokines: 
i) Effect of A.accuminata: 
IL-4 levels were upregulated by 9.3%, 22.81%, 39%, 50.8 % and 63.2% 
in comparison to control in the groups treated with AAEE at 6.25, 12.5, 25, 50 
and 100 mg/kg b.w. [Figure 3.2.10 (A &B )].  
ii) Effect of A.bracteosa : 
As reflected in [Figure 3.2.11 (A&B)], IL-4 is stimulated maximally in 
groups receiving 50 mg/kg b.w ABEE wherein 60.19% stimulation is observed. 
However, the stimulation decreased with further increase in dosage.  
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Figure 3.2.10 (A) The histograms represent the intracellular concentration of the IL-4 on treatment 
with AAEE and Levamisole. Data is expressed as mean ± S.E.M. N= 6; *Denotes comparison between Control (Sensitized) 
group I and other experimental groups. The P values were calculated by One Way ANNOVA. *P < 0.05, ** P < 0.01, *** P < 
0.001, followed by Bonferroni correction multiple comparison test.) (B) Flow cytometry histogram representation for 
Th-2 cytokine IL-4, the signature cytokine of the Th2 response. The histogram represents the counts for one 
representative mouse from each group of control (sensitized), levamisole and AAEE-100 mg/kg b.w. The histograms are acquired 
according to the standard procedures of the BD-LSR flow cytometer. 
B 
A 
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Figure 3.2.11 (A) The histograms represent the intracellular concentration of the IL-4 on treatment 
with ABEE and Levamisole. Data is expressed as mean ± S.E.M. N= 6; *Denotes comparison between Control (Sensitized) 
group I and other experimental groups. The P values were calculated by One Way ANNOVA. *P < 0.05, ** P < 0.01, *** P < 
0.001, followed by Bonferroni correction multiple comparison test. (B) Flow cytometry histogram representation for 
Th-2 cytokine IL-4, the signature cytokine of the Th2 response. The histogram represents the counts for one 
representative mouse from each group of control (sensitized), levamisole and ABEE-50 mg/kg b.w. The histograms are acquired 
according to the standard procedures of the BD-LSR flow cytometer.  
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Chapter – 3.3 
Discussion 
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Rheumatoid arthritis has a strong immune mediated component (Schett & 
Firestein, 2010). Activated T-helper cells have been found in the inflammatory 
infiltrates, blood and synovial fluid in RA patients. DTH response indicative of Th1 
activity has been observed to decrease in case of pregnant women with rheumatoid 
arthritis (Fox et al., 1997). Many studies have also revealed the increased prevalence of 
allergic diseases and atopic conditions in RA patients which is indicative of Th2 
activity (Schulze-koops et al., 2001). It is also marked by increased activated levels of 
Th1 cells and their cytokine like IL-2, IFN-γ with fewer Th2 cells and their cytokines 
like IL-4 (Choy and Panayi, 2001). 
In the last decade there has been a huge upsurge in the use of plant 
extracts which target T-helper lymphocytes for modulation of immune response 
in arthritic disorders. Immune homeostasis is maintained by a fine equilibrium 
between Th1 and Th2 lymphocyte subsets. Hence modulaton of Th1 /Th2 has 
emerged as a vital target for immunomodulation. Immunodulators are categorized 
as Th1, Th2 or mixed Th1 /Th2 agents depending on their effeminacy towards T-helper 
lymphocyte subsets. Atropa accuminata (AA) and Ajuga bracteosa (AB) have been 
previously known to exhibit different pharmacological properties, however so far no 
systematic study has been conducted to assess the regulatory effects on Th1 –Th2 
immune responses. Here in, we reported significant mixed immunomodulatory effects 
of AA and AB on systemic Th1 –Th2 homeostasis. 
Th1 and Th2 cells are regarded as “system supervisors” of the immune 
framework.Th1 cells mediate cellular immune responses (Type 1 pathway) and Th2 
cells mediate the humoral immune responses (Type 2 pathway). Functionally,  
lymphocytes are associated with inflammation and cell mediated responses and also 
provide immunity against mycobacterial infections such as tuberculosis, leishmania etc. 
and viruses  such as influenza. Th2 cells provide support to B-cells for antibody 
production and protection against helminthes, allergy and other viral infections (for 
example measles). Th1 cells are also associated with autoimmune diseases and graft 
rejection. Type 1 and Type 2 pathway together provide an extraordinary effective 
defense system (Romagnani et al.,2000). Levamisole is a potent immunostimulant 
which restores the suppressed immune functions of B-cells, T-cells, monocytes and 
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macrophages (Bozic et al.,2003, Argani, et al.,2006). Hence a comparative study of 
levamisole and both the test extracts (AAEE and ABEE) was designed to evaluate Th1 
–Th2 modulating properties in vivo in SRBC immunized Balb/c mice. The observed 
results demonstrated, that in comparison to levamisole AAEE resulted in significant 
potentiation of Th1 immune responses at lower doses whilst maximal Th2 upregulation 
was seen at higher doses. This indicated a unique immunnomodulatory profile for 
Atropa accuminata. Interestingly ABEE depicted dual biphasic dose dependant 
potentiation of both Th1 as well as Th2 immunity. At higher doses the stimulatory 
effects showed a downward trend. 
The humoral immunity involves interaction of B cells with the antigen and their 
subsequent proliferation and differentiation into antibody-secreting plasma cells. 
Antibody functions as the effector of the humoral response by binding to antigen and 
neutralizing it or facilitating its elimination by cross-linking to form clusters that are 
more readily ingested by phagocytic cells. The T-helper, Type 2 pathway (humoral 
immunity) was anaylsed in terms of the increase in circulating antibody titers post 
immunization with SRBC.As expected, levamisole (2.5 mg/kg b.w) resulted in 
generalized immunostimulation as evident from the raised HA titers while 
cyclphosphomide (100 mg/kg b.w.) showed drastic inhibition of the tires. ABEE at 
doses of 6.25-100 mg /kg b.w. was found to cause an increase in antibody titers in 
relation to control and levamisole with maximal effect seen at 50 mg /kg b.w. However, 
AAEE showed a linear dose dependent stimulatory action. 
Delayed type hypersensitivity (DTH) is an index of cell mediated immunity 
(Th-1 pathway).Treatment with AAEE and ABEE both, was seen to enhance the DTH 
reaction in response to SRBC immunization as evident from the increase in food pad 
thickness. In case of AAEE, maximal effect was observed at 25 mg/kg b.w and in 
contrast to this at higher doses the DTH response subsequently decreased. ABEE 
demonstrated maximum stimulation of DTH reaction at a dose of 50 mg /kg b.w. These  
findings depicted optimum stimulatory effects for AAEE at lower doses and ABEE at 
higher doses on T-lymphocytes and other adjunct cell types needful for the formulation 
of DTH response (Beneacerraf, et al., 1978). DTH is marked by huge influx of 
macrophages and other inflammatory cells (Luster et al, 1982). It requires the specific 
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recognition of a given antigen by activated T lymphocytes, which subsequently 
proliferate and release cytokines. These in turn increase vascular permeability, induce 
vasodilatation and macrophage activation, promoting increased phagocytic activity.The 
overall effect is mediated via the cytokines released by Th1 cells to recruit and activate 
the macrophages, thereby promoting increased phagocytic activity (Cher & Mosmann 
,1987, Romangani,2000). 
 
The ability to invoke efficacious T and B lymphocyte immunity can be depicted 
by the potentiation of lymphocyte proliferation reactions. In the paradigm of               
T-lymphocytes, helper T-cells promotes the antibody secretion from the B-lymphocytes 
and causes the cytotoxic lymphocytes to aid phagocytes for ingestion and elimination 
of intracellular pathogens. B-lymphocytes secrete antibodies which aid in removing 
extracellular pathogens and also neutralize toxins (Abbas et al.,1996). The proliferation 
assay findings indicate that AAEE at 25 mg/kg b.w and 100 mg/kg b.w maximally 
increased the activation potential of T lymphocytes and stimulated their   proliferation 
and differentiation in case of CON A (T-cell.,Th1 response) and LPS (B-cell.,Th2 
response) stimulated proliferation studies, respectively. These results were consistent 
with the mixed immunostimulatory effects observed in earlier experiments on the 
cellular and humoral immune responses and indicated that Atropa accuminata has dual 
but selective dose dependant Th1 /Th2 potentiating activity. The proliferation assay 
with ABEE indicate a significant promotion both with CON A and LPS stimulated 
proliferation at an optimum dose of 50 mg/kg b.w which however got reduced at 100 
mg/kg b.w. dose indicating a reduction in stimulation of Th1 and Th2 pathway at 
higher doses. 
In addition, evidence that lend support to our hypothesis of unique T-helper 
lymphocyte activation and stimulation patterns by AAEE and ABEE was the 
significant potentiating effect on CD4
+
 and CD8
+
 lymphocyte subsets. Our findings 
using flow cytometry revealed a notable increase in CD4
+
 and CD8
+
 percentages in 
peripheral blood for AAEE and ABEE both at the same dosages as seen above with 
CONA stimulation studies. It is already known that B-cells mediate antibody 
production and other immune functions through CD4
+
 and CD8
+
 cells (Constant et 
al.,1997).  Various studies have reported positive correlations between cellular and 
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humoral immunity and CD4
+
 /CD8
+
 percentages in immune altered disease states such 
as cancer ,arthritis ,etc Also T cells that express CD4
+
 are found to be increased 
whenever there is a general expansion due to active immunological activity of T-
lymphocyte subsets for example as seen in RA (Lucy et al., 2004). 
The Th1 /Th2 framework of immune system largely rests on the  dichotomy of 
cytokine profiles corresponding to the two subsets of helper T lymphocytes 
(Oberholzer et al., 2000).In order  to validate the role of T-helper cell derived cytokines 
for the mixed immunomodulatory effects of the test extracts on Th1/Th2 immunity and 
elucidate further the dose dependent dual Th1/Th2 modulating activity, we proceeded 
for estimation of Th1 (IL-2 and IFN-γ) and Th2 (IL-4) cytokines in SRBC immunized 
mice using flow cytometry. Our findings were consistent with the earlier results on 
antibody titers and T-cell and B-cell activation and proliferation. Levamisole showed 
generalized increased concentration in Th1/Th2 intracellular cytokine concentration. 
Based on the pattern of cytokine (IL-2, IFN-γ and IL-4) secretions by extract of Atropa 
acuminata, it may be suggested that AAEE at lower doses (25 mg/kg b.w.) resulted in 
significant increase in IL-2 and IFN-γ (Th1 cytokines).However at higher doses (100 
mg/kg b.w), the stimulatory effects are skewed towards Th2 immune responses with 
increase in IL-4 cytokine production. These results confirmed that Atropa accuminata 
shows dual Th1/Th2 immunpotentiating effects. The pattern of IL-2, IFN-γ and IL-4 
production in the groups treated with different doses of the extract of Ajuga bracteosa 
correlated with the earlier results displayed with antibody production, DTH response 
and T cell/B cell proliferation studies. Noteworthy to mention, the maximal stimulation 
of all the cytokines production (Th1/Th2) was seen at 50 mg/kg b.w.dose.Upon 
antigenic stimulation, the Th-1 immune response is marked by release of  IFN-γ, IL-2 
and TNF-α and Th-2 immune reactions by IL-4 secretion. Cytokines are 
multifunctional and so remain vital at the different stages of immune response. 
(Oberholzer et al., 2000). IL-4 (Type 2 pathway) mediate the antibody production via 
B-cells, eosinophils and mast cells. IL-2 stimulates Th-1 and cytotoxic cells to enhance 
additional proliferation and differentiation of CD4
+
 cells, B-cells and activate 
macrophages. IFN-γ secreted by the Th1 cells drives the inflammatory pathway 
(McInnes and Schett, 2007) and  is  required for selective immunity to intracellular 
bacteria, viruses, and protozoa whereas Th2 produce IL- 4 required for optimal 
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antibody production to T- cell dependant antigens. During the initial stages, IL-2 and 
IFN-γ augument differentiation and proliferation of Th1 cells but in the later stages 
these cause to bring about „apoptosis‟ of the repeatedly stimulated effector cells. 
(Mosman   & Coffman, 1989). Hence Th1 and Th2 proliferation rates are only 
dividends of the concentrations of their cytokine profiles. 
In safety studies, AAEE and ABEE both were   found to be safe upto 2500 
mg/kg b.w. Neither sign of any mortality nor any toxicological consequences were 
observed in mice, signifying that Atropa accuminata and Ajuga bracteosa are safe to 
use. Thus our study clearly demonstrated that Atropa accuminata could significantly 
elicit and stimulate both Th1 and Th2 immune responses with skewed dose dependent 
pattern. On the other side, Ajuga bracteosa could stimulate T- cell mediated effects in a 
biphasic manner. The   selective dose dependent upregulation of Th1/Th2 immunity by 
A.accuminata and biphasic response by A.bracteosa could be attributed to the 
synergstic effects of the different biochemical constituents present in the extract. There 
are numerous examples where plant derived extracts have shown such selectivity in 
immunotherapy. For instance, in Ginnseng (Lee et al.,2006), Withania somnifera 
(Davis et al., 2000, Davis et al.,2002) and Tinospora cordifolia (Kapil et al., 1997; Nair 
et al.,2004,Thatte et al.,1994), the different biochemical constituents have mediated the 
immnomodulatory effects through different targets. Such immunoactive mixtures have 
been reported to deliver synergistic moieties which simultaneously or concurrently 
modulate the different limbs of immune matrix e.g in inflammation, infection, cancer, 
etc. and restore the immune homeostasis (Patwardhan et al.,2005). In conclusion, 
Atropa accuminata and Ajuga bracteosa exhibited selectivity in immune therapy which 
could be useful in effective drug discovery from these botanicals. 
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4.1.1 Chemicals 
Growth medium, DMEM, fetal calf serum (FCS), penicillin, streptomycin, Di-
methyl sulphoxide (DMSO), glutamine, pyruvate, carrageenan, ibuprofen (IBP), Evans 
blue, phenylmethylsulfonylfluoride (PMSF), aprotinin and Tween 20 (Sigma 
Chemicals)., gum acacia (Hi Media)., COX1/2, 5-LOX ELISA kits (Cayman 
chemicals)., PGE2, LTB4, TNF-α and IL-1β ELISA kits (R&D Systems). All other 
chemicals were purchased from Hi-Media and Merck, India. Standard drugs were 
purchased from Sigma-Aldrich chemicals co. (St. Louis O., USA) and all solvents 
used were of HPLC grade (Ranbaxy Chemicals Ltd., Mohali and Punjab, India). 
4.1.2 Test material 
The ethanolic extracts of Atropa acuminata (AAEE) and Ajuga bracteosa 
(ABEE) were prepared as detailed in section 3.1. 
4.1.3 In vitro COX 1 / 2 and 5-LOX Inhibition Assay: 
The in vitro COX 1/2 and LOX was determined using ELISA kit (Cayman 
Chemicals Company).  
(A)  Assessment of Cyclooxygenase (COX 1 and COX 2) inhibitiory activity: 
COX inhibitory activity was measured using an enzyme immunoassay 
(EIA) screening assay kit (Cat. No.: 560131, Cayman Chemical Company, 
USA). The assay kit was used to measure the COX 1/2 derived PGH2 produced 
in the COX reaction and the prostanoid product is quantified using a broadly 
specific antiserum that binds to all major prostaglandins. All samples and 
positive controls were added as ethanol solutions to assay solutions. All 
procedures were performed as indicated in the assay kit instructions. 
Absorbance of assay buffer (160µl of 100mM Tris HCL (pH 8.0),10µl of 
Heme and 10µl of Methanol) and assay buffer with COX enzyme was 
measured as background and 100% Initial Activity.  
(B) Assessment of 5-lipoxygenase inhibitory activity: 
The assay kit measures the hydroperoxides generated from the 
incubation of a lipoxygenase (5-LOX) with either arachidonic or linoleic acid. 
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LOX inhibitory activity was measured using colorimetric (LOX) inhibitor 
screening assay kit (Cat No.760700, Cayman chemical company, USA). The 
assay kit was used to detect and measure the hydroperoxides produced in the 
lipoxygenation reaction using a purified LPO. All samples and positive 
controls were added as ethanol solutions to assay solutions. All procedures 
were performed as indicated in the assay kit instructions. The hydroperoxide 
product thus formed was measured using an immunoreader at 540nm. 
Absorbance of assay buffer (90µl LOX, 10µl assay buffer) was measured as 
Positive control. This assay kit provides an accurate and convenient method for 
screening lipoxygenase inhibitors. Lornoxicam, standard LOX inhibitory drug 
was used as standard control at a concentration of 100 g/ml.  
4.1.4 In vitro effect on NO and pro-inflammatory cytokines: 
(A) Cell culture: 
RAW 246.7 a murine macrophage cell line was grown in DMEM 
medium supplemented by 100 U/ml penicillin, 100µg/ml of streptomycin and 
10 % FCS, 2mM glutamine, 1 mM pyruvate. Cells were maintained at 37 ºC in 
5% CO2 incubator.  
(B) Cell viability assay: 
Cell viability was assessed by using MTT based assay. Cells were 
plated at a density of 1 x 10
4
 cells per well in a 24 well cell culture plate and  
incubated overnight at 37 ºC and 5 % CO2  and then the cells were  exposed to 
various concentrations of 6.25-100 µg/ml of AAEE/ABEE with or without 
LPS (1ug/ ml). At 24 hours after treatment, MTT solution in PBS was added to 
the wells at a final concentration of 1 mg/ml. The medium was aspirated 
carefully and the formazone crystals were dissolved in 100 µl DMSO. 
Absorbance was measured at 520 nm using a micro plate reader to quantitate 
the extent of reduction of MTT (Ha et al.,2006). 
(C) Nitrite assay: 
RAW 246.7 cells were plated at a density of 2 x 10
4
 cells per well in 24 
well cell culture plates and then incubated with or without LPS 1 µg / ml and 
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solvent alone (DMSO) or the plant extract at various concentrations 
(6.25,12.5,25,50,100 µg/ ml). The cells were incubated for 24 hours. DMSO 
concentration did not exceed 0.1 % of the media. Two controls were incubated 
in each treatment, media & DMSO (Vehicle Control) and media, LPS & 
DMSO (LPS Control). The nitrite accumulation in   the assay was determined 
by the Griess reaction (Minghetti et al.,1997). To 100 µl of culture supernatant 
collected an equal volume of Griess reagent (1% sulphanilamide and 0.1% 
naphthyl-ethylenediamine dihydrochloride in 5% phosphoric acid) was added 
followed by 10 minutes  incubation at 37 ºC. Optical density at 550 nm was 
measured and calculated using a standard curve obtained by series 
concentrations of sodium nitrite (NaNO3). 
(D) Determination of TNF-α, IL1-β production in RAW 246.7 macrophages: 
Cell supernatants collected on ice and stored in a -70 ºC freezer were 
used for cytokine estimation. TNF-α and IL1-β was determined in the culture 
supernatant using specific ELISA kit according to the manufacturer’s 
instructions.  
4.1.5 In vivo anti-inflammatory studies: 
(A) Animal Treatment 
Studies were carried out using Male Wistar Albino rats of either sex 
weighing 150-180 grams and Swiss Albino mice (24-30 grams) of either sex. 
They were procured from IIIM, Jammu and kept in animal house, KU. The 
animals were grouped in polypropylene cages with not more than six animals 
per cage and maintained under standard laboratory conditions (temperature 
25±2°C, relative humidity 60% ±15% and with dark & light circle 12hrs 
/14hrs).They were allowed free access to standard dry pellet (Hindustan lever, 
Kolkata, India) and water ad libitum (CPCSEA, 2003). The animals were 
acclimatized to laboratory conditions before commencement of the experiment. 
All animal experiments were approved by the University animal ethical 
committee vides No: 80/03/CA/CPCSEA. 
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(B)  Maximum tolerable dose determination (Selection of doses). 
The effect of test extracts on general behaviour and safety was 
evaluated in mice using the up and down procedure (Organization of Economic 
Co-operation and Development (OECD), Guideline No. 423, 1996) (as 
described in section 3.1). No toxic effects or mortality were observed in mice 
upto 2500 gms (LD-0 gms). Evaluation of the test material for anti-
inflammatory assessment was initiated by giving to the animals one-tenth of 
this dose, 250 mg/kg b.w  as well as lower (62.5 mg/kg b.w &125 mg/kg b.w) 
and higher doses (500 mg/kg b.w). Since no mortality was observed in acute 
safety studies it indicated that the test materials could be safe to use even at 
higher doses. This selection of doses for the test extracts was also supported by 
our results of immonumodulation assessment (Section 3.3) which revealed that 
at higher doses, the immunostimulatory effects of both the test extracts 
decreased. 
(C) Carregenean induced Rat paw edema:  
Anti-inflammatory activity was assayed using the method described by 
Winter et al.,1962. Edema was induced by injection of 1% suspension of 
carrageenan (100 μl) in 0.9% sterile saline solution into the right plantar region 
of the rat. The animals were divided into groups of 6 animals each. Group I , 
(Naïve control), received 1% gum acacia, Group II, received 1% gum 
acacia(Cg control) (Negative control); Group III: AAEE /ABEE (62.5 mg/kg 
b.w.); Group IV: AAEE/ABEE (125 mg/kg b.w); Group V: AAEE/ABEE  
(250 mg/kg b.w); Group VI: AAEE/ABEE  (500 mg/kg b.w); Group VII: 
Ibuprofen (50 mg/kg b.w). All the test extracts worked out at different graded 
doses and standard drugs were dissolved in 1% guma acacia. One hour after 
oral administration of respective groups edema was induced in all treatment 
groups except group I (Naïve Control) by injection of 1% suspension of 
carrageenan (100 μl) in 0.9% sterile saline solution into the right plantar region 
of the rat. The paw edema was measured using a plethysmograph apparatus. 
Before oral administration of the drugs, the average volume of the right hind 
paw of each animal was measured twice (Vc) by the plethysmograph apparatus. 
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The volume of the right hind paw was determined again at 0.5, 1, 2 and 3 hours 
after carrageenan treatment (Vt) to each group. The difference between the 
initial and subsequent reading gave the actual edema volume. The anti-
inflammatory activity was expressed in terms of “percent inhibition” as 
described at the end of this section. 
(I) Quantification of PGE2, LTB4in paw tissue: 
a ) Homogenisation of tissue: 
Before homogenization frozen paws containing bony tissue was 
weighted using an extraction buffer containing 1 mM phenyl methyl 
sulphonyl fluoride(PMSF), 1µM/ ml Apoprition and 0.05 % TWEEN in 
PBS ( 4 ml/g of tissue). The paw tissues were homogenized using 
polytron homogenizer. The homogenate was centrifuged at 5000g for 
15 mintues (Magari et al.,2004 ) and the supernatants stored at -80ºC 
analysis for PGE2 and LTB4 analysis.  
(b) Estimation of PGE2and LTB4: 
PGE2 and LTB4 were estimated using commercially available 
(Cayman chemicals) according to the manufacturer’s instructions.  
(II) Measurement of anti oxidant enzymes: 
The experimental animals of the carragenean induced model from the 
respective gropus were sacrificed. Liver was isolated and whole tissue after 
rinsing in ice cold normal saline was immediately placed in normal saline 
(double this volume) and homogenized at 4ºC. The homogenate was 
centrifuged at 12000 rpm for 5 min and the supernatant stored at -20 ºC was 
used for assay of several anti-oxidant enzymes. The different biochemical 
parameters assessed were as follows. 
a) Estimation of superoxide dismatse (SOD):  
SOD activity was estimated by (Beauchamp and Fridovich, 
1971). The reaction mixture consisted of 0.5ml of hepatic PMS, 1ml of 
50 mM sodium carbonate, 0.4 ml of 25µM NBT and 0.2ml of 0.1mM 
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EDTA. The reaction was initiated by addition of 0.4ml of 1mM 
hydroxylamine- hydrochloride. The change in absorbance was recorded 
at 560nm. The control was simultaneously run without tissue 
homogenate. Units of SOD activity were expressed as the amount of 
enzyme required to inhibit the reduction of NBT by 50%. 
(b) Estimation of Glutatione peroxidase (GPX ): 
GPX activity was assayed using the method of (Sharma et 
al.,2001). The assay mixture consists of 1.49ml of sodium phosphate 
buffer (0.1M p.H 7.4), 0.1ml EDTA (1mM), 0.1ml sodium azide 
(1mM), 0.1ml of  GSH (1mM), 0.1ml of NADPH (0.02mM), 0.01ml of 
H2O2 (1mM) and 0.1ml PMS in a total volume of 2ml. Oxidation of 
NADPH was recorded spectrophotometrically at 340nm and the 
enzyme activity was calculated as nmoles NADPH  oxidized/min/mg of 
protein, using € of 6.22 x 103 M-1 cm-1. 
 
  (c) Estimation of Glutathione Reductase activity (GRX ): 
 
GR activity was assayed by the method of Carlberg and 
Mannervik et al., 1985. 50s µl of  NADPH (2 mM) in 10 mM Tris 
buffer (pH 7.0) were added in cuvette containing 50ul of oxidized 
glutathione (20 mM) in phosphate buffer. One hundred microliters of 
PMS was added to the NADPH-GSSG buffered solution and was 
measured at 340 nm for 3 min. The enzyme activity measured at 340nm 
was calculated as nmoles of NADPH oxidized/min/mg of protein using 
€ of 6.22 x 103 M-1 cm-1. 
(D) Carragenean induced pleurisy (In vivo):    
Pleurisy was induced in male Wistar rats by injecting 0.5 ml (1% w/v ) 
in sterilized normal saline into the pleural cavity following the procedure of 
Meacock and Kitchen et al.,1979.The extract AAEE/ABEE worked out  at 
different graded doses (6.25 ,125, 250 and 500 mg/kg b.w) or standard drug 
(Ibuprofen-50 mg/kg),  was administered 1 hour before and 6 hours after 
carragenean injection. After 24 hours, the rats were anaesthetized with diethyl 
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ether. The chest was carefully opened to collect the pelural fluid. Total 
leukocyte and differential count of the exudate was calculated. Total leucocytes 
count was performed in a Neubauer chamber after diluting the pleural fluid 
with Turk solution (1:200) and cytospin preparations of pleural wash were 
stained with May-Grunwald Giemsa for the differential leucocytes count, 
which was performed under an oil immersion objective. The cell free 
supernatant was assayed for PGE2, LTB4 and nitrite / nitrate concentration. 
Assay for PGE2 and LTB4 was done based on manufacturer’s instructions of 
ELISA kits from Cayman chemicals. Nitrite/nitrate was measured in the 
exudate as previously described on RAW 246.7 macrophage cell line. 
(E) Vascular permeability in mice: 
Evaluation of the effect of AAEE /ABEE on vascular permeability was 
based on the method of Whittle et al.,1964. Mice were orally administered with 
AAEE/ABEE at different doses (62.5-500 mg/kg b.w) and Ibuprofen (50 
mg/kg b.w.). After 30 minutes the animals were injected intravenously with 
0.2% solution of Evan’s blue dye (0.25% w/v normal saline). Later mice were 
injected intra-peritoneally (1 ml/100gms of body-weight) with 0.6% acetic acid 
(v/v) in normal saline. Thirty minutes later the mice were sacrificed and the 
peritoneal cavities were washed with 5 ml normal saline into heparinised tubes 
and the wash was centrifuged for 10 mintues   (3000g). The dye content was 
measured at 610 nm using a UV visible spectrophotometer. The toxicity 
studies of test extracts on mice are described in section 3.1. 
4.1.6   Determination of total phenolic content: 
The concentration of total phenolic compounds in the test material was 
determined by the Folin-Ciocalteau method with a few modifications (Singleton’s et 
al.,1965). The test material AAEE & ABEE were evaluated at a final concentration of 
0.5 mg/ml. To an aliquot of the extract (0.5 ml) in duplicates 2.5 ml of reagent (0.124 
µg/ml ) and 2 ml sodium carbonate  (7.5% ) was added. The reaction mixtures were 
allowed to stand for 1 hour protected from light and the absorbance at 675 nm was 
measured by Hevlett –Packard UV visible spectrophotometer. The concentration of 
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total phenolic compounds for AAEE was calculated on the basis of standard curve 
using Gallic acid.  
4.1.7 Determination of total flavonoids: 
The concentration of flavonoids was determined according to the method of 
Ordonet al 2006. To 0.5 ml of extract 0.5 ml of 2% AlCl3 ethanol solution was added 
followed by 1 hour incubation at 37 ºC. The absorbance of yellow colour (indicating 
the presence of flavonoids) was measured at 420 nm. Extract samples were evaluated 
at a final concentration of 0.5mg/ ml. Total flavonoid content was calculated as 
Querceti nequivalants (mg/g) of the test material. 
 4.1.8   Total flavanols in the test material:  
Total Flavanols in the test material was estimated on the method of Kumaran & 
Karunakarn,1962. An aliquot of the test material and standard, 2 ml of 2% AlCl3 and 3 
ml sodium acetate solution (50 g/l) were added . The samples were allowed to stand 
for 24 hours at 20 ºC followed by measuring absorbance at 440 nm. The total flavanol 
content was determined based as standard curve using Quercitin.  
4.1.9 Data analysis and statistical considerations: 
 Data is expressed as mean ±S.E.M. Statistical significance of differences was 
assessed by One way ANOVA followed by Bonferroni test for multiple comparisons. 
The level of significance was set at P < 0.05. . Percent inhibitory activity in different 
experimental groups was derived using following method:  
 
  x 100 
  
 
 
 
 
 
Chapter – 4.2 
Results 
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4.2.1 Effects on COX 1 / COX 2 enzymes: 
AAEE /ABEE were assayed at graded concentrations from 6.25 to 100 µg/ml 
and compared to the standard reference drugs, Aspirin, Celecoxib and Indomethancin 
at 40 µM, 30 µM and 30 µM, respectively.  
i) Effect of A.accuminata (AAEE): 
As shown in Figure 4.2.1(A)]. AAEE at doses of 6.25 µg/ml, 
12.5µg/ml, 25µg/ml, 50 µg/ml and 100 µg/ml showed 9.23%, 23.4%, 52.7%, 
86% and 89% percentage inhibition in COX-1 activity, respectively. At the 
concentration of 100µg/ml, COX 1 inhibitory activity of AAEE was 
significantly comparable to that of aspirin, standard COX 1 inhibitor. The  
COX 2 inhibitory activity also increased with the increase in the concentration 
of the extract. Maximal COX- 2 inhibition of 69 % was observed at a 
concentration of 100 µg/ml. Standard reference, celocoxib demonstrated an 
inhibition of 92.8% of COX -2. The IC50 values of AAEE for COX 1 /COX 2 
were found to be 23.76 and 30.76 µg/ml, respectively (Table 4.2.1). 
ii) Effect of A.bracteosa (ABEE): 
As depicted in Figure 4.2.1(B) ABEE yielded dose dependant effects 
with maximal inhibition of 85.8 % for COX 1 and 75.02% for COX2 enzyme 
at 100 µg/ml. The IC50 values for ABEE of COX 1 /COX 2 were 36.7 and 
27.06 µg/ml, respectively (Table 4.2.1). The percent inhibition was relatively 
comparable to the percent inhibitory values of standard drugs. Indomethacin, 
the selective COX 1 inhibitor showed 96.8% inhibition and celecoxib 
(selective COX 2 inhibitor) showed 93.2 % inhibition. 
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FIGURE 4.2.1. In vitro COX 1 and COX 2 inhibitory activities of (A) AAEE (B) ABEE. 
Positive controls, aspirin, indomethacin and celecoxib were tested at 60µM , 30µM and 30µM, respectively. Varying 
concentrations of the standards were used. Data is expressed as Mean ± SEM and all values are mean from six 
independent determinations . *Denotes comparison between Control ≠  and other experimental groups. The P values 
were calculated by One Way ANNOVA. *P < 0.05, ** P < 0.01, *** P < 0.001, followed by Bonferroni correction 
multiple comparison test. 
 
(A) 
(B) 
≠ 
≠ 
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4.2.2 In vitro 5-Lipooxygenase inhibitory activities: 
ii) Effect of A.accuminata (AAEE): 
The 5-LOX inhibotry activity was also quantified at different 
concentrations 6.25 -100 g/ml, as shown in Figure 4.2.2 (A). AAEE showed 
LOX inhibition at all the concentrations tested and a concentration dependant 
suppression of LOX activity was observed with IC50 value of 27.61 g/ml 
(Table 4.2.1). Maximal LOX inhibitory activity of 77.23% was observed at a 
concentration of 100 g/ml and the activity was comparable to the standard 
LOX inhibitor, Lornoxicam (81.78 % inhibition). 
ii) Effect of A.bracteosa (ABEE): 
ABEE at all tested concentrations exhibited 5-LOX [Figure 4.2.2 (B)]. 
The percent inhibition of ABEE ranged from 11.8 % (6.25 µg/ml) to 89.16% 
(100µg /ml) with an IC50 value of 27.06 µg/ml (Table 4.2.1). 
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FIGURE 4.2.2 Inhibitory effect of AAEE (A) /ABEE (B) on Lipoxygenase enzyme activity in vitro. 
Indomethacin and lornoxicam were  used as standard reference. Varying concentrations of the standards were used. 
Data is expressed as Mean ± SEM and all values are mean from six independent determinations . *Denotes comparison between 
Control ≠  and other experimental groups. The P values were calculated by One Way ANNOVA. *P < 0.05, ** P < 0.01, *** P < 
0.001, followed by Bonferroni correction multiple comparison test. 
 
TABLE   4.2.1: The IC50 values of AAEE and ABEE on COX 1/COX 2 and 5-LO enzyme activity  
 
Test  
Compounds 
 
IC50 
≠
 
 
COX 1 
 
COX 2 
 
5-LO  
 
AAEE 
 
23.6  
 
30.76 
 
27.61 
 
 
ABEE 
 
36.70 
 
27.54 
 
27.06 
 
 
≠ Concentration in  µg/ml required to inhibit the enzyme activity by 50%, which was    
   determined by regression analysis, using Graphad Instat software. 
(B)
))) 
(A) 
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4.2.3 In vitro studies on RAW 246.7 macrophage cell line  
 (A ) Effect of AAEE/ABEE on Cell viability  
 To test and verify the effect of AAEE/ABEE on cell growth in RAW 
246.7 cells we used the MTT assay as shown in Figure 4.2.3 (A& B). It was 
observed that AAEE and ABEE did not impair cell viability at concentrations 
upto 100 µg/ml. This concentration range was within the concentration range 
exhibiting COX and 5-LOX enzyme inhibition.   
(B) Effect on NO release in LPS stimulated cell lines. 
After discovering the effectiveness of test extracts on COX 1/2 and 5-
LOX enzyme pathway we examined whether or not AAEE/ABEE could 
suppress activation of macrophages, induced by LPS. LPS is one of the most 
potent macrophage activation factors. The activity was measured by 
quantifying release of NO in the presence of LPS and our test extracts. 
i) Effect in presence of A.accuminata (AAEE): 
The effects of AAEE on NO production  in unstimulated and LPS 
stimulated RAW macrophages is as shown in Figure 4.2.3 (C). Low levels of 
nitrate 2.99µM were seen in the unstimulated macrophages. Cells activated 
with LPS (1 µg/ml) after 24 hours caused sustainable increase in nitrate 
production (25.8µM). Co-treatment of macrophages with AAEE 6.25 to 100 
µg/ml and LPS (1 µg/ml) for  24 hours evoked significant decrease in nitrate 
production in a concentration dependent manner. At 100 µg /ml AAEE nitrate 
levels maximally decreased to 4.08µM demonstrating 84.1% inhibitory effect. 
This indicated for strong concentration dependent anti-inflammatory effects for 
AAEE. AAEE at 100 µg /ml alone did not show any appreciable increase in 
NO production. The IC50 value for AAEE was found to be 25.91µg/ml. 
ii) Effect in presence of A.bracteosa (ABEE): 
Co-treatment of LPS and the extract, ABEE demonstrated dose 
dependant suppression of nitrate release from activated macrophages. In 
unstimulated macrophages, low levels of nitrate (2.99µM) were seen. Co-
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treatment with LPS and ABEE for 24 hours at a concentration of 6.25, 12.5, 
25, 50 and 100 g/ml decreased the nitrite levels from 26.4µM in LPS alone 
treated macrophages to 24.93µM, 20.64µM, 12.9 µM, 4.64µM and 4.14µM 
respectively [Figure 4.2.3(D)] with maximal percent inhibitory effect at 100 
µg/ml (IC50 value ., 24.06 µg/ml). 
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FIGURE 4.2.3: Effects Of AAEE /ABEE on cell viability., (a & b):  production of NO (c & d) on macrophage 
cell line after LPS stimulation.  
All values were expressed as Mean ± SD (n=6) .Statistical significance: *P < 0.05, **P < 0.01, *** P < 0.001, versus LPS 
control., 
δ
P < 0.001 versus vehicle control (see section 4.1) (One way ANNOVA followed by Bonferroni Multiple comparison 
test). 
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(C) Effect on the production of pro inflammatory cytokines, TNF-α & Il-1β: 
The levels of pro inflammatory cytokines are important in regulating the extent 
of inflammation. To elucidate the effect of AAEE /ABEE on LPS stimulated TNF- α 
& Il-1β release, the supernatant from the activated macrophages was assayed using 
ELISA kits.  
i) Effect in presence of A.accuminata(AAEE): 
It was observed that concurrent treatment with LPS and AAEE 
inhibited the release of both cytokines TNF- α & Il-1β in a concentration 
dependent manner. The inhibitory effect was 82.14% for TNF- α and 74.14% 
for IL-1β, when AAEE concentration was 100 µg/ml. See Figure 4.2.4 (A). 
ii) Effect in presence of A.bracteosa (ABEE): 
Treatment with LPS alone macrophage cells showed a significant 
increase in both cytokine levels. The inhibitory effect of ABEE on cytokine 
production was concentration dependent [Figure 4.2.4 (B)]. At 100 µg/ml, 
maximal inhibitory effect of 85.09% and 77.96% for TNF- α and                          
IL-1β, respectively was observed. 
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FIGURE 4.2.4: Effects Of AAEE (A) and ABEE (B) on TNF-α & IL-1β production in RAW 246.7 
macrophage cell line after LPS stimulation. All values were expressed as Mean ± SD (n=6) .Statistical significance: 
*P < 0.05, **P < 0.01, *** P < 0.001, versus LPS control., 
δ
P < 0.001 versus vehicle control (see section 4.1) (One way 
ANNOVA followed by Bonferroni Multiple comparison test). 
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4.2.4. Acute safety studies 
There was no noticeable change in behavior nor any mortality observed upto a 
single maximum dose of 2500 mg/kg b.w dose of both test extracts over a period of 14 
days. No adverse effects were observed which hint that doses of AAEE/ABEE used in 
the study are tolerable without any noticeable side effects and was safe to use. 
4.2.5 (A) Inhibition of Carragenean induced rat paw edema: 
Intraperitoneal injection of carragenean to rats caused an inflammatory reaction 
and in presence of our test extracts inhibitory effects were observed one hour before 
the injection of carrageenan. These effects were observed at four time points (0.5,1,2 
and 3 hours). In carregenean administered animals the severe paw swelling observed 
reached maximum at 3
rd
 hour. 
ii) Effect of A.accuminata (AAEE): 
At the end of 3 hours in groups treated with AAEE 62.5, 125, 250 and 
500 mg/kg b.w showed inhibitory effects of 14.6%, 31.7%, 48.7% and 68.2% 
respectively. The percent reduction in paw edema was highly significant in the 
group treated with 500 mg /kg and was more potent than Ibuprofen which 
showed percent inhibition of 49.8% at the end of 3 hours [Figure 4.2.5 (A)]. 
ii) Effect of A.bracteosa (ABEE): 
Our data demonstrated that paw edema was reduced by ABEE in a dose 
dependant manner. In carrageenan administered animals (Group II) swelling 
reached its maximum by the end of 3 hours and in case of Ibuprofen treated 
groups swelling was inhibited to 50 % at the end of 3 hours in comparison to 
carrageenan treated group. In case of groups treated with ABEE, the 
percentage reduction in paw edema was highly significant in the group treated 
with 500 mg /kg b.w with 59.52% at the end of 3 hours.The other treated 
groups showed a dose dependent response as shown in Figure 4.2.5 (B). 
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Figure 4.2.5: Effect of graded doses of AAEE (A)/ ABEE (B)  on carragenean induced paw edema . 
Data represent the Mean ± SEM (n=6) .Statistical significance: *P < 0.05, **P < 0.01, *** P < 0.001, versus with respect to Cg 
control group (One way repeated measures ANNOVA followed by Bonferroni Multiple comparison test). 
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4.2.5 (B) Downregulation of PGE2 and LTB4 in tissue exudates. 
i) Effect of A.accuminata (AAEE): 
At 500 mg/kg b.w, AAEE demonstrated 68% inhibitory effect on PGE2 
production and 75.4 % inhibitory on LTB4 production. Under same 
experimental conditions Ibuprofen reduced the levels to 50.67% and 50.71% in 
case of PGE2 and LTB4 respectively [Figure 4.2.6(A &B)]. 
ii) Effect of A.bracteosa (ABEE): 
At 500 mg/kg b.w. PGE2 and LTB4 levels were downregulated 
maximally to 76% and 86.92%, respectively. These findings demonstrated 
ABEE exhibits more potent effects than standard allopathic drug, Ibuprofen as 
shown in Figure 4.2.6 (C & D). 
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FIGURE 4.2.6: Effects Of AAEE (a&b) and ABEE (c&d) on PGE2 and LTB4 levels in paw exudates 
in the carragenean rat paw model.  
Data represent the Mean ± SEM (n=6) .Statistical significance: *P < 0.05, **P < 0.01, *** P < 0.001, versus with respect to Cg 
control group (One way repeated measures ANNOVA followed by Bonferroni Multiple comparison test). 
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4.2.5 (C) Effect on level of the anti-oxidant enzymes: 
The liver tissues of the animals used for the study were analysed for 
anti-oxidant enzyme activities (SOD, GPX and GR). 
i) Effect of A.accuminata (AAEE): 
As is seen in Table 4.2.2 (A) treatment with carragenean caused a 
distinct decrease in the level of anti-oxidant enzymes. Pre-treatment of AAEE 
followed by carrageenan injection was accompanied with significant dose 
dependant increase in the levels of anti oxidant enzymes. AAEE at 
6.25,125,250 and 500 mg/kg b.wup regulated SOD, GPX and GR levels in a 
dose dependent manner.  
ii) Effect of A.bracteosa (ABEE): 
ABEE at all doses exhibited significant upregulation of the biochemical 
enzymes. At 500 mg/kg AAEE, the effects were fairly comparable to that of 
Ibuprofen [Table 4.2.2 (B)]. 
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Table 4.2.3: Effect of graded doses of(A) AAEE and (B) ABEE on anti-oxidant enzymes in 
carragenean induced model. 
 
Concentration 
(mg/Kg) 
SOD 
(U/mg protein) 
GPX 
( U/(µg GSH 
utilized/minute/mg 
protein) 
GPR 
( U/(µg GSSG 
utilized/minute/mg 
protein) 
Control 
(Naive) 
 
- 
42.24 ± 1.53 33.40 ± 0.33 30.12 ± 1.26 
Cg Control - 15.23 ± 2.73 2.35 ± 0.16 2.092 ± 0.005 
AAEE 62.5 20.52 ± 2.05 6 .87 ±0.12 5.081 ±0.003 
AAEE 125 25.01 ±3.18 10.45 ± 0.14** 11.067 ± 0.006* 
AAEE 250 33.39 ± 1.56*** 19.89 ± 0.18*** 19.045 ± 0.007*** 
AAEE 500 40.17 ± 2.54*** 30.33 ± 0.16*** 30.02 ± 0.004*** 
Ibuprofen 50 41.75 ± 2.21*** 31.65 ± 0.15*** 28.63 ± 0.003*** 
 
 
Concentration 
(mg/Kg) 
SOD 
( U/mg protein) 
GPX 
( U/(µg GSH 
utilized/minute/mg 
protein) 
GPR 
( U/(µg GSSG 
utilized/minute/mg 
protein) 
Control 
(Naive) 
- 46.04 ± 2.03 34.90 ± 1.63 32.12 ± 2.16 
Cg Control - 17.97 ± 3.21 2.66 ± 0.18 2.19 ± 0.006 
ABEE 62.5 20.43 ± 1.89* 7.89 ± 0.15 6.07 ± 0.005 
ABEE 125 23.43 ± 2.65*** 12.43 ± 0.16* 11.06 ± 0.007** 
ABEE 250 35.89 ± 3.06*** 20.77 ± 0.14*** 20.34 ± 0.004*** 
ABEE 500 44.33  ± 2.95*** 30.26  ± 0.18*** 27.01 ± 0.005*** 
Ibuprofen 50 43.65 ± 2.44*** 33.03 ± 0.15*** 29.038 ± 0.006*** 
 
 
 
[ 
 
Data represent the Mean ± SEM (n=6) .Statistical significance: *P < 0.05, **P < 0.01, *** P < 0.001, versus with respect to Cg 
control group (One way repeated measures ANNOVA followed by Bonferroni Multiple comparison test). 
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4.2.6 (A) Effect on Carragenean induced pleurisy in rats  
The pleurisy model in rats serves as an acute model where inflammatory 
response is characterized by the accumulation of fluids in the pleural cavity with a 
large number of polymorphonuclear leukocytes and elevated levels of pro-
inflammatory mediators. 
   (A) Quantification of leukocyte migration and exudate volume: 
i) Effect of A.accuminata (AAEE): 
   As depicted in Table 4.2.3 (A) leukocytes and neutrophil count was 
significantly increased in carrageenan induced group, which however got 
reduced in a dose dependent manner with test extracts and ibuprofen. Treatment 
with 500 mg/kg b.w, AAEE demonstrated maximal reduction in leukocyte and 
neutrophil count. No appreciable effect was seen on mononuclear cells at any 
dose administered. Exudate volume was decreased by AAEE from 10.29% 
(62.5 mg/kg b.w) to 68.7% (500 mg/kg b.w) against the Carragenean (Cg) 
control group. Ibuprofen at the dose 50 mg per kg showed 56.81% and 47.2% 
inhibiton of exudate volume and total leukoctyes respectively. Consistent to 
results of carregenean paw model the inhibitory effects of AAEE were more 
pronounced than Ibuprofen.  
ii) Effect of A.bracteosa (ABEE): 
    In presence of ABEE, again a dose dependant pattern was observed as 
shown in Table 4.2.3 (B). The exudate volume at the different doses of 
62.5,125, 250 and 500 mg/kg b.w. was 2.56 mm, 2.42 mm, 1.74 mm and 0.98 
mm respectively. Maximal decrease of 66.32% was seen at 500 mg kg b.w. This 
effect was more potent than that of Ibuprofen. The total leukocyte and 
neutrophil count was decreased to 20.4 ×10
3
/mm
3
 and 16.15×10
3
/mm
3
, 
respectively by ABEE at 500 mg kg b.w. dose from 69.18 ×10
3
/mm
3
 and 
58.23×10
3
/mm
3
 seen as for carragenean control. For Ibuprofen leukocyte count 
decreased to 70.51% and nuetrophil count to 72.26% at a dose of 500 mg/kg 
b.w. Maximal response was seen in presence of 500 mg/kg dose of the extract 
and this anti-inflammatory response was significant and more potent in 
comparison to Ibuprofen.  
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(B) 
Table 4.2.3:  Effect of AAEE (A) and ABEE (B) on leucocytes migration and exudation in pleural fluid. 
 
 
Data represent the Mean ± SEM (n=6) .Statistical significance: *P < 0.05, **P < 0.01, *** P < 0.001, versus with respect to Cg control group (One way repeated measures ANNOVA followed by Bonferroni Multiple comparison test). 
  
Concentration 
(mg/kg) 
 
Total cells 
(×10
3 
/  mm
3
 ) 
 
Nuetrophils 
(×10
3 
/  mm3 ) 
 
Mononuclear cells 
(×10
3 
/  mm
3
 ) 
 
Exudate volume 
(ml) 
 
NC - 1.82 ± 0.41 1.52 ± 0.13 0.7 0± 0.01 
0.31± 0.01 
Cg Control - 68 .19± 3.91 56 .72 ± 4.21 12 .42± 0.65 3.01 ± 0.34 
AAEE 62.5 60 .8 ±4.09 50 .8 ± 2.12 12 ± 0.50 2.7 ± 0.18 
AAEE 125 55.09  ± 3.86 42.20 ± 2.96*** 11.47 ± 0.69 2.28 ± 0.19 
AAEE 250 38 .50 ± 4.51*** 30.45 ± 1.23*** 10.86 ± 0.42 1.56 ± 0.10** 
AAEE 500 22 .02 ± 3.98*** 18.31 ± 1.94*** 9.66 ± 0.50** 0.96  ±  0.2*** 
Ibuprofen                       50 36 ±1.02  *** 24.92 ± 2.29*** 10.08 ± 0.35* 1.30  ±  0.21*** 
 
Concentration 
(mg/kg) 
 
Total cells 
(×10
3 
/ cmm) 
 
Nuetrophils 
(×10
3 
/ cmm) 
 
Mononuclear cells 
(×10
3 
/ cmm) 
 
Exudate volume 
(ml) 
 
NC - 1.82     ±  0.38 1.86     ±  0.23 0.7     ±  0.01 0.26  ±  0.01 
Cg Control - 69 .18  ±  4.41 58 .23  ±  4.11 13.08   ±  0.49 2.91  ±  0.30 
ABEE 62.5 64 .90   ±  4.39 55 .01  ±  2.02 12.70   ±  0.32 2.56  ±  0.28 
ABEE 125 59.40   ±  4.59 49.40  ±  2.66 11.80  ±  0.27 2.42  ±  0.22 
ABEE 250 42.30   ±  4.01** 37.80  ±  1.44*** 11.19  ±  0.40* 1.74  ± 0.10** 
ABEE 500 20 .40  ±  3.80*** 16.15   ±  1.01*** 10.38  ±  0.50*** 0.98  ±  0.17*** 
Ibuprofen 50 34.21   ±  1.82*** 28.07  ±  2.19*** 11.12  ±  0.29* 1.26  ±  0.13*** 
(A) 
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4.2.6 (B) Suppression of arachidonic acid metabolites (PGE2& LTB4) and NO: 
  i) Effect of A.accuminata (AAEE): 
 Following carragenean injection into the pleural fluid, the levels 
of PGE2, LTB4 and NO got elevated. The group treated with Ibuprofen 
showed a significant inhibition of 50 % on PGE2, 51.49% on NO and 
28.51% on LTB4 at a dose of 100 mg/kg b.w [Figure.4.2.7 (A&B)]. 
Comparatively AAEE at doses ranging from 62.5 to 500 mg/kg b.w 
down regulated both PGE2 AND LTB4 levels in pleural fluid in a dose 
dependant manner. At a dose of 500 mg PGE2 and LTB4 levels 
decreased maximally to 68.71% and 65%. At 500 mg/kg b.w. AAEE 
inhibited NO production by 64.1 %.These effects were higher than 
Ibuprofen. In case of NO the levels were attenuated significantly 
following treatment with Ibuprofen and AAEE. However the effects 
were more pronounced for AAEE in contrast to Ibuprofen. 
ii) Effect of A.bracteosa (ABEE): 
Figure 4.2.7 (C&D) depicts the dose dependant suppressive 
response of ABEE on PGE2, LTB4 and NO production in comparison to 
standard drug, ibuprofen. For ABEE, PGE2 AND LTB4 levels were 
downregulated  at all the doses with maximum decrease of 72.36 % and 
70% seen at 500 mg/kg b.w. dose The NO levels were decreased to 
5.9%, 20.98%, 38.85% and 71.06% at doses of 62.5, 125, 250 and 200 
mg/kg b.w. respectively. At a dose of 500 mg/kg of ABEE maximal 
effect was observed and the effect was quite potent in comparison to 
standard drug, ibuprofen. 
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Figure 4.2.7. Effect of graded doses of AAEE/ABEE on PGE2 & LTB4 (a&c) and nitrite/nitrate        
(b & d) levels in cells free supernatant of pleural fluid.  
Data represent the Mean ± SEM (n=6) Statistical test employed is One Way ANNOVA followed by post Bonferroni test. with N= 6 
in each group. *P < 0.05, **P < 0.01, *** P < 0.001, Comparisons were made between Cg Control group and other experimental 
groups.  
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4.2.7 Effect on Vasuclar permeability in mice: 
Acetic acid-induced vascular permeability in a mouse model is a commonly 
used vascular permeability assay. The inflammatory response is a physiological 
characteristic of vascularized tissue. 
i) Effect of A.accuminata (AAEE): 
In this model, AAEE at all graded doses significantly decreased 
vascular permeability in a dose dependent manner. Ibuprofen reduced 
the dye concentration with 39.28 % inhibitory effect in comparison to 
control. Under same experimental conditions, AAEE  decreased 
vascular permeability with 10.71%, 19.04%, 32.14% and 57.14%  
inhibitory effect at 62.5 ,125 ,250 and 500 mg/kg b.w dosages as shown 
in Table 4.2.4 (A). Interestingly the effect of AAEE at 500 mg/kg b.w 
was more potent when compared with the Ibuprofen treated group. 
b) Effect of A.bracteosa (ABEE): 
ABEE also decreased the vascular permeability in a dose 
dependant manner. At 500 mg/kg b.w ABEE demonstrated 61.76% 
decrease in vascular permeability which was higher than ibuprofen 
which caused 41.57% inhibitory effect [Table 4.2.4 (B)].  
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Table 4.2.4.Effect of graded doses of AAEE (A) and ABEE (B) 
on vascular permeability. 
 
 
Concentration 
(mg/kg) 
 
Dye Concentration 
(mg/kg) 
 
 
% Inhibition             
(against control) 
 
Control (Vehicle) - - - 
 
Control 
 
- 
 
0.84 ± 0.04 
 
- 
 
AAEE 
 
62.5 
 
0.75 ±0.03 
 
10.71 
 
AAEE 
 
125 
 
0.68 ± 0.04** 
 
19.04 
 
AAEE 
 
250 
 
0.57 ± 0.04*** 
 
32.14 
 
AAEE 
 
500 
 
0.36 ± 0.01*** 
 
57.14 
 
Ibuprofen 
 
50 
 
0.51 ± 0.02*** 
 
39.28 
 
  
 
Concentration 
(mg/kg) 
 
 
Dye Concentration 
(mg/kg) 
 
 
% Inhibition             
(against control) 
 
Control 
(Vehicle) 
- - - 
 
Control 
 
- 
 
0.89 ± 0.06 
 
- 
 
ABEE 
 
62.5 
 
0.82 ±0.03 
 
7.86 
 
ABEE 
 
125 
 
0.71± 0.05* 
 
20.22 
 
ABEE 
 
250 
 
0.55 ± 0.04*** 
 
38.20 
 
ABEE 
 
500 
 
0.34 ± 0.03*** 
 
61.76 
 
Ibuprofen 
 
50 
 
0.52 ±0.04*** 
 
41.57 
 
Data represent the Mean ± SEM (n=6) Statistical test employed is One Way ANNOVA followed by post Bonferroni test. with N= 6 
in each group. *P < 0.05, **P < 0.01, *** P < 0.001, Comparisons were made between Cg Control group and other 
experimental groups 
 
 
(A) 
(B) 
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4.2.8   Determination of total phenolic content: 
Both the test extracts we found to have high content of phenolics as 
depicted in Table 4.2.5.  
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Table 4.2.5: Polyphenolic contents of the test extract of Atropa accuminata 
(AAEE) and Ajuga bracteosa (ABEE)  
 
PHENOLICS 
 
AAEE 
 
ABEE 
 
Total polyphenols 
(mg GAE/g)
$
 
 
104.19 
 
77.21 
 
Flavanoids 
(mg QRC/g)
#
 
 
1.19 
 
0.89 
 
Total Flavanols 
(mg QRC/g)
§
 
 
0.97 
 
0.80 
 
$ Expressed as mg Gallic acid equivalents/g of dry plant material 
# Expressed asmgquercetin /g of dry plant material 
§ Expressed asmgquercetin /g of dry plant material 
 AAEE-Ethanolic fraction of Aropa accuminata. 
ABEE-Ethanolic fraction of Ajuga bracteosa 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
Chapter – 4.3 
Discussion 
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Inflammation is an overt or covert component of several conditions and 
illnesses affecting humans. Although, inflammation is a process protecting the 
integrity of organisms against physical, chemical and infective insults, yet the 
inflammatory response to several insults erroneously leads to damaging of normal 
tissues (Gethin et al., 2012) and wide range of chronic diseases such as arthritis, 
asthma, inflammatory bowel disease and others (Nakagome et al.,2011; Yamnam       
et al.,2012). Inflammatory response is basically a dynamic process typified by 
swelling, redness, heat and pain. It is known to involve a complex set of interactions 
among soluble factors and cells that arise in any tissue in response to traumatic, 
infectious, post–ischemic, toxic or auto immune injury (Zedler et al.,2006). 
The present study was intended to investigate the modulatory effect of 
A.accuminata and A .bracteosa on in vitro and in vivo acute inflammatory models for 
its possible ability as anti-arthritic principle and also to elucidate its mechanism of 
action on the basis of its potential modulation of cytokine production, generation of 
nitric oxide and eicosanoid metabolites, including prostaglandins and leukotrienes. 
Cycoloxygenase 1 & 2 and 5-Lipoxygenase are the rate limiting enzymes that 
catalyze the formation of two multifunctional inflammatory mediators, prostaglandins 
and leukotrienes (Simmons et al., 2004).  In order to screen and evaluate the test 
extract for its anti-inflammatory properties, we first aimed to examine its inhibitory 
effects on both COX 1, COX 2 and 5 -LOX pathways in vitro. 
COX exists in two isoforms COX 1 and COX 2.COX 1 is a constitutive 
isoform expressed in platelets, kidney, GIT and liver whereas COX 2 is an inducible 
isoform (Vane et al.,1998). Our in vitro study revealed that the extract of Atropa 
accuminata and Ajuga bracteosa exhibited dose dependant inhibitory effects on COX 
1 as well as COX 2 enzymes with maximal inhibitory effects observed at a 
concentration of 100µg/ml. This concentration related inhibitory activities were highly 
comparable to indomethacin and Celecoxib, the standard COX1 and COX2 inhibitors, 
respectively.  
Several plant extracts have been reported for in vitro inhibitory effects on COX 
enzymes (Alberto et al.,2009, Li et al.,2004, Farabaksh et al.,2011). Many compounds 
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like procumentin, gossyptein and chrysin isolated from different plants have 
demonstrated significant COX 2 enzyme inhibition. Many flavanoids and phenolic 
components have been reported to inhibit COX enzymes via iNOS mechanism (Mada 
et al.,2009). It has been reported that in macrophages and in other cell types, 
lipoplysaccharides induce co-expression of inducible nitric oxide synthase (iNOS) and 
cyclooxygenase-2 (COX-2) resulting in the production of large pro-inflammatory 
mediators, nitric oxide and prostaglandins, at the inflammatory site (Lee et al.,1992). 
The COX inhibitory activities of AAEE and ABEE could be attributed to its regulation 
at the level of iNOS and COX 2 gene. Rosa Rugosa reported anti-inflammatory effects 
have been shown to suppress both iNOS and COX 2 expression (An et al.,2011).  
5–LOX, a non heme iron containing dioxygenase is implicated to play a critical 
role in cardiovascular, asthma and various associated inflammatory disorders (Peters-
Golden et al.,2007). For 5 -LOX pathway both the test plant extracts, AAEE/ABEE 
afforded concentration dependant inhibition with maximal inhibition at 100 µg/ml 
which in turn was significantly comparable to standard drugs, indomethacin and 
lornoxicam. It has been reported that several whole plant extracts like that of 
Tinospora smilancan and Cissus quadrangularis act as potent inhibitors of LOX 
(Bhujade et al., 2012, Li et al.,2004). Many phenolic components isolated from olives 
have also been reported to have 5-LOX inhibitory activities (Kohyama et al.,1997). 
Further many Boswellic acid derivatives from Boswellia seratta have also been found 
to act as novel and specific inhibitors for LOX (Ammon  et al.,1992). We know that 5-
LOX is the main enzyme catalyzing the production of leukotrienes, another important 
group of inflammatory mediators playing a critical role in the pathogenesis of 
inflammatory process. LTB4 is an important mediator in the development and 
maintenance of inflammatory reactions (Back et al.,2008). Several leukotriene 
synthesis inhibitors also have been reported to be used for treatment of inflammatory 
disorders. Many plant based molecules have also been reported to significantly 
suppress LTB4 formation via inhibition of 5-LOX and possess potent anti 
inflammatory effectiveness (Fan et al., 2012,Feisst et al.,2009).  
AAEE and ABEE exhibited dual inhibitory effects on COX 1, COX 2 and      
5-LOX enzymes. Interestingly the effects of both AAEE & ABEE on 5 -LOX pathway 
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were higher compared to COX enzymes. In recent years, several investigations have 
suggested that both traditional NSAIDS and newer Celecoxibs inhibit the COX 
enzymes but in turn shunt the arachidonic acid metabolism towards LTB4 biosynthesis 
(Burnett et al.,2012) consequently leading to renal dysfunction (Perazella et al.,2000) 
and GIT side effects (Hinz et al.,2002).Therefore the use of “dual inhibitory agents”, 
which could inhibit not only COX 1 &COX 2 enzymes but also leukotriene 
biosynthesis via 5-LOX pathway has evolved as a vital target for anti-inflammatory 
therapies (Brune et al.,2004). Such agents tend to balance the arachidonic acid 
metabolism in the body and are therefore considered to be particularly effective in 
minimizing the gastric and cardiovascular side effects (Leone et al.,2007). Our in vitro 
data indicated AAEE/ABEE exhibiting potential for similar dual inhibitory effects. 
Anthocyanins present in different varieties of cherries have also been reported to have 
significant dual COX and 5-LOX enzyme inhibitiory activities (Mulabagal et 
al.,2009).  
To gain more information on the underlying mechanisms of the anti-
inflammatory effects of our test extracts we extended studies on murine macrophage 
cell line RAW 246.7 for the effects on NO, IL-1β and TNF-α production in the 
presence of LPS, a stimulant. Our results demonstrated that AAEE and ABEE 
markedly down regulated the LPS induced NO production along with the pro 
inflammatory cytokines in RAW cells. Parallel to the findings on COX 1, COX 2 and 
5 -LOX enzymes, macrophages when treated with various concentrations of AAEE 
/ABEE revealed concentration dependent decrease in NO, TNF and IL-1 production. 
Maximal inhibitory effects were observed for AAEE and ABEE at 100 µg/ml. To rule 
out any cytotoxicity induced anti inflammatory effects of AAEE on RAW cells, MTT 
assay was carried out in absence of LPS. Both the test extracts did not affect cell 
viability upto 100 µg/ml. Henceforth, it was evident that test plant extracts inhibited 
the production of NO and pro-inflammatory cytokines in activated macrophages 
without any toxic effects.  
Macrophages play a crucial role in regulating cell mediated inflammatory 
reactions in response to microbes and microbial products such as LPS. Macrophages 
secrete NO and a series of cytokines particularly – TNF- α, IL-1β (Bogdan et al.,2001) 
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and aberrant or overproduction of these mediators has been implicated in the 
pathogenesis of several chronic inflammatory diseases such as arthritis, multiple 
sclerosis, parkinson’s disease and Alzheimer’s (Takahashi et al.,1997). NO is reported 
to activate both the constitutive COX1 as well as the inducible COX 2, the rate 
determining enzymes (Salvemini et al.,1993), thus the in vitro inhibition of COX 
enzymes by AAEE and ABEE could be attributed to suppressive effects on NO 
production, presumably a consequence of iNOS  inhibition at transcription level. iNOS 
is the key enzyme involved in NO production under pathological conditions. LPS 
activated macrophages have been reported to co-induce iNOS, COX 1 and COX 2 
enzymes. In addition, TNF-α, the pivitol anti-inflammatory cytokine can stimulate the 
release of a cascade of other cytokines inclulding IL-1β and chemokines as well as 
expression of adhesion molecules and inducible enzymes (Arias-Negrete et al.,1995). 
Both TNF-α and IL1-β synergistically are involved in chronification of inflammatory  
reactions thorough induction of COX 2 expression in activated immune cells and also 
enhances the production of PGE2 (eicosanoids). Therefore, inhibition of COX 2 
activity by the extracts could also inturn modulate local and systemic cytokine 
responses. Hence, pro-inflammatory cytokine inhibition could help to target the entire 
intracellular cytokine cascade as well as co-inhibit prostanoid production. Cytokines 
are reported to upregulate NF-κB expression in LPS activated macrophages to co 
induce iNOS and COX 1&2  (Vila-del et al.,2005). Hence we could possibly relate the 
COX enzyme inhibitory activities of AAEE/ABEE and suppression of NO production 
in vitro to the down regulation of pro inflammatory cytokines. Our findings  that 
AAEE/ABEE inhibits formation of NO, pro inflammatory cytokines, COX 1,COX 2  
and 5-LOX enzyme activities point to their role in the anti-inflammatory effects  of 
our test extracts . 
The data of test extracts obtained from in vitro studies was tested further by 
carrying out various in vivo studies in different acute models of inflammation. In the 
animal models, AAEE   and ABEE exhibited potent anti inflammatory activity when 
administered orally. Upto 2500 mg/kg b.w. no signs of mortality nor any toxicological 
consequences were observed for AAEE and ABEE indicating about their safe usage 
even at higher doses. 
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The carragenean induced paw edema has been commonly used as an 
experimental model to assess the contribution of mediators involved in vascular 
changes associated with acute inflammation (Winter et al., 1962) and was used to 
assess the anti-inflammatory potential of our test extracts. The development of edema 
in rat hind paw following an injection of carragenean has been categorized as a 
biphasic event in which various mediators operate in a sequence to produce 
inflammatory response. The initial rapid phase (0-1 hour) of the inflammation has 
been attributed to the release of histamine, serotonin, bradykinin and 5-
hydroxytryptamine and similar substances (Di Rossa et al.,1971). The latter 
accelerating but sustained phase of swelling (upto 3 hours) is sustained by proteases, 
lysozymes, prostaglandin release, leukotrienes and NO  by polymorphonuclear cells 
and has been attributed to the induction of inducible cycloxygenase and  iNOS 
(Sidhapuriwala et al.,2007). AAEE and ABEE both at a dose of 500 mg/kg reduced 
edema to a greater extent than standard drug, ibuprofen. NSAIDS like ibuprofen are 
reported not to be effective in the later phase of such edema formation (Boughton-
Smith et al.,1993). In our study, dose dependent suppressive effects on paw edema by 
AAEE and ABEE were observed in both the phases, however significant inhibitory 
effect was seen only at 3 hours suggesting a more potent inhibition on PGE2 release 
than histamine or serotonin. Consistent to these reports, the production of eicosanoids., 
PGE2 and leukotrienes., LTB4 in paw exudates was also significantly reduced and the 
effects seen, were more potent than ibuprofen.  
The carragenean induced inflammatory response has also been strongly linked 
to the release of neutrophil dervived mediators like H2O2, SO2, OH radicals. ROS 
produced for the neutrophils and macrophages contribute to macromolecular based 
tissue injuries during inflammatory reactions (Winrow et al.,1993).There has been 
large body of evidence to link the production of free radical species (ROS) to the 
pathophysiolgy of tissue damage associated with inflammatory response In various, in 
vivo models it has been revealed that many of the anti inflammatory agents mediate 
their effects through the inhibition of free radical generation by activated neutrophils 
(Winyard et al.,1999). Among the compensatory responses against ROS generation, 
SOD, GPX and GRX are the enzymes of particular interest.  
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In our findings, we observed a significant dose dependent increase in these 
antioxidant enzymes by the test plant extracts. Both the test extracts, AAEE and ABEE 
upregulated the levels of glutathione peroxidase (GPX) and glutathione reductase 
(GR).The effects were comparable highly with Ibuprofen. GPX, a selenium containing 
enzyme catalyzing the reduction of a variety of hydroperoxides (ROOH and H2O2) 
using GSH has been shown to protect mammalian cells against oxidative damage. 
During carragenean induced inflammation, the activity of the GPX is observed to be 
seriously depressed (Kalpakcioglu et al., 2008). 
Another enzyme, superoxide dismatse (SOD) takes care of the superoxide 
anion radical (O2
ˉ
) that is one of the common radicals produced in the cell under both 
normal and diseased conditions. In acute inflammation superoxide is produced at the 
rate that overwhelms the capacity of the endogenous SOD enzyme defense system to 
remove it. Our results, suggested that both the test extracts show positive modulation 
of the SOD following carragenean treatment indicating that these have the potential to 
affect free radical scavenging. In particular, the comparable results of ABEE/AAEE 
and Ibuprofen suggest that there is a positive correlation between modulation of SOD 
and the final inflammation. Superoxides have been implicated in number of effects 
which may include release of cytokines and the recruitment of neutrophils at the site of 
inflammation. The activity level of SOD is an important biochemical parameter in 
inflammation as it modulates superoxide anion activity which is known to cause tissue 
damage and consequent inflammation (Boughton-smith et al.,1993). 
Overall these findings in carragenean rat paw model indicated that AAEE and 
ABEE show anti-inflammatory activity significantly to traditional NSAIDs 
(Ibuprofen).They continue to show good anti-inflammatory potency during the later 
stage of edema formation. 
The pleurisy model has been reported to be involved in exudation and 
infiltration of neutrophils and mono nuclear cells in various proportions. Leukoctye 
migration is a hall mark of inflammatory cascade of reactions. Carragenean injection 
in the pleural fluid promoting an acute inflammatory response resulted in increased 
total leukocyte counts in particular the neutrophil counts and also increased exudation 
volume (Di Palo et al.,2004). Normally the pleural fluid contains a few lymphocytes 
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not more than 100 cells/ml (Light et al.,1990). However carragenean injection in the 
pleural fluid caused noted exudation, increased neutrophil and total leukocyte count. In 
contrast treatment with Ibuprofen and test plant extracts decreased the cell count and 
also the exudate volume, with maximal effects seen at 500 mg/kg body weight. The 
decrease in exudate volume by test extracts may be attributed to suppressive effects of 
AAEE/ABEE on vascular permeability, since both the extracts also decreased acetic 
acid induced vascular permeability in mice model. Acetic acid unleashes the release of 
several mediators such as bradykinin, substance P and prostaglandins, as well as 
cytokines such as IL-1β, TNF-α and IL-8 (Sekiya et al.,1982). Total decreased 
leukocyte count could be attributed to significant inhibition of neutrophils. Neutrophils 
have been implicated for potential tissue damage in chronic inflammatory diseases by 
the production of tissue degrading enzymes and metalloproteinases. Neutrophils are 
also involved in the synthesis of leukotrienes and thromboxane A2 and in several 
inflammatory conditions cause potential tissue damage by the production of tissue 
degrading enzymes, oxygen and nitrogen species and metalloproteinase (Kitz et 
al.,2006). AAEE and ABEE were observed to have potent capacity to significantly 
reduce the migration of neutrophils to the site of inflammation. 
PGE2 is synthesized in substantial amounts at target sites of inflammation to 
potentiate vasodilation, increase blood flow, cause increased vascular permeability and 
potentiate the effect of pro-inflammatory cytokines (IL-1β) (Legler et al.,2010). LTB4 
is a strong chemoattractant for neutrophils and implicated in cardiovascular asthmatic 
diseases. Taken together, these cause vascular leakage and extravasation of fluid and 
cause pain, erythema and swelling, all symptoms of acute inflammation (Sadik et 
al.,2012). We observed reduced production of eicosanoids and leukotrienes for both 
A.accuminata and A.bracteosa possibly from downregulation of COX 1& COX 2 and 
5- LOX in both acute inflammatory responses.  
Our findings also demonstrated decreased NO production after treatment with 
AAEE and ABEE in the pleural fluid which could be responsible for the decrease in 
PGE2 production. NO maintains the carragenean evoked inflammatory response by 
activation of COX pathway (Salvemini et al, 1993). It can be speculated that COX 
pathway might not have been activated in absence of  activation signals by NO after 
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treatment with AAEE/ABEE and which in turn caused the suppression of PGE2 
production and the subsequent inhibition of inflammation. The significant suppression 
of NO and acute tissue damage with increased dosage of the test extracts indicated for 
diverse range of effects for A.accuminata and A.bracteosa. Since NO activity has been 
related to activated leukocytes, cell migration and exudation, low NO levels after oral 
AAEE administration could be explained by decreased influx of leukocytes. In 
addition NO promotes entry of phagocytes into inflamed areas by increasing 
permeability of post capillary venules (Winyard et al.,1999). Also NO and PGE2 
production is reported to be regulated by NO synthase and cytokines . This indicates 
for an extensive range of action for A.accuminata and A.bracteosa. The significant 
decrease of NO and PGE2 could be attributed to the downregulation of cytokines and 
the consequent decreased of expression of iNOS and COX enzymes. 
Plants contain an array of secondary metabolites which include phenolic 
compounds, (phenols, flavonoids, coumarins), nitrogen compounds (alkaloids, 
nitosoamines and other components). Many of such naturally occurring compounds 
such as polyphenolics, diterpenoids, triterpenoids are reported to ameliorate 
inflammatory response. Experimental data has revealed significant correlation between 
the high content of phenolic compounds and the pharmacological activities of natural 
products (Spada et al.,2008). The qualitative and quantitative screening of 
phytochemicals showed AAEE/ABEE to have significant high phenolic content. Total 
flavonoid and flavanol concentration was also significantly high.  Flavonoids also 
have biochemical effects including inhibition of enzymes such as lipoxygenase, 
cycloxygenase, etc. and have been found to have anti-inflammatory activity in both 
proliferative and exudative phases of inflammation. It has also been demonstrated that 
flavonoids inhibit the expression of isoforms of inducible nitric oxide synthase, 
cyclooxygenase and lipooxygenase, which are responsible to cause diminished 
formation of pro-inflammatory mediators (prostaglandins, leukotrienes, reactive 
oxygen species, nitric oxide) as well as other mediators of the inflammatory process 
such as cytokines, chemokines or adhesion molecules. Various flavonoids have found 
application as therapeutic inflammatory agents (Rathee et al.,2009). The diverse mode 
of action of  A.accuminata and A.bracteosa maybe attributed possibly due to the high 
polyphenolic and flavonoid content present in the extract. 
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Collectively our results with Atropa accuminata and Ajuga bracteosa 
demonstrated highly potent anti-inflammatory effects mediated by suppression of 
release of inflammatory mediator, NO, prostaglandins, leukotrienes and pro-
inflammatory cytokines. Since pro inflammatory cytokines upregulate the expression 
of such genes (NF-kB) that are involved in inflammatory response and cause co- 
induction of iNOS and COX2, the two pivotal enzymes related to NO and eicosanoid 
production in inflamed tissues, Atropa accuminata and Ajuga bracteosa can be 
presumed to act through inhibition of NF-κB signaling pathway leading to reduced 
expression of interdependent cytokine and NO production and in turn lead to 
decreased COX enzyme activity. 
 
  
 
 
 
 
 
Chapter - 5 
Assessment of  
Anti-arthritic effects of  
Atropa accuminata  
and  Ajuga bracteosa 
 
 
 
 
  
 
 
 
 
 
 
Chapter – 5.1 
Materials and Methods 
 
Evaluation of anti-arthritic effects of Atropa accunminata and Ajuga bracteosa 
 
-108- 
5.1.1 Chemicals: 
Complete Fruend’s adjuvant (CFA), DMSO, ibuprofen (IBP), phenyl 
methylsulfonyl fluoride (PMSF), aprotinin, (Sigma Chemical), Tween 20 (Santa 
Cruz), Gumacacia (Hi Media), PGE2 and LTB4 ELISA (Cayman chemicals), IL-1β, 
IL-2, IFN-γ, IL-4, IL-6 and IL-10 ELISA kits (R&D Systems). All the other 
chemicals were purchased from Hi-Media and Merck, India. Standard drugs were 
purchased from Sigma-Aldrich chemicals co. (St. Louis O., USA) and all solvents 
used were of HPLC grade (Ranbaxy Chemicals Ltd., Mohali, Punjab, India).  
5.1.2 Test material: 
The ethanolic extracts of Atropa acuminata (AAEE) and Ajuga bracteosa 
(ABEE) were prepared as detailed in section 3.1. 
5.1.3 Animals: 
Studies were carried out using Male Wistar Albino rats of either sex weighing 
150-180 grams. They were procured from IIIM, Jammu and kept in animal house, 
KU. The animals were grouped in polypropylene cages with not more than six 
animals per cage and maintained under standard laboratory conditions (temperature 
25±2°C, relative humidity 60% ±15% and with dark & light circle 12hrs /14hrs).They 
were allowed free access to standard dry pellet (Hindustan lever, Kolkata, India) and 
water ad libitum (CPCSEA, 2003). The animals were acclimatized to laboratory 
conditions before commencement of the experiment. All animal experiments were 
approved by the University animal ethical committee vides No: 80/03/CA/CPCSEA. 
5.1.4 Induction of arthritis: 
Adjuvant induced arthritis is the best available model having nearest 
approximation to human rheumatoid arthritis (Pearson and Wood, 1963). Briefly, on 
day 0, rats were weighed and were marked directly above the ankle joints to provide 
an anatomical marker to minimize variability when measuring paw volume. Next day, 
on Day 1 adjuvant arthritis was induced by the sub-plantar injection of 100 µl of CFA 
containing heat killed and dried mycobacterium tuberculosis (strain H37Ra, ATCC-
25177) into the dorsum of the right hind paw between the third and fourth digits of 
each rat. The animals were divided into groups of 6 animals each. Group I, (Normal 
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control), received 1% gum acacia, Group II, received 1% gum acacia (Arthritic 
control); Group III: AAEE /ABEE (62.5 mg/kg b.w.); Group IV: AAEE/ABEE (125 
mg/kg b.w); Group V: AAEE/ABEE (250 mg/kg b.w); Group VI: AAEE/ABEE  
(500mg/kg b.w); Group VII: Ibuprofen (50mg/kg b.w).All the  test extracts and 
standard drugs  were dissolved in 1% guma acacia and were given orally one day 
(Day 0) before the adjuvant injection and then once daily for 21 days (Newbould et 
al., 1963). Ten days after injection, secondary inflamed lesions were detected on the 
left hind paw, which began to increase in thickness and also in the fore-paws, ears and 
tail. All groups were induced with arthritis by injection of CFA except group I (Naïve 
Control).  The dosage of the test extracts was fixed as described in section 4.1. 
5.1.5 Evaluation of Severity of arthritis: 
To evaluate the arthritic progression of CFA-induced arthritis in rats, three 
different parameters were measured: paw volume (primary and secondary lesions), 
squeaking score in the ankle flexion test and arthritic score. 
i) Assessment of mean paw volume ( primary and secondary lesions) : 
The volume of the injected hind paws (“primary” lesions) and un-
injected hind paws (“secondary” or immune-mediated response) 
(Arrigoni-Martelli and Brannm,1976) were measured using 
plethysmometer (UGO, Basile, Italy) on alternate days from day 1 to 
day 21 after the adjuvant injection. Any changes in paw volume were 
calculated as the difference between volumes on day 0 and volumes 
recorded on days 3, 5, 7, 9, 11, 13, 15, 17 and 19. The paw volume was 
measured as relative values to that of Day 1, when CFA was injected. 
ii) Assessment of ankle flexion score : 
The squeaking test (ankle flexion test) involved gentle flexion and 
extension of CFA injected hind limb (Kwon et al., 2001). This elicited 
vocalization (squeaking) that were scored on a scale (squeaking score). 
The procedure of flexion and extension was repeated 10 times in every 
5 secs and the rating of 0 (null) or 1 (vocalization) was given to each 
hind limb. This test was performed only once a day in each animal. 
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iii) Assessment of arthritic score: 
The rats were assessed daily for signs of arthritis between days 7 and 25 
post-CFA using a well-established, widely-used scoring system 
developed to evaluate the severity of adjuvant-induced arthritis. Paws 
were examined and graded for severity and loci of erythema, swelling 
and induration using a 5-point scale: 0 = no signs of disease, 1 = signs 
involving the ankle/wrist, 2 = signs involving the ankle plus tarsal of the 
hind paw and/or wrist plus carpals of the forepaw, 3 = signs extending 
to the metatarsals or metacarpals and 4 = severe disease involving the 
entire hind or fore paw (Durai et al., 2004). The maximum arthritic 
score per rat was set at 16 (4 points × 4 paws). 
5.1.6 Measurement of body organ weights: 
During the experimental period, the body weight was measured using a digital 
weighing balance on day 0 and day 21
st
. At the end of 21 days after sacrificing the 
animals, thymus and spleen once removed were also weighed. 
5.1.7 Local tissue collection: 
On Day 21 post-injection, blood was collected from the animals from retro-
orbital plexus in EDTA containing tubes for serum preparation which was stored at -
20°C till further analysis and on the same day, the rats were deeply anesthetized with 
sodium pentobarbital (80 mg/kg, i.p.). The paw tissue was collected, weighed and 
frozen. 
 Homegenisation of tissue: 
Tissue from frozen paws containing bony tissue were weighed,broken 
into pieces on dry ice  and homogenized with an extraction buffer containing 1 
mM phenyl methyl sulphonyl fluoride (PMSF), 1µM/ ml Apopritin and 0.05 
% TWEEN in PBS (4 ml/g of tissue) using polytron homogenizer. The 
homogenate was centrifuged at 5000g for 15 mintues (Magari et al., 2004) and 
the supernatants obtained were stored at -80ºC analysis. Some of the retained 
paw tissue was washed with normal saline, fixed in 10 % formalin and stored 
at 4°C for histopathological studies. 
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The supernatant from homogenized paw samples and serum samples 
were subjected to further biochemical and haematological examination. Liver, 
thymus and spleen were removed from the sacrificed animals and weighed 
(Hu et al., 2005). 
5.1.8 Haematological examination: 
Haematological parameters., WBC, RBC, Hemoglobin and erythrocyte 
sedimentation rate (ESR) were assessed in serum samples using the routine laboratory 
methods in serum samples on day 21.  
5.1.9 Biochemical studies: 
C-Reactive protein (CRP) and Rhuematoid Factor (RF) were estimated in 
serum using kits according to manufactures instructions (Monzyme India Private 
Limited). 
5.1.10 Measurement of anti oxidant enzymes: 
The experimental animals of CFA induced model from respective groups were 
sacrificed. Liver was isolated on day 21
st
 as described earlier and whole tissue after 
rinsing in ice cold normal saline was immediately placed in normal saline (double this 
volume) and homogenized at 4ºC. The homogenate was centrifuged at 12000 rpm for 
5 min and the supernatant stored at-20ºC was used for assay of several anti-oxidant 
enzymes. The different biochemical parameters assessed were as follows. 
a) Estimation of superoxide dismutase (SOD ): 
SOD activity was estimated by (Beauchamp and Fridovich, 1971). The 
reaction mixture consisted of 0.5ml of hepatic PMS, 1ml of 50 mM sodium 
carbonate, 0.4 ml of 25µM NBT and 0.2ml of 0.1mM EDTA. The reaction 
was initiated by addition of 0.4ml of 1mM hydroxylamine- hydrochloride. The 
change in absorbance was recorded at 560nm. The control was simultaneously 
run without tissue homogenate. Units of SOD activity were expressed as the 
amount of enzyme required to inhibit the reduction of NBT by 50%.   
b) Estimation of Glutatione peroxidase (GPX ): 
GPx activity was assayed using the method of (Sharma et al., 2001). 
The assay mixture consists of 1.49ml of sodium phosphate buffer (0.1M p.H 
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7.4), 0.1ml EDTA (1mM), 0.1ml sodium azide (1mM), 0.1ml 1mM GSH, 
0.1ml of NADPH (0.02mM), 0.01ml of 1mM H2O2 and 0.1ml PMS in a total 
volume of 2ml. Oxidation of NADPH was recorded spectrophotometrically at 
340nm and the enzyme activity was calculated as nmoles NADPH  
oxidized/min/mg of protein, using € of 6.22 x 103 M-1 cm-1. 
c) Estimation of Glutathione Reductase activity(GRX): 
GR activity was assayed by the method of Carlberg and Mannervik et 
al., 1985. 50s µl of  NADPH (2 mM) in 10 mM Tris buffer (pH 7.0) were 
added in cuvette containing 50ul of oxidized glutathione (20 mM) in 
phosphate buffer. One hundred microliters of PMS was added to the NADPH-
GSSG buffered solution and was measured at 340 nm for 3 min. The enzyme 
activity measured at 340nm was calculated as nmoles of NADPH 
oxidized/min/mg of protein using € of 6.22 x 103 M-1 cm-1. 
5.1.11 Histopathological studies: 
Histopathological examination was performed to determine the degree 
of infiltration of immune cells in the paw tissue upon adjuvant challenge. 
Tissues taken from the rat paws of all the different groups on Day 21
st
 after 
fixing in 10% formalin, were then dehydrated through a graded ethanol series, 
cleared in xylene, and processed for embedding in paraffin wax with routine 
protocols. A microtome was used to cut 4 μm-thick sections that were 
subsequently stained with hematoxylin and eosin (H&E) stain (Bancroft, 
2007). The degree of inflammation was evaluated on a scale from 0 to 5 by 
three different pathologists lacking information about the details of the 
experimentation. The scale was defined as follows: 0 = no inflammation, 1 = 
mild inflammation, 2 = mild/moderate inflammation, 3 = moderate 
inflammation, 4 = moderate/severe inflammation and 5 = severe inflammation. 
5.1.12 Quantification of PGE2, LTB4, NO: 
PGE2 and LTB4 were estimated in serum as well as paw homogenate using 
commercially available kits (Cayman chemicals) according to the manufacturer’s 
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instructions. NO was measured in the homogenate as previously described on RAW 
246.7 macrophage cell line in chapter 3.1.  
5.1.13 Assay of cytokines: 
Cytokines.,IL-1β, IL-2,IFN-γ, IL-4, IL-6 and IL-10 were determined in serum 
and homogenate samples using enzyme linked immunosorbent assay ( ELISA) kits 
according to the manufacturer’s instructions (R&D Systems). The results of cytokine 
assays were expressed as respective cytokine concentrations in pg/ml. 
5.1.14 Data analysis and statistical considerations: 
 Data is expressed as mean ±S.E.M. Statistical significance of differences was 
assessed by One way ANOVA followed by Bonferroni test for multiple comparisons. 
The level of significance was set at P < 0.05. Percent inhibitory activity in different 
experimental groups was derived using following method:  
 
  x 100 
  
 
 
 
 
 
 
Chapter – 3.2 
Results 
 
 
 
 
 
Evaluation of anti-arthritic effects of Atropa accunminata and Ajuga bracteosa 
 
-114- 
In order to determine the anti-arthritic effects of Atropa accuminata and 
Ajuga bracteosa, arthritis-induced animals were prophylactically treated with their 
different doses from 62.5 to 500 mg/kg b.w over a period of 21 days. Different 
parameters were assessed to suggest the possible mechanism involved in their action. 
5.2.1: Effect on hind paw edema:  
The determination of paw edema is an apparently simple, sensitive and quick 
procedure for evaluating the anti-arthritic activity and assessing the effectiveness of 
the treatment. Edema in the injected paws (adjuvant injected paw) was apparent from 
the day of adjuvant injection (DAY 1). In the uninjected paws of the same animal 
where adjuvant was not injected edema is developed on Day 9 onwards and this is 
used to determine secondary lesions. 
(A) Effect on primary lesions (injected hind paw edema): 
i) Effect of A.accuminata (AAEE): 
AAEE demonstrated significant dose dependant inhibition of swelling 
in the in the injected hind paw on all alternate days through the entire period 
of study as depicted in Table 5.2.1. Maximal suppression of paw edema was 
observed at a dose of 500 mg/kg b.w with 52%inhibition on day 21
st
, which 
was statistically highly significant. Inhibition shown by Ibuprofen on Day 21
st
 
 
was 51.38%. 
ii) Effect of A.bracteosa (ABEE): 
Paw volume measurements revealed that ABEE caused significant 
inhibition of injected paw edema as compared with arthritic control and the 
suppressive effects were dose dependant. It is noteworthy that at the dose of 
500 mg/kg b.w. ABEE the reduction in the primary lesions was highly 
comparable to that of Ibuprofen on all alternate days, with maximal inhibitory 
effect of 53.52% on day 21
st
 (Table 5.2.2). 
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Table 5.2.1: Effect of graded doses of AAEE on primary lesions (injected paw edema) in 
adjuvant induced arthritic and treated animals over 21 days. 
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* 
 
1.68 
± 
0.13 
** 
 
1.78 
± 
0.19 
** 
2.04 
± 
0.10 
* 
1.94 
± 
0.19 
** 
2.30 
± 
0.15 
* 
2.08 
± 
0.19 
** 
2.28 
± 
0.12 
*** 
 
AAEE 
 
 
500 
- 0.66 
± 
0.10 
** 
 
1.01 
± 
0.18 
*** 
1.30 
± 
0.08 
*** 
1.10 
± 
0.16 
*** 
 
1.26 
± 
0.13 
*** 
1.30 
± 
0.12 
*** 
1.4 
± 
0.13 
*** 
2.10 
± 
0.10 
** 
1.50 
± 
0.22 
*** 
1.56 
± 
0.2 
*** 
 
Data represent the Mean ± SEM (n=6) .Statistical significance: *P < 0.05, **P < 0.01, *** P < 0.001, versus with respect to 
arthritic control (AC) group (One way repeated measures ANNOVA followed by Bonferroni Multiple comparison test). 
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Table 5.2.2: Effect of graded doses of ABEE on primary lesions (injected paw edema) in 
adjuvant induced arthritic and treated animals over 21 days. 
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(m
g
/k
g
)     
 
Edema 
(ml) 
{ Mean ± SEM } 
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A
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D
A
Y
 3
 
  
D
A
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D
A
Y
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D
A
Y
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D
A
Y
 1
1
 
 
 
D
A
Y
 1
3
 
 
 
D
A
Y
 1
5
 
 
 
D
A
Y
 1
7
 
 
 
D
A
Y
 1
9
 
 
D
A
Y
 2
1
 
 
Normal 
Control 
 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
Arthritic 
Control 
 
 
- 
 
- 
 
1.48 
±  
0.10 
 
2.35 
± 
0.19 
 
 
2.91 
± 
0.2 
 
 
2.45 
± 
0.12 
 
 
2.8 
± 
0.16 
 
 
2.86 
± 
0.20 
 
 
2.98 
± 
0.08 
 
 
3.12 
± 
0.2 
 
 
3.2 
± 
0.08 
 
 
3.4 
± 
0.14 
 
 
Ibuprofen 
 
 
50 
 
- 
0.68 
± 
0.06 
** 
 
1.28 
± 
0.21 
** 
1.58 
± 
0.11 
*** 
1.22 
± 
0.16 
*** 
1.43 
± 
0.12 
*** 
1.42 
± 
0.17 
*** 
1.50 
± 
0.16 
*** 
1.54 
± 
0.2 
*** 
1.60 
± 
0.16 
*** 
1.60 
± 
0.18 
*** 
 
ABEE 
 
 
62.5 
 
- 
1.40 
± 
0.10 
 
2.23 
± 
0.13 
 
2.72 
± 
0.13 
 
2.34 
± 
0.19 
 
2.68 
± 
0.18 
 
2.72 
± 
0.18 
 
2.86 
± 
0.23 
 
3.01 
± 
0.13 
 
3.04 
± 
0.23 
 
3.24 
± 
0.14 
 
 
ABEE 
 
 
125 
 
- 
1.3 
± 
0.12 
 
2.01 
± 
0.10 
 
2.48 
± 
0.16 
 
2.15 
± 
0.20 
 
2.42 
± 
0.22 
 
2.44 
± 
0.21 
 
2.54 
± 
0.20 
 
2.66 
± 
0.14 
 
2.8 
± 
0.20 
 
2.94 
± 
0.21 
 
 
ABEE 
 
 
250 
 
- 
1.08 
± 
0.18 
1.68 
± 
0.18 
 
1.96 
± 
0.14 
*** 
1.78 
± 
0.23 
*** 
1.96 
± 
0.16 
* 
1.96 
± 
0.20 
* 
2.18 
± 
0.06 
* 
2.25 
± 
0.12 
* 
2.30 
± 
0.06 
** 
2.44 
± 
0.09 
** 
 
ABEE 
 
 
500 
- 0.64 
± 
0.14 
*** 
1.10 
± 
0.16 
*** 
1.34 
± 
0.10 
*** 
 
1.16 
± 
0.06 
*** 
1.30 
± 
0.18 
*** 
1.36 
± 
0.23 
*** 
1.38 
± 
0.18 
*** 
1.48 
± 
0.18 
*** 
1.52 
± 
0.18 
*** 
1.58 
± 
0.10 
*** 
 
Data represent the Mean ± SEM (n=6) .Statistical significance: *P < 0.05, **P < 0.01, *** P < 0.001, versus with respect to 
arthritic control (AC) group (One way repeated measures ANNOVA followed by Bonferroni Multiple comparison test). 
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5.2.1 (B) Effect on secondary lesions (uninjected hind paw edema): 
i) Effect of A.accuminata (AAEE): 
As seen in Table 5.2.3, AAEE at all doses significantly reduced the 
edema in the uninjected paw (secondary lesions) from Day 9 through 21 [Table 
5.2.3)]. An increase in percentage inhibition was observed for AAEE on day 
21
st
 at doses of 62.5 mg/kg b.w, 125mg/kg b.w, 250mg/kg b.w and 500 mg/kg 
b.w. At 500 mg/kg b.w the suppressive effects on secondary lesions were more 
effective than ibuprofen on Day21
st
. 
ii) Effect of A.bracteosa (ABEE): 
ABEE inhibited the secondary reaction to adjuvant reaction markedly 
and in a dose dependant fashion (Table 5.2.4). Maximal inhibitory effect of 
ABEE on secondary reaction in paw was observed at 500 mg/kg b.w. on day 
21
st
 and the results was highly comparable to that of Ibuprofen. 
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Table 5.2.3: Effect of graded doses of AAEE on secondary lesions (uninjected paw 
edema)in  adjuvant induced arthritic and treated animals  over 21 days. 
 
 
Data represent the Mean ± SEM (n=6) .Statistical significance: *P < 0.05, **P < 0.01, *** P < 0.001, versus with respect to 
arthritic control (AC) group (One way repeated measures ANNOVA followed by Bonferroni Multiple comparison test). 
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  (
m
g/
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(ml) 
{ Mean ± SEM } 
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D
A
Y
 2
1
 
 
Normal 
Control 
 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
Arthritic 
Control 
 
 
- 
 
- 
 
- 
 
- 
 
- 
 
0.52 
± 
0.05 
 
 
0.72 
± 
0.10 
 
 
0.92 
± 
0.10 
 
 
1.12 
± 
0.10 
 
 
1.18 
± 
0.10 
 
 
1.25 
 ± 
0.11 
 
 
1.28 
± 
0.06 
 
 
Ibuprofen 
 
 
50 
 
- 
 
- 
 
- 
 
- 
0.27 
± 
0.04 
*** 
 
0.40 
± 
0.08 
 
0.52 
± 
0.08 
* 
0.60 
± 
0.08 
*** 
0.65 
± 
0.08 
*** 
0.72 
± 
0.10 
** 
0.74 
± 
0.10 
*** 
 
AAEE 
 
 
62.5 
 
- 
 
- 
 
- 
 
- 
0.48 
± 
0.02 
 
0.68 
± 
0.08 
 
0.86 
± 
0.05 
 
1.06 
± 
0.04 
 
1.12 
± 
0.04 
 
1.18 
± 
0.08 
 
1.22 
± 
0.08 
 
 
AAEE 
 
 
125 
 
- 
 
- 
 
- 
 
- 
0.44 
± 
0.02 
 
0.60 
± 
0.06 
 
0.80 
± 
0.10 
 
0.98 
± 
0.08 
 
1.00 
± 
0.08 
 
1.08 
± 
0.06 
 
1.10 
± 
0.06 
 
 
AAEE 
 
 
250 
 
- 
 
- 
 
- 
 
- 
0.38 
± 
0.02
* 
 
0.50 
± 
0.12 
 
0.68 
± 
0.09 
 
0.82 
± 
0.06 
 
0.84 
± 
0.06 
* 
0.90 
± 
0.04 
* 
 
0.90 
± 
0.10 
* 
 
AAEE 
 
 
500 
- - - - 0.24 
± 
0.01 
*** 
 
0.32 
± 
0.06 
* 
 
0.50 
± 
0.08 
* 
0.54 
± 
0.04 
*** 
0.58 
± 
0.04 
*** 
0.62 
± 
0.10 
*** 
0.64 
± 
0.08 
*** 
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Table 5.2.4: Effect of graded doses of ABEE on secondary lesions (uninjected paw edema) 
in adjuvant induced arthritic and treated animals over 21 days. 
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  (
m
g/
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Edema 
(ml) 
{ Mean ± SEM } 
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D
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5
 
  
D
A
Y
 1
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D
A
Y
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1
 
 
Normal 
Control 
 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
Arthritic 
Control 
 
 
- 
 
 
 
- 
 
 
 
- 
 
0.47 
± 
0.08 
 
 
0.68 
± 
0.06 
 
 
0.90 
± 
0.10 
 
 
1.08 
± 
0.10 
 
 
1.14 
± 
0.10 
 
 
1.21 
 ± 
0.08 
 
 
1.29 
± 
0.06 
 
 
Ibuprofen 
 
 
50 
  
- 
  
- 
0.24 
± 
0.04 
 
0.38 
± 
0.04 
* 
 
0.48 
± 
0.04 
** 
0.56 
± 
0.04 
*** 
0.64 
± 
0.04 
*** 
0.70 
± 
0.02 
*** 
0.74 
± 
0.04 
*** 
 
ABEE 
 
 
62.5 
  
- 
  
- 
0.42 
± 
0.08 
 
0.80 
± 
0.04 
 
0.84 
± 
0.06 
 
0.85 
± 
0.06 
 
0.93 
± 
0.06 
 
1.07 
± 
0.04 
 
0.98 
± 
0.06 
* 
 
ABEE 
 
 
125 
  
- 
 
 
 
- 
0.34 
± 
0.06 
 
0.7 
± 
0.08 
 
0.82 
± 
0.08 
 
0.80 
± 
0.08 
 
0.88 
± 
0.21 
 
1.09 
± 
0.06 
 
0.9 
± 
0.08 
** 
 
ABEE 
 
 
250 
  
- 
  
- 
0.26 
± 
0.04 
 
0.6 
± 
0.09 
 
0.72 
± 
0.06 
 
0.78 
± 
0.08 
* 
0.80 
± 
0.15 
** 
0.98 
± 
0.06 
 
0.86 
± 
0.04 
*** 
 
ABEE 
 
 
500 
 -  - 0.20 
± 
0.02 
* 
 
0.30 
± 
0.06 
   ** 
0.40 
± 
0.03 
*** 
0.50 
± 
0.04 
*** 
0.56 
± 
0.18 
*** 
0.60 
± 
0.04 
*** 
0.64 
± 
0.08 
*** 
 
Data represent the Mean ± SEM (n=6) .Statistical significance: *P < 0.05, **P < 0.01, *** P < 0.001, versus with respect to 
arthritic control (AC) group (One way repeated measures ANNOVA followed by Bonferroni Multiple comparison test). 
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5.2.2: Effect on arthritis as assessed with squeaking scores (ankle flexion score) over 
21 days. 
The vocalizations caused by flexion or extension of the injected ankle (hind 
limb) reached a maximum point on day 1 after CFA injection and was sustained at a 
maximum level in untreated rats (arthritic control group) through the end of the 
experiment. A value of 0 represented no pain and a value of 10 indicated maximum 
pain  
i) Effect of A.accuminata (AAEE): 
The assessment made over a period of 21 days showed that the AAEE 
and Ibuprofen treatments had significantly reduced the ankle flexion score in 
the respective treatment groups as compared with the CFA arthritic control 
group as shown in Figure 5.2.1(A).Arthritic rats treated with AAEE 
demonstrated a dose dependant decrease in the number of vocalizatitions on all 
days. It was observed that in case of 500 mg/kg b.w. AAEE treated group, the 
squeaking scores were lower that that of Ibuprofen. 
ii) Effect of A.bracteosa (ABEE): 
As shown in Figure 5.2.1 (B) in comparison to the untreated arthritic 
control group ABEE reduced the ankle flexion score in a dose dependant 
manner. 
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Figure 5.2.1: Effect of graded doses  of AAEE (A) and ABEE (B) on arthritis as assessed with 
squeaking scores (ankle flexion score) over 21 days. A value of 0 represents no indication of  pain .  
Data represent the Mean ± SEM (n=6) .Statistical significance: *P < 0.05, **P < 0.01, *** P < 0.001, versus with respect to 
arthritic control (AC) group on day 21st (One way repeated measures ANNOVA followed by Bonferroni Multiple comparison test). 
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5.2.3: Effect on arthritis as assessed with arthritic scores 21 days. 
Arthritic score represents the index for severity of arthritis. 
i) Effect of A.accuminata (AAEE): 
In the CFA-induced arthritis control group , the adjuvant uninjected paw 
joints also started to show erythema, swelling  and rigidity on day 9 and  the 
arthritic score reached the maximum level on day 21
st
 [Figure  5.2.2 (A)]. 
Ibuprofen suppressed the arthritic score significantly from day 9 through day 
21st. AAEE at all tested doses reduced signs of arthritis development as 
indicated by the decrease in arthritic score. The suppressive effects of AAEE 
were observed to be dose dependant and at 500 mg/kg b.w dose, AAEE 
maximally reduced the arthritic score  to 4.5 on day 9
th
  and to 3 day 21
st
 in 
comparison to arthritic control group. 
ii) Effect of A.bracteosa (ABEE): 
Treatment with ABEE at different graded doses in arthritis induced rats 
reduced the arthritic scores between days 9 and 21
st
 in a dose dependent fashion 
as shown in Figure 5.2.2 (B) 
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Figure 5.2.2: Effect of graded doses of AAEE (A) and ABEE (B) on arthritis as assessed with 
arthritic scores. A value of 0 represents no indication no arthritic disease.. 
 Data represent the Mean ± SEM (n=6) .Statistical significance: *P < 0.05, **P < 0.01, *** P < 0.001, versus with respect to 
arthritic control (AC) group on day 21st (One way repeated measures ANNOVA followed by Bonferroni Multiple comparison test). 
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5.2.4: Effect on Body weight and organ weight changes. 
i) Effect of A.accuminata (AAEE): 
The challenge with CFA showed significant decrease in the average 
body weight and increase in the spleen and thymus  weight in arthritis control as 
compared to the normal control. Under similar conditions, Ibuprofen and all the 
AAEE treated groups showed average gain in body weight. The results are 
depicted in Table 5.2.5 (A).  
ii) Effect of A.bracteosa (ABEE): 
As shown in Table 5.2.5 (B), ABEE was found to improve the body 
weight gain and decreased spleen and thymus weights in arthritic rats. These 
effects were dose dependant and maximally marked at the tested dose of 500 
mg/kg b.w. of ABEE. 
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Table 5.2.5: : Effect of graded doses  of AAEE (A) and ABEE (B) on Body weight and 
organ weight changes in  adjuvant induced arthritic and treated animals. 
 
  
Concentration 
(mg/kg) 
 
 
Body weight 
(g) 
 
 
Thymus 
(mg) 
 
 
 
Spleen 
(g) 
 
Initial Wt 
(g) 
Final Wt 
(g) 
Normal 
Control - 165.23± 1.44 171.34± 1.74 118.16±12.1 0.5± 0.003* 
 
 
Arthritic 
Control 
 
- 162.78± 1.87 157.81± 1.24 210.34± 14.33 1.42± 0.12 
 
Ibuprofen 
 
50 160.9± 1.44 168.14± 1.32*** 132.11± 13.11** 0.75± 0.08*** 
AAEE 
62.5 164.14± 1.53 164.17± 1.12 198.34± 12.87 1.40± 0.05 
AAEE 125 163.90± 1.94 165.1± 1.89* 168.70 ± 11.88 1.18± 0.06 
AAEE 
250 165.21± 1.28 174.34± 1.23*** 140.34± 14.22* 1.002± 0.28* 
AAEE 
500 165.01± 1.77 178.21± 1.11*** 126.21± 11.91** 0.78± 0.11*** 
 
 
 
 
 
 
Concentration 
(mg/kg) 
 
 
Body weight 
(g) 
 
 
 
Spleen 
(g) 
 
 
 
Thymus 
(g) 
 Initial Wt 
(g) 
Final Wt 
(g) 
Normal 
Control - 165.23± 1.12 171.34± 1.28 118.16± 14.12 0.50± 0.002 
 
Arthritic 
Control 
 
- 
160.23± 1.87 155.07± 1.21 210.34± 12.11 1.60±0.21 
Ibuprofen 50 165.19± 1.65 172.2± 1.11*** 208.34± 13.21*** 0.93±0.08*** 
ABEE 
 
62.5 165.9± 1.89 165.10± 1.76*** 201.2± 11.10 1.50±0.03 
ABEE 
 
125 163.2± 1.24 165.7± 1.44*** 186.31± 12.43 1.26±0.02* 
ABEE 
 
250 164.9± 1.5 170.8± 1.33*** 168.02±12.89 1.10±0.09*** 
ABEE 
500 165.12± 1.32 80.6± 1.89*** 125.2±12.23*** 0.94±0.08** 
 
Data represent the Mean ± SEM (n=6) .Statistical significance: *P < 0.05, **P < 0.01, *** P < 0.001, versus with respect to 
arthritic control (AC) group on day 21st (One way repeated measures ANNOVA followed by Bonferroni Multiple comparison test). 
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5.2.5: Effect on haematological parameters: 
i) Effect of A.accuminata (AAEE): 
The changes in hematological parameters as monitored on day 21
st
 in all 
treated groups adjuvant induced arthritic rats are shown in Table 5.2.6 (A). In 
CFA induced untreated group, there was a significant decrease in RBC count 
and hemoglobin and also a marked increase in WBC count and ESR. However 
treatment with AAEE reversed these altered hematological parameters and the 
effects for AAEE were found to be dose dependant. At 500 mg /kg b.w the 
levels of hemoglobin was up regulated to 14 and of RBC count to 
9.5x10
3
/mm
3
as compared to untreated arthritic controls in each case. Also the 
WBC count was reduced to 4.5x10
3
/mm
3
and ESR to 13 mm/hr. 
ii) Effect of A.bracteosa (ABEE): 
ABEE significantly restored all the CFA induced haematological 
perturbations [Table 5.2.6(B)].The effects of ABEE were dose dependant and 
ABEE at 500 mg /kg b.w depicted maximal effects.  
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Table 5.2.6: Effect of graded doses of AAEE (A) and ABEE (B) on hematological alterations 
in adjuvant induced arthritic and treated animals. 
 
  
 
 
 
Concentration 
(mg/kg) 
 
 
RBC 
(×10
6
/ mm
3
) 
 
 
WBC 
(×10
3 
/ 
mm
3
) 
 
 
ESR 
(mm/h) 
 
 
Hb 
(mg %) 
 
Normal 
Control 
- 10.6±0.8 3.8±0.6 10±0.4 16±0.4 
 
Arthritic 
Control 
 
- 
 
7.8±0.4 
 
12.2±0.3 
 
16±0.2 
 
11±0.4 
Ibuprofen 50 9.8±0.28*** 4.7±0.4*** 12±0.4*** 14±0.4*** 
AAEE 62.5 8.0±0.4 9.8±0.4* 16±0.3 11±0.3 
AAEE 
 
125 9.0±0.2 8.0±0.6* 15±0.2 12±0.2 
AAEE 
 
250 10.3±0.3*** 6.2±0.4* 14±0.4*** 13±0.2** 
AAEE 
 
500 9.5±0.3** 4.5±0.2*** 13±0.2*** 14±0.4*** 
 
  
Concentration 
(mg/kg) 
 
 
RBC 
(×10
6
/ mm
3
) 
 
 
WBC 
(×10
3 
/ mm
3
) 
 
 
ESR 
(mm/h) 
 
 
Hb 
(mg %) 
 
 
Normal 
Control 
 
- 10.8±0.4 3.4±0.6 10±0.2 16±0.4 
 
Arthritic 
Control 
 
- 8.0± 0.2 13.2±0.4 15±0.4 12±0.4 
Ibuprofen 
 50 10.0±0.3*** 5.7±0.2*** 11±0.2*** 15±0.4*** 
ABEE 
 
62.5 8.40±0.2 11.4±0.3*** 14±0.2 12±0.3 
ABEE 
 
125 9.0±0.3 9.6±0.3*** 13±0.4*** 13±0.2 
ABEE 
 
250 9.4±0.1** 7.8±0.2*** 11±0.3*** 14±0.3** 
ABEE 
 
500 9.8±0.2*** 5.0±0.1*** 10±0.2*** 15±0.3*** 
 
Data represent the Mean ± SEM (n=6) .Statistical significance: *P < 0.05, **P < 0.01, *** P < 0.001, versus with respect to 
arthritic control (AC) group on day 21st (One way repeated measures ANNOVA followed by Bonferroni Multiple comparison test). 
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5.2.6: Effect on C-reactive protein and Rhuematoid factor: 
The serum CRP and RF are markers of systemic inflammation and antibody 
production, respectively against the injected adjuvant. 
i) Effect of A.accuminata (AAEE): 
High levels of serum CRP (9.2 mg/dl) and serum RF (76 IU/ml) were 
observed in the CFA control group rats [Table 5.2.7 (A)]. AAEE and Ibuprofen 
treatments were observed to reduce the increase in the levels of both CRP and 
RF in the serum. 
ii) Effect of A.bracteosa (ABEE): 
Table 5.2.7(B) shows significant decrease in the levels of CRP and RF 
in serum in ABEE treated groups as compared to arthritic control group. These 
effects were significantly dose dependant. 
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Table 5.2.7: Effect of graded doses of (A) AAEE and (B) ABEE on C-reactive protein and 
Rheumatoid factor in adjuvant induced arthritic and treated animals. 
 
 
  
Concentration 
(mg/kg) 
 
 
CRP 
 (×10
6
/ mm
3
) 
 
 
RF 
(×10
3 
/ mm
3
) 
 
 
Normal Control 
 
- 
1.6±0.6 18±0.9 
 
Arthritic Control 
 
 
- 
 
9.2±1.2 
 
76±6.7 
Ibuprofen 
 50 2.2±0.8*** 26±3.3*** 
AAEE 
 62.5 8.6±0.9 68±4.3 
AAEE 
 125 6.0±0.8 50±4.2** 
AAEE 
 
250 4.8±0.4* 40±3.2*** 
AAEE 
 
500 2.6±0.4*** 28±4.0*** 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Data represent the Mean ± SEM (n=6) .Statistical significance: *P < 0.05, **P < 0.01, *** P < 0.001, versus with respect to 
arthritic control (AC) group on day 21st (One way repeated measures ANNOVA followed by Bonferroni Multiple comparison test). 
 
  
Concentration 
(mg/kg) 
 
 
CRP 
 (×106/ mm3) 
 
 
RF 
(×103 / mm3) 
 
 
Normal Control 
 
 
 
- 
1.6±0.8 19±0.7 
 
Arthritic Control 
 
 
- 
10.5±0.5 
 
78±5.4 
Ibuprofen 
 50 2.0±0.6*** 24±2.7*** 
ABEE 
 62.5 8.8±0.4 69.5±2.3 
ABEE 
 125 6.2±0.6* 54±2.7*** 
ABEE 
 
250 3.8±0.6*** 38.5±4.0*** 
ABEE 
 
500 2.4±0.8*** 25.2±3.5*** 
(A) 
(B) 
Evaluation of anti-arthritic effects of Atropa accunminata and Ajuga bracteosa 
 
-130- 
 
 
5.2.7: Effect on the levels of anti-oxidant enzymes : 
i) Effect of A.accuminata (AAEE): 
As shown Table 5.2.8 (A) in the animals of group II (CFA arthiritic 
control) the levels of antioxidant enzymes (SOD, GPX and GR) were markedly 
reduced. Treatment with Ibuprofen and AAEE significantly  up regulated the 
levels of SOD ,GPX and GR in comparison to  the control group .The effects of 
AAEE were dose dependent and at 500 mg/kg b.w. the levels of SOD,GPX and 
GR were upregulated  maximally. 
b) Effect of A.bracteosa (ABEE): 
Treatment with ABEE significantly up regulated the levels of SOD, 
GPX and GR and in a dose dependant pattern [Table 5.2.8(B)]. These effects 
were fairly comparable to that of Ibuprofen. 
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Table 5.2.8: Effect of graded doses of (A) AAEE and (B) ABEE on the level of                    
anti-oxidant enzymes on day 21
st
 after CFA challenge. 
 
 
 
Data represent the Mean ± SEM (n=6) .Statistical significance: *P < 0.05, **P < 0.01, *** P < 0.001, versus with respect to 
arthritic control (AC) group on day 21st (One way repeated measures ANNOVA followed by Bonferroni Multiple comparison test). 
 
 
 
Concentration 
(mg/Kg) 
 
SOD 
( U/mg protein) 
 
GPX 
( U/(µg GSH 
utilized/minute/mg 
protein) 
 
GPR 
( U/(µg GSSG 
utilized/minute/mg 
protein) 
Normal  
Control 
- 46.24 ± 2.03 34.40 ± 0.12 30.92 ± 0.006 
 
Arthritic 
Control 
- 11.98 ± 1.23 3.90± 0.18 1.98 ± 0.008 
AAEE 62.5 15..70 ± 1.52 5.98 ±0.62 3.66 ±0.004 
AAEE 125 26.32 ±2.68 11.21 ± 0.34** 10.28 ± 0.008* 
AAEE 250 33.22 ± 3.66*** 21.90 ± 1.48*** 19.44 ± 0.002*** 
AAEE 500 43.10 ± 2.30*** 32.20 ± 1.36*** 28.02 ± 0.004*** 
Ibuprofen 50 44.02 ± 1.11*** 31.65 ± 1.85*** 27.33 ± 0.006*** 
 
 
Concentration 
(mg/Kg) 
 
SOD 
( U/mg 
protein) 
 
GPX 
( U/(µg GSH 
utilized/minute/
mg protein) 
 
GPR 
( U/(µg GSSG 
utilized/minute/mg 
protein) 
Normal  
Control  
- 45.20 ± 3.22 34.40 ± 2.21 26.92 ± 0.01 
 
Arthritic 
Control 
 
- 12.08 ± 1.98 5.80± 1.08 2.18 ± 0.003 
ABEE 62.5 13.90 ± 1.56 7.80 ± 1.10 4.60 ±0.002 
ABEE 125 19.32 ±2.89 15.61 ± 2.12** 11.18 ± 0.006* 
ABEE 250 36.10 ± 2.77*** 26.08 ± 2.08*** 17.14 ± 0.001*** 
ABEE 500 41.10 ± 3.25*** 30.08 ± 2.18*** 25.02 ± 0.008*** 
Ibuprofen 50 41.02 ± 3.44*** 31.50 ± 2.04*** 24.52± 0.008*** 
(A) 
(B) 
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5.2.8: Histopathogical findings with adjuvant arthritis in the rats. 
i) Effect of A.accuminata (AAEE): 
The tissue sections of CFA injected hind paws of the arthritis control 
revealed marked pathological changes correlating with arthritis [Figure 5.2.3 
(B1-B2]. In particular, marked infiltration  of the sub cutaneous tissue of the rat 
paw (foot pad) by dense chronic inflammatory cells consisting of lypmhocytes 
and neutrophils. Normally the sub cutaneous tissue of the paw (foot pad) 
consists of barely visible layer of simple squamous cells and fibro collagenous 
tissue [Figure 5.2.3 (A1-A2]. However upon antigenic challenge of CFA, the 
normal tissue is replaced by a massive accumulation of cells (inflammatory 
polymorphonuclear cells). As such these sections from CFA group were graded 
with Score of 5 with chronic type of inflammation consisting mainly of 
lymphocytes. In groups treated with AAEE showed little massive influx of 
inflammatory cells and the pattern of dose dependant effects was evident in 
these findings also [(Figure 5.2.3 (D-G)]. 
ii) Effect of A.bracteosa (ABEE): 
The observed histopathological changes of hind paw tissue of the 
experimental groups are shown in Figure 5.2.3 (H - K). The overall prevention 
of the inflammatory signs in the rat paw (foot pad) was significant in ABEE and 
ibuprofen treated groups. ABEE treatment at 500 mg/kg b.w. showed least 
inflammatory signs like scanty leukocyte infiltration as shown in Figure 5.2.3 
(J1-J2). Comparatively the treatment with ABEE at 250 mg/kg b.w. showed 
moderate  cellular infiltrates on the particular surface [(Figure 5.2.3 (I1-I2)]. 
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Figure 5.2.3:  Histopathogical analysis of paw tissues in adjuvant induced arthritic rats: 
Each picture is representative of five specimens for each group as follows: (A) Normal 
control, (B) Arthritic-control, (C) Ibuforen- 50 mg/kg b.w, (D) AAEE-62.5 mg/kg b.w, (E) 
AAEE-125 mg/kg b.w, (F) AAEE-250 mg/kg b.w, (G) AAEE-500 mg/kg b.w, (H) ABEE-
62.5 mg/kg b.w, (I) ABEE-125 mg/kg b.w, (J) ABEE-250 mg/kg b.w and (K) ABEE-500 
mg/kg b.w. Each group is assessed at two magnifications 10X (A1-F1) and 40X (A2-F2). 
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 The massive tissue inflammation evident in the injected hind paw (group II)- 
arthritic control), shows typical features of the inflammation observed as at day 
21st; SCORE 5 (B-B2).  
 Treatment with ibuprofen produced a more marked reduction in inflammatory 
infiltrate; SCORE 1 (C1-C2).  
 Treatment of the rats with  Atropa accuminata (AAEE) after adjuvant injection 
reduced soft tissue inflammation; AAEE-62.5 mg/kg b.w, SCORE 4 (DI-D2); 
AAEE-125 mg/kg b.w, SCORE 3 (E1-E2); AAEE-250 mg/kg b.w, SCORE 2 
(F1-F2); AAEE-500 mg/kg b.w, SCORE 1 (G1-G2).  
 Treatment of the rats with  Ajuga bracteosa (ABEE) for 21 days after adjuvant 
injection reduced soft tissue inflammation; ABEE-62.5 mg/kg b.w, SCORE 4 
(H1-H2); ABEE-125 mg/kg b.w, SCORE 3 (I1-I2); ABEE-250 mg/kg b.w, 
SCORE 1 (J1-J2); ABEE-500 mg/kg b.w. SCORE 1 (K1-K2). 
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5.2.9: Effect on Prostaglandin E2 (
 
PGE2)  production in serum and paw homogenate 
         supernatant: 
i) Effect of A.accuminata (AAEE): 
PGE2 levels were found dramatically elevated in CFA-induced untreated 
arthritic group at the end of 21 days. Treatment with Ibuprofen, however 
demonstrated a significant inhibition of PGE2 production in both serum 
(23.07%) as well as paw homogenate. Likewise, AAEE demonstrated a dose 
dependant pattern for the down regulation (51.22%) n in serum and paw 
homogenate PGE2 levels [Figure 5.2.4(A)]. However, in case of serum 
measurements, the PGE2 inhibition was less pronounced at all doses. 
b) Effect of A.bracteosa (ABEE): 
Treatment with ABEE at different graded doses significantly suppressed 
the levels of PGE2 in both serum as well as paw homogenates in a dose 
dependant pattern [Figure 5.2.4(B)]. ABEE at 500 mg/kg b.w maximally 
reduced serum and paw homogenate PGE2 levels by 35.7% and 57%, 
respectively. 
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Figure 5.2.4: Effect of graded doses  of AAEE (A) and ABEE (B)  on  PGE2 production expressed 
in supernatant from pawhomgenates and serum. 
Data represent the Mean ± SEM (n=6) .Statistical significance: *P < 0.05, **P < 0.01, *** P < 0.001, versus with respect to 
arthritic control (AC) group on day 21st (One way repeated measures ANNOVA followed by Bonferroni Multiple comparison test). 
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5.2.10: Effect on leukotriene B4 (LTB4) production in serum and paw homogenate 
          supernatant: 
i) Effect of A.accuminata (AAEE): 
As shown in [Figure 5.2.5(A)] AAEE significantly decreased LTB4 
levels in both serum as well as paw homogenate in a dose-dependent manner, in 
comparison to arthritic control rats. Ibufrofen did not show any appreciable 
effect on LTB4 production reducing serum and paw homgenate LTB4 levels  by 
18.4 % and 20% respectively. The paw homogenate levels of LTB4 were 
reduced to 12 %, 26%, 39% and 54% at AAEE at 62.5, 125, 250 and 500 mg/ 
kg b.w. doses of AAEE, respectively. Similarly, the serum levels were also 
reduced by AAEE in a dose dependent manner. 
ii) Effect of A.bracteosa (ABEE): 
Treatment with ABEE at all doses down regulated LTB4 levels both in 
serum as well as paw homogenate when compared to untreated arthritic rats 
[Figure 5.2.5(B)]. Maximal inhibitory effect was demonstrated upon treatment 
with ABEE at 500 mg/kg b.w. where serum levels of LTB4 were decreased by 
34.08% in serum and by 63 % in rat paw homogenate. 
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Figure 5.2.5: Effect of graded doses of AAEE (A) and ABEE (B) on  LTB4 production expressed in 
supernatant from paw homgenates and serum.  
Data represent the Mean ± SEM (n=6) .Statistical significance: *P < 0.05, **P < 0.01, *** P < 0.001, versus with respect to 
arthritic control (AC) group on day 21st (One way repeated measures ANNOVA followed by Bonferroni Multiple comparison test). 
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5.2.11: Effect on Nitrite (NO) production in serum and paw homgenatesupernatant:. 
i) Effect of A.accuminata (AAEE): 
In the animals receiving Ibuprofen, the standard drug nitrite levels  were 
reduced to 18.8 µM from 40 µMin serum and to 644 µM from1400 µM in paw 
homogenate in comparison, to untreated CFA control rats. Parallel to these 
findings, AAEE down regulated the nitrite levels in serum and paw homogenate 
dose dependently. A dose, dependent suppression was shown by AAEE at 62.5 
-500 mg/kg b.w. doses, where nitrite levels decreased to 11% (62.5mg/kg b.w.) 
and 52.2% (500mg/kg b.w.) in case of paw homogenate and in case of serum 
7% (62.5mg/kg b.w.) and 48% (500mg/kg b.w.) [Figure 5.2.6(A)]. 
ii) Effect of A.bracteosa (ABEE): 
Administration of ABEE at 500 mg /kg b.w. maximally decreased nitrite 
levels in serum to 25.76 µM from  46 µM and to 630 µM from 1512 µM in paw 
homogenate, in comparison to control group and the effects were more potent 
than that of Ibuprofen. The effects seen with the other dosages are represented 
in [Figure 5.2.6(B)] . 
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Figure 5.2.6: Effect of graded doses  of AAEE (A) and ABEE (B)  on  NO production expressed in 
supernatant from paw homgenates and serum.  
Data represent the Mean ± SEM (n=6) .Statistical significance: *P < 0.05, **P < 0.01, *** P < 0.001, versus with respect to 
arthritic control (AC) group on day 21st (One way repeated measures ANNOVA followed by Bonferroni Multiple comparison test). 
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5.2.12: Effect on Interleukin IL-1β in adjuvant induced arthritic and treated animals. 
i) Effect of A.accuminata (AAEE): 
A significant increase in the paw homogenate levels of IL-1β 
concentration was observed on Day 21 after CFA injection. AAEE reduced the 
levels in serum as well as paw tissue in a dose dependent manner showing 
significant inhibition of IL-1β. The results are depicted in Figure 5.2.7(A). 
ii) Effect of A.bracteosa (ABEE): 
ABEE at graded doses of 62.5, 125, 250 and 500 mg/kg b.w. doses 
mg/kg significantly decreased the IL-1b levels to 5.38%, 26.5%, 38% and 56% 
in paw tissues [Figure 5.2.7(B)].  
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Figure 5.2.7: Effect of graded doses  of (A) AAEE and (B) ABEE  on  IL-1β production expressed 
in supernatant from paw homgenates.  
Data represent the Mean ± SEM (n=6) .Statistical significance: *P < 0.05, **P < 0.01, *** P < 0.001, versus with respect to 
arthritic control (AC) group on day 21st (One way repeated measures ANNOVA followed by Bonferroni Multiple comparison test). 
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5.2.13: Effect on Th1 cytokines (IL-2, IFN-γ, TNF-α and IL-12): 
i) Effect of A.accuminata (AAEE): 
On day 21 post CFA injection, the levels of Th1 cytokines., IL-2, IFN-γ, 
TNF-α and IL-6 in arthritic control, both in paw tissues as well as in serum were 
markedly elevated in comparison to that observed in non arthritis, normal 
control group. However, AAEE treatment in all the groups ranging from 62.5 to 
500 mg /kg b.w. significantly suppressed the levels of all the aforementioned 
cytokines in both serum and paw. Maximal suppressive effects were maintained  
at the highest dose of 500 mg /kg b.w for each tested cytokine.  
As shown in Figure 5.2.8 (a) AAEE  significantly down regulated IL-2 
levels in paw tissue by 7%, 18%, 36.3% and 54% at 62.5,125, 250 and 500 
mg/kg b.w. respectively in comparison  to control. Similarly, their levels in 
serum were also suppressed in a dose dependent manner [Figure 5.2.8 (b)]. 
IFN-γ levels were decreased at all doses. However, at 500 mg/kg b.w  its 
levels were decreased by 52% and 46.2% in rat paw homogenate and serum in 
comparison to untreated group and these inhibitory effects were  fairly potent 
than that of Ibuprofen [Figure 5.2.8 (b) and Figure 5.2.9 (b)] 
TNF-α and IL-12 levels were again reduced in a dose dependant manner 
in both paw homogenate as well as serum as shown in Figure 5.2.8 (c) & 
Figure 5.2.9 (c) [TNF-α]  and Figure 5.2.8 (d) & Figure 5.2.9 (d) [IL-12]. 
Treatment with AAEE at 500 mg/kg b.w. maximal decreased the levels of TNF-
α and IL-12 in paw homogenate to 50 % and to 56%, respectively. A similar 
pattern was observed for these cytokine levels in serum. 
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Figure 5.2.8: Effect of graded doses of AAEE on production of Th1 cytokines (IL-2 (a) ,IFNγ 
(b), TNF-α (c) and IL-12 (d) in supernatant from paw  homgenates.  
Data represent the Mean ± SEM (n=6) .Statistical significance: *P < 0.05, **P < 0.01, *** P < 0.001, versus with respect to 
arthritic control (AC) group on day 21st (One way repeated measures ANNOVA followed by Bonferroni Multiple 
comparison test). 
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Figure 5.2.9: Effect of graded doses of AAEE on production of Th1 cytokines (IL-2 (a), IFNγ (b), 
TNF-α (c) and IL-12 (d) in serum.  
Data represent the Mean ± SEM (n=6) .Statistical significance: *P < 0.05, **P < 0.01, *** P < 0.001, versus with respect to 
arthritic control (AC) group on day 21st (One way repeated measures ANNOVA followed by Bonferroni Multiple comparison test). 
 
SERUM  LEVELS 
(a) (b) 
(c) (d) 
Evaluation of anti-arthritic effects of Atropa accunminata and Ajuga bracteosa 
 
-148- 
 
 
5.2.13 (ii) Effect of A.bracteosa (ABEE): 
Treatment  with ABEE for 21 days post CFA injection also suppressed 
the levels of all the evaluated cytokines in a dose dependent manner in  both 
serum as well as paw tissues. For all cytokines (IL-2, IFN-γ,TNF-α and IL-12), 
the inhibitory effects exhibited by ABEE were most significant and potent at the 
dose of 500 mg/kg b.w.  
As is clear from Figures 5.2.10 ABEE at 500 mg b.w significantly 
suppressed the paw tissue levels of IL-2, IFN-γ, TNF-α and IL-12  to 56% , 
58%, 57.01% and 53.2%, respectively in comparison to arthritic control .  
Similarly in serum, the levels of IL-2, IFN-γ, TNF-α and IL-12  were 
also reduced by ABEE in a dose dependant manner with maximal  
downregulation in comparison to control at a dose of 500 mg/kg.(Figure 
5.2.11). 
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Figure 5.2.10: Effect of graded doses of ABEE on production of Th1 cytokines (IL-2 (a), 
IFNγ (b), TNF-α (c) and IL-12 (d) in supernatant from paw  homgenates.  
Data represent the Mean ± SEM (n=6) .Statistical significance: *P < 0.05, **P < 0.01, *** P < 0.001, versus with respect 
to arthritic control (AC) group on day 21st (One way repeated measures ANNOVA followed by Bonferroni Multiple 
comparison test). 
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Figure 5.2.11 Effect of graded doses of ABEE on production of Th1 cytokines (IL-2 (a), 
IFNγ (b), TNF-α (c) and IL-12 (d) in serum.  
Data represent the Mean ± SEM (n=6) .Statistical significance: *P < 0.05, **P < 0.01, *** P < 0.001, versus with respect 
to arthritic control (AC) group on day 21st (One way repeated measures ANNOVA followed by Bonferroni Multiple 
comparison test).pl  
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5.2.14: Effect onTh2 cytokines, IL-4 and IL-10: 
i) Effect of A.accuminata (AAEE): 
The level of both the cytokines was raised in a dose dependent manner 
by the test extract, AAEE in comparison to CFA untreated control. The levels of 
both cytokines at AAEE, 500mg/kg b.w. were raised in paw tissues [Figure 
5.2.12 (a & b)]. The effects on both the cytokines showed similar pattern in 
serum also [Figure 5.2.12 (c & d)] 
ii) Effect of A.bracteosa (ABEE): 
As is clear from the Figure 5.2.13 ABEE in contrast displays a decrease 
in IL-4 and IL-10 cytokine levels. Maximal inhibition was observed at 500 
mg/kg b.w. with 26.86% in IL-4 and 31.21%  in  IL-10 levels in case of paw 
homogenate [Figure 5.2.13 (a & b)]. Similar dose dependant suppressive 
effects were observed for serum levels of both cytokines [Figure 5.2.13 (c & 
d)]. 
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Figure 5.2.12: Effect of graded doses  of  AAEE  on  production of Th2 cytokines (IL-4  and      IL-
10)  in supernatant from paw homogenate (a&b) and  serum (c&d). 
Data represent the Mean ± SEM (n=6) .Statistical significance: *P < 0.05, **P < 0.01, *** P < 0.001, versus with respect to 
arthritic control (AC) group on day 21st (One way repeated measures ANNOVA followed by Bonferroni Multiple comparison test). 
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Figure 5.2.13: Effect of graded doses  of  ABEE  on  production of Th2 cytokines (IL-4  and      IL-
10)  in supernatant from paw homogenate (a&b) and  serum (c&d).  
Data represent the Mean ± SEM (n=6) .Statistical significance: *P < 0.05, **P < 0.01, *** P < 0.001, versus with respect to 
arthritic control (AC) group on day 21st (One way repeated measures ANNOVA followed by Bonferroni Multiple comparison test). 
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Rheumatoid arthritis is a chronic autoimmune inflammatory disorder of 
unknown aetiology. The disease is characterized by periarticular inflammation of 
multiple joints which progresses to joint damage and severe disability. The etiologic 
cause of arthritis has not been clearly delineated so far. Cumulative evidence suggests 
that multiple components of immunity and inflammation like T and B lymphocytes, 
neutrophils, monocytes and the vascular endothelium, all play a role in the onset and 
progression of the disease (McInnes et al.,2001). 
In this section of our study, we aimed to investigate the immune 
pharmacological efficacy of Atropa accuminata and Ajuga bracteosa on chronic 
adjuvant induced-arthritis and its associated immune responses. In order to delineate 
the possible mode of action of our test extracts,  chronic inflammation in male Wistar 
rats  was initiated by  injecting heat killed Mycobacterium tuberculosis (CFA) and 
their regulatory/differential effects  of our test extracts on inflammatory mediators 
like cytokines and several associated immunological parameters relevant to arthritis 
was evaluated. 
CFA-induced experimental model for arthritis is considered closest to 
simulating human rheumatoid arthritis and therefore it is the most widely used chronic 
test model in which the associated clinical and histopathological changes are 
comparable to those seen in human form (Billingham et al.,1979, Butler et al.,1992). 
In this model, dead tubercle bacilli in liquid paraffin (CFA)   initiate an immune-
mediated inflammatory reaction which ultimately culminates in chronic inflammation 
and polyarthritis  (Cai  X et al.,2006).Initially the injection of CFA into the right hind-
foot produces an inflamed swelling in the paw which reaches to its maximum during 
the first 3 days. Thereafter, the swelling is slow until the 8th day when the foot begins 
to swell again. As the disease progresses, on day 10
th 
more severe oedema develops in 
the injected paw and inflamed lesions termed as secondary lesions are detected in the 
uninjected paw. The secondary lesions then begin to appear and increase in thickness., 
in the fore-paws, ears and tail. After the 13th day further swelling of the feet or joints 
occurs and by the 21
st 
day the inflammation starts to subside leaving pale 
granulomatous swellings around the joints (Newbould et al.,1963). The initial 
reaction of edema and soft-tissue thickening at the depot site is considered to be 
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caused by the irritant effect of the adjuvant used while as the late-phase arthritic 
events are presumed to be due to immunologic events (Ward et al.,1965). Our study 
demonstrated that the test extracts of Atropa accuminata and Ajuga bracteosa dose 
dependently attenuated adjuvant induced arthritis and also facilitated recovery as 
measured by the decreasing paw edema and arthritic and squeaking scores. 
The assessment of paw edema, an apparently simple, sensitive and quick 
procedure for evaluating the degree of inflammation in arthritic rats was done on 
alternate days in both the hind paws after adjuvant injection. Treatment with  AAEE 
and ABEE test extracts showed dose dependent suppression in edema of both the 
injected paw (primary lesions) as well as the uninjected paw (secondary lesions). 
Maximal effects were observed at the dose of 500 mg/kg b.w. for both AAEE and 
ABEE. Reduction of the primary and secondary lesions could be attributed to 
immunological protection rendered by our test extracts. The appearance of secondary 
lesions, i.e. non-injected paw swelling is a manifestation of cell-mediated immunity 
(T-cell response). It has been established that the process involved in the development 
of secondary lesions is not infectious and instead these are produced as a result of the 
generalized immunological response to constituents of the tubercle bacilli, which 
become disseminated after injection (Pearson and Wood, 1963). AAEE and ABEE 
were found to effectively reduce the secondary lesions in arthritic rats. The 
suppression of this response therefore suggests any immunosuppressive activity for 
our test extracts. Moreover, this effect of test extracts was comparable to that of 
ibuprofen. This reveals potent suppression of cell-mediated immunity in arthritic rats 
by our test extracts. 
Arthritis is associated with hyperalgesia and severe functional impairment. 
The hyperalgesia associated with arthritis is mediated through prostaglandins and 
other endogenous mediators (Schaible et al.,2006). In the present study, the effect of 
AAEE and ABEE on arthritis-induced hyperalgesia was evaluated by visually 
attributed arthritic scores and the dorsal flexion pain test. It has been reported that a 
selective reduction in the arthritis score distinguishes the immunosuppressive effects 
of a drug from its anti-inflammatory effects (Yu et al., 2006).In our study the arthritis 
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score was significantly reduced by both AAEE and ABEE which indicates for a 
possible immunosuppressant effect of test extracts. 
Ankle flexion test is commonly used to assess the functional impairment in 
arthritis (Kumar et al.,2006). Parallel to the findings on paw edema, it was found that 
AAEE and ABEE both reduced the ankle flexion score also, significantly and in a 
dose dependant manner indicating for a reduction in pain. Though the actual 
quantification of the mediators of pain was not performed in this study, based on the 
results it is proposed that test extracts could possibly be acting through its effects at 
the level of these endogenous pain mediators. 
During the development of the arthritic syndrome, the rats invariably lost 
weight as compared to normal control but in the test extracts and ibuprofen treated 
groups, the body weights of the rats did not decrease. The results of our study 
therefore indicated that there is a relationship between the extent of inflammation and 
loss of body weight. Reports suggest that the decrease in the body weight during 
inflammation is due to deficient absorption of nutrients through the intestine (Patil et 
al., 2004). The evident maintenance of the body weight increase of rats in the AAEE 
and ABEE treated groups may involve improvement of intestinal absorption of the 
nutrients and a reduction in the distress caused by the severity of the arthritis. 
In addition, the weight of thymus and spleen which increased in arthritic rats 
was significantly reduced in all  the test extracts treated groups. It is reported that the 
reduction in spleen weight and thymus weight are related to a variety of effects on the 
immune system (Padernera et al.,2006). These results further support the observed 
immunosuppressant activity of test extracts in case of paw edema inhibition. 
With the development of arthritis post CFA challenge, all rats developed 
anaemia due to decrease in red blood cells (RBC) count and hemoglobin (Hb) levels. 
It has been proposed that the reduction in the Hb and RBC count during arthritis 
results from reduced erythropoietin levels, premature destruction of red blood cells 
and also due to abnormal storage of iron in the reticuloendothelial system and 
synovial tissue (Mowat et al.,1971).Our findings further revealed that both AAEE and 
ABEE reversed these alterations in the  hematological parameters and maximal 
effects were observed at maximal testing dosage in each case. The reversal of RBC 
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counts and Hb levels observed in case of test extract treated groups could be attributed 
to the protective effects on tissue repair and deceleration of disease progression. 
Further reports of a significant rise of WBC count, in arthritic control group is 
possibly due to the stimulation of immune system against the invading antigen and 
also to an IL-1β mediated rise in the respective colony-stimulating factors. In addition 
an increase in ESR is a common feature in rheumatoid arthritis (Glen et al.,1971) and 
this increase in the ESR is attributed to the accelerated formation of endogenous 
proteins such as fibrinogen and a/b globulin, and such a rise in the ESR indicates an 
active but obscure disease process (Hu et al.,2005).Our test extract tended to 
normalize the WBC count and ESR probably through their immune modulation 
effects . 
CFA-induced arthritis in rats is associated with an increase in the plasma 
levels of C-Reactive Protein (CRP) and Rheumatoid Factor (RF) (Neilen et al., 
2006).The treatment with our test extracts significantly reduced the levels of these 
biomarkers in all the treated groups. Maximal effects were observed at 500 mg/kg 
b.w. dose for both the test extracts. The serum CRP concentration directly reflects the 
intensity of the pathological process in RA. It has been reported that inflammatory 
stimuli prompt the release of IL-1,IL-6, and TNF-α, which in turn stimulates the liver 
to produce CRP. Alternatively, CRP has also been found to have a more direct pro-
inflammatory role (Gabay et al.,1999). It is reported to activate endothelial cells to 
express ICAM-1, VCAM-1 and E-selectin which recruits cascade of inflammatory 
cells and imparts profound pro-inflammatory property to it (Pasceri et al.,2000). 
Significant reduction in the level of this biomarker indicates for their inhibitory 
effects on inflammatory cascade in the progression of arthritis.  
Moreover, rhuematoid factor (RF) is considered as a potential systemic marker 
for autoimmune stimulation in the pathogensis of rheumatoid arthritis. Although, the 
production of  RF may be a consequence of the polyclonal activation promoted by the 
immunization with complete Freund's adjuvant (CFA), the presence of arthritis  has 
been found to be associated with persistence of high titers of rheumatoid factor and 
for period longer  than would be expected from immunization with CFA alone (Brum-
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fernandes et al.,1988).The significant decrease in the levels of RF in case of test 
extracts treatment therefore indicated for their potent anti-arthritic activity. 
In arthritic animals, damage to the synovial cavity has been correlated with the 
overproduction of ROS, dysregulation of anti-oxidant enzymes and free radical-
scavenging molecules in the joint (Cuzzocreo et al.,2006).  In our study, both  the test 
extracts ( AAEE / ABEE) upregulated the levels of anti-oxidant enzymes., SOD, GPX 
and GR in a dose dependant manner and the effects at the highest dosage were quiet 
comparable to that of used dosage of ibuprofen. It has already been reported that 
arthritic patients have low levels of circulating SOD and these levels significantly 
improve with NSAID therapy. In addition, aberrant expression of glutathione 
peroxidase (GPx)  has been reported to contribute to the etiology of rheumatoid 
arthritis (RA) and levels of glutathione and glutathione peroxidase activity have been 
found to be decreased in plasma in RA patients (Taysi et al., 2002,Vijaykumar et al., 
2006). Another anti-oxidant enzyme GR, which reduces glutathione has also been 
unusually found to get decreased in the synovial fluid of patients with RA (Aryaeian 
et al., 2011).The significant up regulation of antioxidant enzymes., SOD, GPX and 
GR by our test extracts supports their role in anti-arthritic potential through effects on 
antioxidant parameters. 
Inflammation is central to the pathophysiology of RA. In the chronically 
inflamed tissues in RA, early in the course of the disease the very first change that 
occurs is an increase in the number cells. RA is characterized by mononuclear cell 
infiltration and proliferation of fibroblasts in the inflamed tissues. An increase in these 
cells induces other alterations in the tissue. There is also an increase in the volume of 
intracellular fluid leading to edema. In our study the histopathogical examination of 
the  hind paws disclosed that AAEE and ABEE both suppressed the massive  influx  
and accumulation  of  inflammatory cells like lymphocytes, neutrophlis, etc. in the 
foot pad after CFA challenge, all of which are the characteristics of chronic 
inflammation, as observed in the untreated anti arthritic rats. The suppressive effects 
were observed at all doses of the test extracts. 
Prostaglandins, leukotrienes, and nitric oxide are the ubiquitous mediators 
exerting numerous vascular and inflammatory effects and are responsible for the 
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development of clinical symptoms of arthritis. They cause vasodilatation, increase 
permeability of blood vessels and also induce migration of leukocytes to the site of 
inflammation. CFA-induced model of chronic inflammations a model of complex 
responses involving different mediators, and there is therefore a possibility of multiple 
interactions (Fatlahi et al., 2012). 
Prostaglandins (PGs) are found elevated in the inflamed tissues such as the 
synovium in RA and also in serum. Our results indicated that the test extract treated 
groups were associated with a selective decrease in the level of PGs in paw 
homogenates as well as serum. Treatment with AAEE and ABEE dose dependently 
decreased the levels of PGs in inflamed paw homogenates. However though AAEE 
significantly affected the levels of PGE2 in the inflamed paw tissue during chronic 
inflammation, it did not modify the content of this eicosanoid in serum. Therefore, 
AAEE was observed to selectively reduce PGE2 in paw tissue without reduction of its 
levels in other tissues. ABEE however, exhibited protective effects in both paw 
homogenate and serum. PGE2 production in arthritis is predominantly regulated by 
COX 2 enzyme and the expression of COX 2 itself is induced by endotoxins, 
mitogens or cytokines., IL-1β and TNF-α (Raz et al.,1988). It has been observed that 
both IL-1β and TNF-α enhance the production of PGE2 and COX 2 in synoviocytes in 
RA patients (Egg et al.,1984).In addition prostanoids have been observed to influence 
the function of mature lymphocytes. PGE2 in particular regulate a wide range of T and 
B cell functions, which includes inhibition of T lymphocytes, activation and 
proliferation of B lymphocytes (Kojima et al.,2005).Taken together, these findings 
suggest that the decreased production of PGs by our test extracts could possibly have 
resulted results from selective  down regulation of COX 2 biosynthesis possibly 
induced by decreased cytokine release from T-cells. Several plant extracts have been 
found to selectively inhibit COX, and suppress PGE2 production in arthritis. For 
example, the anti-arthritic activity of an extract of Gentiana macrophylla 
(Gentianaceae) has been associated with reduced PGE2 levels in the inflamed tissues 
(Yu  et al.,2004). Also Bidens pilosa extract was shown to inhibit IL-1β induced COX 
2 expression and PGE2 production (Yoshida et al.,2008).Similarly, total flavonoids 
derived from Turpinia Arguta were shown to reduce the production of IL-1β and 
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PGE2 in peritoneal macrophages and this effect was found to correlate with their anti-
arthritic activity observed in rats (Zhang et al., 2008). 
Leukotrienes have been recognized as important factors in numerous systemic 
inflammatory diseases such as rheumatoid arthritis. In our study, AAEE and ABEE at 
all graded doses significantly decreased LTB4 levels in inflamed paw tissues and 
serum at the end of 21 days in the arthritic rats. LTB4 which is found to be highly 
elevated in arthritic joints is considered as the most potent chemotactic agent and 
mediates the infiltration of leukocytes into the RA joint (Mathis et al.,2007). In 
addition, it induces the formation of suppressive and cytotoxic T-Lymphocytes. 
Although the mechanism of action, for leukotrienes in RA pathogenesis is not fully 
established yet, it has been speculated that it must be exerting its effects through 
induction IL-1β production in synovial cells. Further, leukotrienes are  generated by 
the 5-lipoxygenase pathway and inhibition of 5-lipoxygenase has been found to 
indirectly reduces the expression of TNF-alpha and decelerate the chronic 
inflammatory response in arthritis (Ammon et al.,1992). It may be hypothesized that 
our test extracts might be down regulating leukotrienes production, which in turn 
could be involved in reduction of expression of TNF-α and IL-1β cytokines, both 
already reported to be associated with anti-arthritic activity. These properties clearly 
emphasize anti-arthritic potential for our test extracts. 
Nitric oxide (NO) is a pleiotropic inflammatory mediator overproduced 
in arthritis-affected joints. There is significant evidence that in patients with RA 
endogenous NO synthesis is increased which suggests that overproduction of NO is 
vital in the pathogenesis of RA (Holoshitz et al.,2007). Both test extracts 
demonstrated dose dependent inhibitory effects on production of NO in serum and 
inflamed paw tissues and the activity was equipotent to that of Ibuprofen. NO is 
generated by several different cell types in the inflamed synovium and its production 
is regulated by the inducible isoform of nitric oxide synthase (iNOS) (Salvemini et 
al.,1993). The expression of iNOS in turn is regulated by catabolic cytokines, such as 
IL-1β and TNF-α. Thus it could be inferred that possibly our extracts reduce NO 
production again by inhibiting cytokine production which in turn reduce the 
expression of iNOS. iNOS inhibition has been reported to decrease disease activity in 
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experimental RA (Mc Cartany et al.,1993).Several anti arthritic drugs, including 
nonsteroidal anti-inflammatory drugs, immunosuppressive agents and tetracyclines 
have also been demonstrated to attenuate the activity of NO. 
IL-1β, main pleitropic pro-inflammatory cytokine is considered a pivotal 
participant in the pathophysiology of RA (Miyakasa et al.,1988). Plasma IL-1β 
concentrations have been found to be elevated in patients with RA and its levels 
correlate with several measures of disease activity, including the duration of morning 
stiffness, and pain score. Upon treatment with AAEE and ABEE significant 
dowregulation of IL-1β levels was found in the inflamed paws at all grade doses. It is 
known that IL-1β can stimulate its own production (Proudman et al.,1996). In 
addition, IL-1β along with  TNF-α also stimulates synoviocytes and chondrocytes to 
release MMPs and other proteinases that degrade cartilage, and these MMPs then up-
regulate the expression of pro-inflammatory genes, including cyclooxygenase-2 and 
nitric oxide synthase, leading to increased production of various pro-inflammatory 
mediators, such as PGE2 and NO (Kay et al.,2004). The significant inhibition of IL-1β 
levels by our test extracts, therefore could explain the down regulated expression of 
prostaglandins and NO and thereby confirming their contributions for their observed 
potent anti-arthritic activity. 
To further delineate the possible mechanism underlying the potent anti-
arthritic effects of our test extracts and to extrapolate their observed inhibitory effects 
on multidimensional inflammatory mediators, the test extracts were also examined for 
effects on Th1/Th2 cytokines. T cells along with its cytokines are known to have 
unbeatable role in the initiation and maintenance of arthritic disorders. T-cells 
proliferate and secrete cytokines after antigenic stimulus which in turn control the 
entire immune status of several immune cells (Schulze-Koops et al.,2001). Changes in 
these proteins can be monitored to determine how a given treatment is altering the 
disease progression.  
The pathogensis of RA is based on the preferential activation of Type 1          
T-helper cells which suggests that Th1 cytokines (IL-2, IFN-γ, TNF-α and IL-12) are 
predominantly involved in its pathogenesis. It was found that in arthritic patients Th1 
pro-inflammatory cytokines were abundant in synovial tissues (Othoro et al.,1999). In  
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our study prophylactic treatment with AAEE and ABEE  after CFA challenge  down 
regulated the levels of all the evaluated Th1 cytokines in a dose dependant manner. 
IL-2 produced by CD4
+
 T-helper cells, a pro-inflammatory cytokine 
considered to play a central role in the therapeutic manipulation of the immune 
system in RA, stimulates the synthesis of IFN-γ in T cells as well as induces the 
secretion of pro-inflammatory cytokines such as TNF-α by activated macrophages, 
neutrophils and other cell types (McInnes and Schett, 2007). In our study, it was 
particularly interesting that IL-2 concentrations in the test extract treated groups were 
significantly lower in supernatant from tissue homogenate as well as in serum when 
compared to non-treated arthritic control groups. Even more striking were the findings 
that both AAEE as well as ABEE significantly decreased TNF-α and interferon-
gamma (IFN-γ) levels also. It therefore could be speculated that the inhibition of IL-2 
by AAEE and ABEE is possibly responsible for reducing IFN-γ expression by T cells 
and TNF-α by macrophages and neutrophils. Since IFN-γ and TNF-α are Th1-type 
(pro-inflammatory) cytokines, their inhibition shows a strong correlation with the 
anti-arthritic activity of the test compound. 
TNF-α itself is generated by many cells including macrophages, especially 
after priming by IFN-γ and the inhibition of TNF-α by our extracts strongly signals 
anti-inflammatory effect of the test extracts. TNF-α is also reported to  regulate IL-1β 
expression (Brenann et al.,2008) which in turn is critically important for the induction 
of prostanoid and matrix metalloproteinase production by synovial fibroblasts and 
chondrocytes (Arend et al.,1995). In addition, TNF-α mediates cellular interactions 
along with IL-1β and initiates an obscure   sequence of events leading to cartilage 
damage in RA (Hata et al.,2004). TNF-α also appears to be an important mediator of 
matrix degradation and a pivotal cytokine in inducing synovial membrane 
inflammation. The strong inhibitory effects of AAEE and ABEE on TNF-α 
production, therefore explains the inhibitory effects observed on IL-1β, PGE2 and NO 
production and also the decreased synovial inflammation in test extract treated 
arthritic rats. 
IL-12 is the main stimulator of IFN-γ production and of the development of 
Th1 autoimmune response. Levels of IL-12 are elevated in serum and synovial fluids 
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in RA patients and have a direct correlation with severity of the disease (Kim et 
al.,2000). IFN-γ itself has been found to be critical in priming Th1 cell 
development.When produced IFN-γ also induces IL-12 p40 production by 
macrophages (Ma et al.,1996), thus establishing an autocrine loop which the amplifies 
the Th1 immunity. We found that on treatment with AAEE and ABEE there was 
highly significant inhibition of IL-12 cytokine in dose dependant manner. Therefore 
we could conclude that down regulation of IL-12 levels possibly decrease the levels 
of IFNγ which in turn would reduce the development of Th1 cells and this might be 
responsible for the significant and potent suppression of adjuvant-induced arthritis by 
our test extracts. 
Keeping in view, the significance of Th2 cytokines, we further studied the 
effect of AAEE and ABEE treatment on Th2 cytokines and found that while AAEE 
upregulated the levels of Th2 cytokines in a dose-dependent manner, ABEE however 
significantly inhibited the same cytokines at the same doses.Th1/Th2 cytokines 
function  mutually antagonist to each other and each suppresses the activity of the 
other. While Th1 cytokines are responsible for initiation of disease in RA, activation 
of Th2 cytokines correlates with disease regression. Th2 cytokines have been found to 
antagonise the effect of Th1 cytokines, suppress the production of pro-inflammatory 
cytokines, stimulate the production of other anti-inflammatory molecules block and 
the migration of inflammatory cells and thereby prevent joint damage in RA (Agarwal 
and Malaviya, 2005). 
Our findings demonstrated that a dosed dependant increase of IL-4 and IL-10 
by extracts of Atropa accuminata. IL-4, Th2 cytokine is known to be a potent anti-
inflammatory cytokine which acts by directly inhibiting the synthesis of pro-
inflammatory cytokines such as IL-1β, TNF-α, IL-6, IL-8 and IL-12 by macrophages 
and monocytes (De Kruyff et al., 1995). In arthritic patients, IL-4 is not detected in 
synovial fluid and tissues (Miossec et al.,1997) and it is this lack of IL-4 which 
contributes to the uneven Th1/Th2 balance in chronic RA. IL-4 inhibits the activation 
of Th1 cells and this in turn decreases the production of both TNF-α and IL-1β. It also 
suppresses metalloproteinase production and stimulates tissue inhibitor of 
metalloproteinase-1 production in human mononuclear phagocytes and cartilage 
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explants, which indicates a protective effect of IL-4 towards extracellular matrix 
degradation (Lacraz et al.,1992). In addition, IL-10 another Th2 cytokine, is known to 
suppress the progression of arthritis in animal models and it has been reported that 
rheumatoid patients treated with recombinant human IL-10 satisfactory clinical 
improvement was observed (Katsikis et al.,1994).Treatment with anti-IL-10 shortly 
before onset of RA has been found to  accelerate the disease expression of RA 
(Joosten et al.,1996). It is well known that IL-10 is a potent inhibitor of Th1 cytokine 
production and it inhibits the production of pro-inflammatory cytokines including IL-
1β, TNF-α, and IL-2 (de Waal-Malefyt et al.,1991).  Also IL-10 and IFN-γ are 
reciprocally regulated., IL-10 possibly inhibiting IFN-γ production and IFN-γ 
regulating IL-10 (Chomart et al.,1993). Another report indicates that IL-10 might be a 
potent recruitment signal for leukocyte migration in vivo (Te velde et al.,1992). Our 
findings of the induction of the high levels of IL-4 and IL-10 by AAEE could possibly 
be involved in the downregulation of Th1 cytokines. Interestingly, ABEE inhibited 
IL-4 and IL-10 levels, inferring a non involvement of Th2 mechanism in its arthritic 
potential. 
Several studies have been carried out in the past where plant extracts have 
demonstrated potent anti arthritic effects by acting as potent immunosuppressants of 
cytokine profile (Ahmed et al.,2006,Chauhan et al.,2011, Chevrier et al.,2005, Kang 
et al.,2004,Pandey et al.,2011) and also by acting as strong anti-inflammatory agents 
via differential  inhibition of cytokine profiles (Ahmed et al.,2012, Bani et al.,2005, 
Nazir et al.,2007,  Pandey et al.,2010). 
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Figure 5.3.1. Anti-arthritic activity of Atropa accuminata and Ajuga bracteosa. 
Cross marks indicate inhibition of CFA induced immunological alterations in rats by Atropa acuminata and Ajuga bracteosa. 
CFA induced arthritic is mark by decrease of anti-inflammatory cytokines., IL-4 and IL-10 as depicted in diagram above. 
Atropa Accuminata here upregulated their levels however Ajuga bracteosa further inhibited their levels. 
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From the summary of our studies, it can be concluded that Atropa accuminata 
and Ajuga bracteosa might be containing the components that have potent anti-
arthritic potential, the mode of action of which is related Th1/Th2 cytokine 
modulation causing suppression of nitric oxide, prostaglandin and leukotriene 
production and subsequent inhibition of chronic inflammation. This report is the first 
of its kind concerning the pharmacological properties of these plants under study. The 
significant dose related suppression of  pro-inflammatory cytokines viz. IL-2, IFN-γ 
and TNF-α levels along with the enhanced expression of IL-4 and IL-10 in the tissue 
homogenate supernatant as well as serum by A.accuminata suggest an inhibitory 
arthritic properties.  A.accuminata not only inhibited the T cells and Th1 cytokines 
but also elevated the natural capacity of the immune system to keep the Th1 cytokines 
under control by increasing IL-4 and IL-10. On the basis of this, it can be concluded 
that A.accuminata might be exhibiting its potent anti-arthritic activity through a mode 
of action associated with selective T cell modulating properties causing significant 
inhibition of pro-inflammatory (Th1) cytokines and also corresponding increase in 
anti-inflammatory (Th2) cytokines. In contrast,  A.bracteosa inhibited Th2 cytokines 
(IL-4 and IL-10) levels, indicating that it might be pronouncing its effects through a 
relatively different mechanism . The cell-mediated immune response plays an 
important role during the development of arthritis and inhibition of this response by 
A.bracteosa, particularly IFN-γ produced by CD4+ T cells, correlates strongly with its 
anti-arthritic activity. 
The therapy of arthritis usually employs NSAIDs, steroids or disease-
modifying drugs. The long-term use of these, however, limits the disease progression 
leading to joint deformity. In addition, all of these drugs have side effects and the 
search for a novel anti-arthritic drug continues. In safety studies, oral dose of 
A.accuminata and A.bracteosa as high as 2,500 mg/kg did not cause any sign of 
mortality or any observable negative symptoms in the general behavior of mice over a 
period of 2 weeks, indicating its apparent safety. Repeated once daily dosing up to 
500 mg/kg b.w. in a poly-arthritis test also did not cause any deviation from normal 
general behavior when compared to the control group, or induce mortality  in rats up 
to 21 days. Taken together with long standing usage as folk medicine and no 
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observable lethality, both the herbs therefore could be considered as a safe option for 
an array of  prophyalctic and therapeutic uses against arthritis after the studies. 
The potent anti-arthritic effects exerted by our extracts seem to be based on 
the complex mechanism of action of this extract. This could be attributed to be due to 
the additive effects of the bioactive constituents present in A.accuminata and 
A.bracteosa ethanolic fraction. Whether  our extracts inhibits iNOS and COX 2 gene 
expression as well as cytokine gene expression by interaction of nuclear factors or by 
other mechanisms remains yet to be determined. The work in this direction is to be 
worked out further. The multi targeted and  potency of the extracts provide us leads 
for novel anti arthritic bioactive agents that could be used as new therapeutic options 
for this chronic disease, arthritis.   
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